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The ribosome is essential to life as it transforms polynucleotides into polypeptides. 
In addition, ribosomes facilitate protein folding, protein degradation, stress response and 
mRNA surveillance. Studies on secondary and three-dimensional structures of rRNA 
evidenced that ribosomes of all species share a conserved common core of rRNA. 
Divergence in size and structure between prokaryotic and eukaryotic rRNAs and among 
eukaryotic rRNAs is focused on expansion segments (ESs). ESs are hypervariable 
eukaryotic rRNAs that emerge from the surface of the common core. In protists, ESs are 
important for ribosome biogenesis, rRNA processing and stabilization, translation 
initiation, and recruitment of non-ribosomal factors. 
In this work, we investigate the functions of expansion segment 7 (ES7) of 
Saccharomyces cerevisiae, Candida albicans and human. ES7 is an extension of Helix 25 
of the prokaryotic ribosome and is among the largest ESs of the ribosome. Thermal 
denaturation studies and footprinting experiments confirmed that isolated ES7 of multiple 
species are stable and maintain near-native secondary and tertiary conformations. In vitro 
RNA-protein pull-down experiments using ES7 as baits indicated that ES7 are binding 
hubs for a variety of non-ribosomal proteins that are essential to ribosomal function in 
eukaryotes. We hypothesize that larger rRNAs of complex organisms could confer 
increased functionality to the ribosome.  
Pull-down experiments performed using ES7 of S. cerevisiae indicate that ES7-
associated proteins cluster into four groups based on biological process: (i) response to 
abiotic stimulus, (ii) ribosomal large subunit biogenesis, (iii) protein transport and 
xxi 
localization, and (iv) transcription elongation. Seven amino acyl tRNA synthetases (Ala-, 
Arg-, Asp-, Asn-, Leu-, Lys- and Tyr-RS) appear to associate with ES7. Affinities of 
AspRS, TyrRS and LysRS for ES7 were confirmed by binding assays in vitro. The results 
suggest that ES7 of S. cerevisiae could play a role analogous to the multi-synthetase 
complex present in higher order organisms and that it could be important for the 
appropriate function of the ribosome. 
Protein association to human ESs were also investigated using pull-down assays. 
Human ESs associate with a variety of critical proteins, including members of the 
ubiquitin-proteasome system. The results suggest that protein synthesis is physically 
coupled with protein degradation in humans. Proteins involved in metabolism, 
transcription and translation also associate with human ESs. In addition, human ESs 
contain sequences that are suggestive of potential G-quadruplex sequences. Single-
stranded ES fragments show K+-dependence of circular dichroism spectra which is 
generally characteristic of G-quadruplex formation. 
At last, we investigated whether ES rRNAs contain useful targets for 
chemotherapeutics directed at eukaryotic pathogens. C. albicans and ES7 were used to test 
the general utility of ES rRNAs for small molecule targeting of eukaryotic pathogens. We 
demonstrated high affinity and selectivity of selected aminoglycoside-derived compounds 
for ES7. We also demonstrate that molecules that bind specifically and with high affinity 
to ES7 also induce mortality on C. albicans, but not in human cells. The results are 
consistent with our hypothesis that ESs in pathogenic eukaryotes represent useful targets 






1.1 The Ribosome 
 The ribosome helps define life, transducing information between polynucleotides 
and polypeptides. Every protein in the cell is synthesized by ribosomes. Ribosomes can 
navigate through the cytosolic cavity or can be attached to the endoplasmic reticulum (ER); 
they are also components of mitochondria and chloroplasts in eukaryotic cells. Cytosolic 
ribosomes produce soluble proteins that remain inside the cell. ER-attached ribosomes 
produce membrane proteins and proteins destined for secretion (e.g. cell surface receptors 
and digestive enzymes). 
 The ribosome is composed of two subunits that assemble together, in combination 
with messenger RNA (mRNA), charged transfer RNA (tRNA) and protein factors, to 
achieve translation. The large ribosomal subunit (LSU) and the small ribosomal subunit 
(SSU) are composed of one or more ribosomal RNA (rRNA) chains and many ribosomal 
proteins (rProteins). Ribosomal subunits are commonly identified by their sedimentation 
coefficients, expressed in Svedbergs (S). Bacterial ribosomes are commonly composed of 
50S (5S and 23S rRNAs, 33 rProteins) and 30S (16S rRNA and 21 rProteins) particles (1). 
Eukaryotes have larger and more diverse ribosomes in comparison to prokaryotes (2-4). 
Saccharomyces cerevisiae ribosomes are composed of 60S (5S, 5.8S and 28S rRNAs and 
46 proteins) and 40S (18S rRNA and 32 proteins) particles (1). Mass ratios of rRNA to 
rProtein can vary significantly, from ~ 2:1 bacteria, and ~ 3:2 in chloroplast ribosomes, to 
~ 1:2 in protozoa and ~ 1:3 in mammalian mitochondrial ribosomes (5). 
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 The ribosome is catalogued as a ribozyme (6). No protein is present at the peptidyl 
transferase center (PTC), which is composed entirely of rRNA (7). Therefore, only rRNA 
catalyzes peptide bond formation in the LSU. 
 
1.1.1 All ribosomes share a common core 
The assembled Escherichia coli ribosome (70S particle) has been characterized by 
cryo-electron microscopy (cryo-EM) (8-12) and X-ray crystallography (13-14). Similarly, 
three-dimensional structures of bacterium Thermus thermophilus (15), archaean 
Haloarcula marismortui (16), fungus S. cerevisiae (17), common wheat Triticum aestivum 
(18) and higher order metazoans, like Drosophila melanogaster (19) and Homo sapiens 
(19-20), have also been determined. Compilation of structural information reinforce the 
idea that ribosomes share a conserved secondary- and three-dimensional structure of rRNA 
known as the ‘common core’ (Figure 1.1) (2, 4, 19, 21). Covariation allows conservation 
of structure at locations where sequence is totally divergent. The common core comprises 
regions of universal ribosome function such as the A and P sites for tRNA binding, the 5S 
RNA binding site, the PTC, and few additional RNA helices. Structural conservation of 
the ribosomal core across species allows identification, comparison and study of rRNA 
regions outside the common core in eukaryotic ribosomes.  
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Figure 1.1 LSU rRNA secondary structures of A) E. coli, B) S. cerevisiae, C) D. 
melanogaster and D) H. sapiens. The common core is shown in orange. The regions outside 
the common core are shown in black. Figure provided by Chad R. Bernier.  
 
1.1.2 The accretion model of ribosomal growth 
Increase in rRNA size, protein quantity, and consequently, ribosomal mass, is 
observed over the phylogenetic tree. This increase is small for bacteria and archaea but can 
be substantial in eukaryotes, where ribosome sizes diverge widely (4). Comparison of H. 
marismortui and T. thermophilus 23S rRNAs confirmed the high degree of conservation in 
sequence, structure and size within the LSU of bacteria (22). However, eukaryotic rRNAs 
are bigger and more complex by up to ~ 40%, when compared with rRNAs of smaller 
organisms (comparison between E. coli and H. sapiens LSU rRNAs). Higher order species 
have larger LSU rRNAs: S. cerevisiae ~ 3554 nucleotides (nts), D. melanogaster ~ 4078 
nts, Gallus gallus ~ 4725 nts and H. sapiens ~ 5227 nts. The rRNA of the LSU particle 
increased significantly due to the incorporation of hundreds to thousands of nucleotides to 
the 23S rRNA chain. The rRNA length of the SSU, in contrast, maintained a constant size 
(23). 
Comparison of eukaryotic ribosomes suggest that ribosomal growth initiated in the 
PTC with recursive addition of sequence and structurally diverse RNA fragments. Insertion 
of these fragments within the ribosome occurred successively and accretion can be detected 
4 
at the atomic level (4, 24). Each accretion step enlarged the previous RNA template without 
perturbing the underlying structure (Figure 1.2). For this reason, many people describe the 
ribosome as ‘a mosaic of evolutionarily conserved structural elements interrupted by 
blocks or expansions of non-conserved sequences and structures’ (3, 25). 
 
 
Figure 1.2 Helix 25/ES7 shows the serial accretion of rRNA onto a frozen core. This image 
illustrates at the atomic level how Helix 25 of the LSU rRNA grew from a small stem loop 
in the common core into a large rRNA domain in metazoans. Each accretion step adds to 
the previous rRNA core but leaves the core unaltered. Common ancestors are indicated. 
Pairs of structures are superimposed to illustrate the differences and to demonstrate how 
new rRNA accretes with preservation of the ancestral core rRNA. Each structure is 
experimentally determined by X-ray diffraction or cryo-EM. This figure is reproduced with 
permission from Petrov et al. 2014 (4). 
 
1.1.3 rRNA expansion segments 
The first complete sequences of non-mitochondrial eukaryotic rRNAs became 
available in the early 1980s. SSU sequences of S. cerevisiae (26) and Xenopus laevis (27) 
and the LSU sequence of Saccharomyces carlsbergensis (28) were the first to be 
determined. The obtention of these sequences provided the first insights on the divergence 
trends of eukaryotic ribosomes and how they differ from prokaryotic scaffolds, mainly 
composed by the common core and represented by E. coli or T. thermophilus secondary 
structures. 
5 
Veldman et al. noticed initially that S. carlsbergensis rRNA is 640 nts bigger than 
E. coli rRNA. These nucleotides are localized in 9 specific regions, rather than at random 
locations, described by Veldman as ‘insertions’. ‘Insertions’ could be reduced or increased 
without altering the protein synthesis function of the ribosome and fold as separate, 
individual stem-loop structures (2, 28). Evidence suggests that eukaryotic rRNA ‘inserts’ 
are located at regions of rRNA deletion in mammalian mitochondrial rRNAs (29-31). The 
absence of significant ‘insertions’ in domains V and VI of S. carlsbergensis in comparison 
to E. coli highlights the importance of the structural integrity of these domains for 
ribosomal function. Chan et al. re-named the ‘insertions’ as ‘variable’ or V-regions (23) 
whereas Hassouna et al. called them ‘divergent’ or D-domains (32). Clark et al. introduced 
the term ‘expansion segments’ (ESs) for these regions, which has been widely adopted and 
remains popular today (33). 
At the beginning of these studies there was a lack of consistency in the 
nomenclature and definition of ESs. Many ESs were named and defined taking as a base 
the organism in which the study was being performed and following the nomenclature, if 
any, for that particular organism (34-35). The absence of a standardized naming system 
and the interchange between ‘variable regions’, ‘divergent domains’ and ‘expansion 
segments’ by different authors makes it hard to compare side-by-side functional or 
structural remarks between ESs of different organisms. One of the goals of the introductory 
review presented here is to adopt the terminology developed by Clark and Gerbi in 1996 
and re-emphasize the importance of a universal nomenclature system that facilitates the 
study and deciphering of ESs within the upcoming years. However, to maintain the fidelity 
of the work done by our preceding colleagues the designation used in the original 
6 
manuscripts will be retained in parenthesis when their work is referenced to, using the table 
of comparisons made by Clark et al. (3). 
 
1.1.4 Expansion segments: origins, size and sequence composition 
As more rRNA sequences became available and comparative alignment analysis 
tools evolved, the heterogeneity of ESs over phylogeny became evident. GC content is 
more conserved between ESs of a given organism than between organisms for a given ES. 
Expansion segments 7 (D2) and 27 (D8) of the LSU possess GC contents ranging from 
40% in slime mold Dictyostelium discoideum to 80-86% in vertebrates (2). In general, 
closely related species shared similar GC content in their ESs which suggest that nucleotide 
composition of ESs might be related throughout evolution (2). It is known that GC content 
of prokaryotic rRNAs and tRNAs is correlated with optimum growth temperature and 
secondary structure for these microorganisms (36-37). However, no evidence of this or a 
similar behavior was found in the literature for eukaryotic organisms or its ESs. 
Close inspection revealed that ESs can be organized in regions of short tandem 
repeats (38-41). Hancock and Dover observed in 1990 that while the nucleotide 
composition of the common core in human LSU rRNA is mainly random, the base 
composition of ESs have bias towards specific trinucleotides and tetranucleotides 
sequences like CGG, GCG and GGC. Trinucleotide and tetranucleotide compositions vary 
along human ESs with some trinucleotides being more frequent in one segment of the 
rRNA and other trinucleotides being more frequent in another segment of the same ES. 
Tautz et al. suggested the existence of a mechanism able to create such sequence patterns 
throughout most of the genome, and proposed it to be slippage (42-43). It is therefore 
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hypothesized that some ESs evolved as the result of slippage-like mechanisms during 
replication of ribosomal DNA (rDNA). To a less extent it has been also proposed that ESs 
may have arisen by unequal homologous exchange between sisters chromatids (38-39). 
Large shifts in base composition of ESs, in specific cases, can also occur over 
closely related species. ES9 (D3) of isopods possess a GC content of 32% for the species 
Jaera albifrons, while a variety of other isopods have a GC content of 54-64% for the same 
ES (44). Sequence composition of ESs can vary to such a degree that high frequency 
variation in rDNAs of human LSU rRNAs from different samples (e.g. ES15 (D6)) 
suggests heterogeneity of RNA transcripts (38). Dipterians D. melanogaster and 
Chironomus thummi thummi represent a small sub-set of organisms with predominant AT 
rich ESs. C. thummi thummi exhibits AT rich composition in at least six ESs and D. 
melanogaster exhibit it in all of its ESs (45-47). 
Expansion segments typically project from apical regions of stems extending from 
the consensus eukaryotic core. This reference to a stem structure attached to the ribosomal 
core is what allows them to retain an invariant location. Boundaries are commonly 
delineated by their independent folding criteria (2). 
The lack of size and sequence consensus between ESs has made it a challenge to 
determine their role in ribosome function (31). Both phenomena, the presence as well as 
the absence of ESs in the ribosome have shown to have no deleterious effect in protein 
synthesis in selected examples. Expansion segments are not involved in base-pair 
interactions with the rRNA of the common core and therefore have been allowed in mature 
rRNA during evolution (25, 32). Three different categories of rDNA ‘insertions’ have been 
proposed to affect the size of an rRNA gene and are based on the fate of the ‘insertion’: 
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introns, ESs and transcribed spacers (25, 33). The first category, the intron transcripts, 
cannot be tolerated by mature rRNA due to interruption of function and are spliced out of 
precursor rRNA. Expansion segments, the second group of ‘insertions’, are not removed 
from mature rRNA transcripts, enlarging the size of the eukaryotic ribosome. At last, 
internal transcribed spacers, are made up of sequences that divide distinct portions (or 
subunit rRNA chains) of immature rRNAs at the genetic level and are removed after 
transcription by processing events. Similarities such as the cryptic simplicity in sequence, 
the low degree of evolutionary constraint in both, ESs and transcribed spacers, and the 
hypothesis that ESs are degenerate transcribed spacers that cannot be excised out of rRNA, 
suggest that transcribed spacers and ESs may share common evolutionary origins (3, 40, 
48-49). 
As first pointed out by Michot et al., enlargement of LSU rRNA in eukaryotes 
mainly resides in ES7 (D2) and ES27 (D8) with a size variation of 600-800 nts in mammals 
(2). These ESs account for over 70% of the enlargement of the LSU observed in eukaryotic 
rRNA. Overall, ESs contain sequences responsible for more than 80% increase in the size 
of the human LSU rRNA over that of E. coli (39). Despite their large presence in the 
eukaryotic ribosome, many of the functions of ESs remain still unknown. 
 
1.1.5 Expansion segments: locations 
Studies performed with methidiumpropyl-EDTA·Fe (II) and EDTA·Fe (II) in the 
LSU and SSU rRNAs of D. melanogaster provided the first insights on the locations of 
ESs in the ribosome (50). The accessibility of ESs to cleaving reagents suggested that these 
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RNAs were located near or at the surface of the ribosome, at sites where they are less likely 
to interfere with the assembly and function of the ribosomal common core (50-51). 
Comparison of cryo-EM reconstructions of rabbit reticulocyte ribosomes against E. 
coli ribosomes was performed to determine the location of the three-dimensional structures 
of mammalian ESs (52). The largest ES of the LSU particle and the ribosome as a whole 
is ES7, an expansion of Helix 25. ES7 cross-links with proteins eL13 and eL21 that lie on 
the solvent accessible surface of the LSU. The results from this study confirmed that 
several ESs were located at the surface of eukaryotic ribosomes (52). 
Researchers in Japan used the ‘systematic selection of functional sequences by 
enforced replacement’ method to systematically inserted short RNA fragments into rRNAs 
of E. coli, and demonstrated the tolerance of intrinsic rRNAs to short insertions (53). Most 
of the functional insertions were located in the periphery of the ribosome and solvent-
exposed surfaces, ordinarily avoiding rProteins binding sites. In fact, many of the insertions 
overlapped with ES locations in both, LSU and SSU rRNAs of E. coli, reaffirming the 
tolerance of ESs to alterations without disruption in ribosomal function (53). 
 Recent studies on the structure of S. cerevisiae at 3 Å resolution showed that the 
majority of the ~1.35 MDa of eukaryote-specific parts (of which 350 kDa are ESs) are 
located on the surface of the ribosome, wrapping and protecting the common core (17, 54). 
S. cerevisiae and Tetrahymena thermophila three-dimensional structures demonstrated that 
most of the eukaryotic specific SSU rRNA is located where the two largest ESs of the SSU 
(es3 and es6) strongly interact (17, 55). The same trend is observed in human and 
Drosophila SSU particles, with es3 and es6 (19). ESs distribution in the LSU is quite 
different. Expansion segments from S. cerevisiae are uniformly distributed through the 
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whole LSU in a ring-like conformation. T. thermophila ESs distribution resemble that of 
S. cerevisiae, with the majority of the ESs exposed to the ribosomal surface, except for 
ES31 and ES41, which occupy positions at the subunit interface (56). ESs of human and 
Drosophila are located mainly in the back and the sides of the particle with agglomerates 
formed near the uL1 and P stalks. 
Due to the strategic location of ESs along the ribosome surface it could be 
considered that perhaps one of its functions is to protect the common core from proteolytic 
cleavage and therefore, ensure protein synthesis and cell survival. Perhaps, another 
function could be to confer structural stability to the overall ribosome assembly, like 
rProteins. Few theories suggest that ESs are dispensable, make no contribution, have no 
relevance towards ribosome function and therefore could not be located near functional 
regions where protein synthesis and decoding happens. However, we hypothesized in this 
work that ESs at least could be accessible for functional interactions with other 
macromolecules given their proximity to the ribosome surface. The limited information 
available on the role of ESs is discussed below. 
 
Table 1.1 Proteins from the LSU of S. cerevisiae that interact with ESs, along with the 
helices from which ESs are derived from. 
Expansion 
Segment 
Helix Protein interactions (57) 
ES3 9 uL23 
ES4 10 eL8, eL15, uL23, uL29 
ES7 25 
uL4, eL6, uL13, eL14, eL20, uL22, uL30, eL32, 
eL33 
ES8 28 uL4, eL13, eL15 
ES9 31 eL13, eL18, eL29, eL44 
ES12 38  uL18, eL21, eL29 
ES19 52 uL2, eL8, uL23 
ES20 54 eL27, eL34 
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ES27 63 eL19 
ES31 79 uL2, eL8, eL15, uL23, eL27, eL30, eL34, eL43 
ES39 98 uL3, eL6, uL6, uL13, eL14, eL20, uL22, eL33 
ES41 101 uL3, eL24, eL31 
ES43 18 uL24, uL29, eL37 
 
Table 1.2 Proteins from the SSU of S. cerevisiae that interact with ESs, along with the 
helices from which ESs are derived from. 
Expansion 
Segment 
Helix Protein interactions (57) 
es3 9 eS4. eS8, uS17 
es6 10 eS4, uS4, eS7, uS8, uS15, uS17, eS24 
es7 26 eS1, uS15, eS26, eS27 
es9 39 uS9, uS10, eS19 
es10 41 uS3, uS7, uS9, uS10, uS13, eS14, es19, eS25 
es12 44 eS6, eS8, uS12, eS30 
 
Table 1.3 Proteins from the LSU of H. sapiens that interact with ESs, along with the helices 
from which ESs are derived from. 
Expansion 
Segment 
Helix Protein interactions (57) 
ES3 9 uL23 
ES4 10 eL8, eL15, uL23, uL29 
ES7 25 
uL4, eL6, uL13, eL13, eL14, uL15, uL18, eL20, 
eL21, eL28, uL30, eL32, eL33 
ES8 28 uL4, eL13, eL15, uL24 
ES9 30, 31 eL13, uL15, eL18, eL29, eL36 
ES10 38 uL30 
ES12 38 uL18, eL29 
ES15 45 uL4, eL6, eL18, eL28, uL30, eL32 
ES19 52 eL8, uL23 
ES20 54 eL27, eL34 
ES27 63 eL19, eL27 
ES30 78 uL1 
ES31 79 uL2, eL8, eL15, eL27, eL34, eL43 
ES39 98 uL3, eL6, uL6, uL13, eL14, eL20, eL33 
ES41 101 uL3, eL24, eL31 




Table 1.4 Proteins from the SSU of H. sapiens that interact with ESs, along with the helices 
from which ESs are derived from. 
Expansion 
Segment 
Helix Protein interactions (57) 
es3 9 eS4, eS8 
es6 21 uS4, eS4, eS7, uS8, uS15 
es7 26 eS1, uS8, uS15 
es9 39 uS9, uS10 
es10 41 uS3, uS7, uS9, uS10, uS13 
es12 44 uS5, eS8, uS12, eS30 
 
1.1.6 Expansion segments: functions 
1.1.6.1 Expansion segments analysis of function by nucleotide alteration, addition or 
deletion 
In the late 1980s, the first studies on genetic engineering of ESs were performed. 
As a result, initial insights on the functions of ES became available. The first system for in 
vivo mutational studies of eukaryotic rDNAs was developed by Yao and co-workers and 
consisted in transforming conjugated T. thermophila cells with mutated rDNA (58-59). 
Sweeney et al. performed experiments in which cloned micronuclear rDNA of T. 
thermophila was altered by the insertion of random DNA segments into coding and non-
coding regions, including ESs (58). The most striking finding of their work was the ability 
to produce apparent functional ribosomes possessing normal doubling times in the presence 
of mutated 26S rRNA containing a 119 nucleotide linker in an ES near the 3’ end (58, 60). 
These results provided the first indication that the primary structure of ESs does not have 
to be fixed to produce functional ribosomes. 
Later on, an 18-mer tag was attached to ES43 of S. cerevisiae 26S rRNA to perform 
mutational studies on yeast rDNA (61). Observations from this study revealed that the 
concise structure of ES43 in S. cerevisiae is not essential for ribosome biogenesis or 
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function. However, the possibility of secondary effects on maturation kinetics could not be 
discarded. Similarly, an experiment designed to monitor the effects of rDNA mutations in 
the 40S subunit of S. cerevisiae was performed by the addition of a 19 nucleotide tag to 
es9 (V8) (62). Analogous to the 26S rRNA tag incorporation, addition of this tag to es9 in 
17S rRNA did not produce signs of harmful effects in 40S subunit formation or function. 
Therefore, it was concluded that the structure of es9 in the SSU is not of critical importance 
to the ribosome. Still, later experiments using an alternative in vivo system suggested that 
incorporation of the tag into es9 has lethal effects in few essential ribosomal functions, 
being translation and termination the ones with most probability (63). Additional attempts 
to insert two different oligomer tags into es3 (V3) of 17S rRNA turned out to be deleterious 
to the formation of small ribosomal subunits, although the 37S pre-rRNA and the LSU 
production remained unaffected, indicating that not all ESs of mature rRNAs have 
structural flexibility (62). 
Further studies were performed by Musters et al. to analyze the structure-function 
relationship of ES19 (V9) of yeast 26S rRNA. ES19 is located in domain III of the LSU 
and forms part of the conserved binding site for ribosomal protein uL23. Its counterpart in 
E.coli is composed of only 3 nucleotides. In these studies ES19 was exchanged with 
equivalent regions from other species or excised by in vitro loop out mutagenesis (64). The 
results indicated that both, the presence or absence of ES19, has no detectable deleterious 
effects on the function of S. cerevisiae LSU and therefore it is a dispensable region (64). 
However, later experiments observed a two-fold-reduction in the growth of cells 
expressing only mutated rRNA (65). 
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Similar to Musters et al., experiments were performed in which ES27 (D8) of T. 
thermophila was either removed or replaced by a variety of related sequences (60). 
Opposite to what was observed with ES19 of yeast, the results indicated that ES27 is 
essential and plays a role in either rRNA processing or stabilization of mature rRNA pieces 
of T. thermophila. Additionally, ES27 of T. thermophila, S. cerevisiae, D. discoideum, and 
Caenorhabditis elegans can be exchanged without any lethal effect for T. thermophila, 
being hypothesized that the tertiary structure of rRNA might be the reason for this behavior. 
Further studies on ESs from yeast revealed that helix 6, which forms a considerable 
portion of S. cerevisiae V1 region (no equivalence in nomenclature could be established) 
in the SSU, is important in maintaining normal production of 18S rRNA as well as its 
correct assembly into the 40S subunit (66). Augmenting the helical or loop portions of 
helix 6 strongly diminished the production of 18S rRNA possibly due to steric inhibition 
with protein uS15, an essential rProtein (66). However, almost complete deletion of this 
helix has less severe effects since significant amounts of accurately processed mutant 18S 
rRNA still accumulate and cells containing this mutant continue to grow. 
As it can be observed the majority of genetic studies on ESs mentioned so far target 
the addition or alteration of nucleotides into existing ES scaffolds. The disadvantage of this 
approach arises from the high rates of false positives that could relate ribosome impairment 
(caused by disturbance to rRNA structure by nucleotide addition) to the essentiality of these 
regions in the ribosome. For this reason, ES7 (V3) and ES27 (V13) of S. cerevisiae LSU 
were subjected to study by deletion analysis (67). Removal of a portion of Helix 63 from 
ES27 resulted to be dispensable for ribosome biogenesis and function (67). The results 
suggested that the lethal phenotype observed in T. thermophila by nucleotide deletion in 
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ES27 (60) is not due to the destruction of an essential functional element, but rather to 
disturbances in pre-rRNA processing or steric hindrance with rProteins (67). Almost 
complete elimination of S. cerevisiae ES27 to mimic its prokaryotic counterpart proved to 
be lethal. Deletion of ES7 in the same study reveals that partial removal of Helix 25 caused 
severe growth defects while its whole deletion, as ES27, was lethal. Metazoans contain 
ES30 and ES43, segments not present in yeast and Tetrahymena (19). This adds up 
additional complexity as to whether all or only few expansion segments are essential for 
cell survival. 
 
1.1.6.2 Expansion segments analysis of function by studying translation mechanisms 
Cryo-EM data of Trypanosoma cruzi reveals unusual structural components in the 
secondary structure of ESs (68). Fragments of es6 and es7, form part of a large helical 
structure termed “the turret” located in the most lateral side of the 40S subunit and present 
only in Trypanosomes. The turret structure is believed to be involved in the unique 
translation initiation mechanism of Trypanosomes along with the spliced leader sequence 
and cap 4-structure at the 5’ end of mRNA (68). Otherwise, ES19 (D7a) of C. thummi 
thummi its been known to be involved in the rRNA processing of insects (47). Both, the 
primary and secondary structures of ES19 in dipterans, seems to be essential for the 
cleavage of 26S rRNA (47). 
Interaction studies between ES24 of yeast and the Sec61 translocon suggests that 
ES24 can play a role in recruiting and coordinating the access of non-ribosomal factors 
such as chaperones, modifying enzymes or signal recognition particles (SRP) (69). Further 
studies to investigate the degree of conservation of ES structures in fungi were performed 
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using Thermomyces lanuginosus as a model, and compared against data obtained for S. 
cerevisiae (70). Although numerous changes were detected in the primary structure of ESs, 
the most dramatic conformational differences were located in ES7, ES27 and ES39 of 25S 
rRNAs. Only the base of ES27 was visible in the cryo-EM structure of T. lanuginosus 
suggesting that the allosteric mechanism of S. cerevisiae for this helix is also shared by this 
thermophile (70). Moreover, conformational changes in ES7 and ES39 caused by 
ribosomal protein uL4 in T. lanuginosus are hypothesized to influence the binding of non-
ribosomal factors, such as SRP, that are located close to these rRNA elements and therefore 
be of functional importance for the regulation of the peptide binding site (70). The tip of 
ES7 in S. cerevisiae is believed to interact with protein P0, a component of the P-stalk that 
recruits G proteins into the ribosome (17, 71). Since the same set of core rProteins exists 
in both fungi, deciphering of ESs functions in one species can be easily transferred to the 
other one. 
Human and Drosophila ESs are also involved in the recruitment of external, non-
ribosomal factors. es3 and es6 of the SSU contribute to the binding of eukaryotic initiation 
factors eIF3 and eIF4-G for eukaryotic translation (19, 72-74). Structural variations within 
these segments and the absence of this behavior in other eukaryotic organisms reflects the 
difference in eukaryotic translation mechanisms evidenced previously by the 
Trypanosomes’ turret structure. Dynamic rearrangements between ES27 and ES31 in D. 
melanogaster in the presence of eukaryotic elongation factor eEF-2 seems to enable 
communication between the mRNA exit site in the SSU and the tunnel exit site in the LSU 
(19). This behavior is not observed in human ribosomes and evidence the variety of 
functions that could be acquired by ESs in phylogeny. 
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1.2 Antibiotic/Antimicrobial Resistance 
1.2.1 Antibacterial targeting, resistance and development  
The discovery of penicillin against gram-positive bacteria by Alexander Fleming 
marked a historical landmark towards the treatment of infectious diseases (75). The quick 
development of penicillin derivatives along with the discovery of additional classes of 
compounds possessing antibacterial activity (i.e. sulfa drugs, aminoglycosides, 
chloramphenicols, macrolides, tetracyclines, quinolones, etc.) led to the golden era of 
antibiotic discovery between the 1940s and 1960s. However, the rapid rate of success of 
antibiotic development was overshadowed by the emergence of resistance. Bacterial 
resistance against antibiotics emerged as early as the 1940s. Studies on microorganism 
susceptibility against penicillin demonstrated that Staphylococcus produced an enzyme 
with the ability to minimize the treatment efficiency provided by penicillin (76). As this, 
there are many other examples where antibiotic resistant bacterial strains have emerged, 
reaching alarming levels (i.e. tetracycline resistant Shigella, methicillin resistant 
Staphylococcus, penicillin resistant Pneumococcus, gentamicin resistant Enterococcus, 
vancomycin resistant Enterococcus, etc.). 
The Center for Disease Control and Prevention (CDC) estimated in 2013 that 
approximately 2 million people each year become infected with antibiotic resistant bacteria 
and 23,000 died as a consequence of these infections (77-78). An assessment conducted by 
this entity concerning antimicrobial resistant threats revealed a list of 18 microorganisms, 
mostly bacteria, that represent either urgent, serious or concerning threats to the public 
health. Antibiotic resistance in these organisms at large scale emerged from multiple 
reasons: incorrect prescribed drugs to treat non-bacterial infections, incorrect dosing, 
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spread of resistant-strain bacteria from person to person, antibiotic use in food animals, 
among others (79). 
Strictly speaking the simple use of antibiotics creates resistance. The introduction 
of drugs to susceptible bacterial environments increases the selective pressure of bacteria 
to acquire resistance against it. Bacteria will have to adapt to the new environment or 
otherwise die. It has been suggested that the simplest method to fight bacterial resistance 
is to stop taking antibiotics (80). Many drug resistance mechanisms confer a fitness cost to 
bacteria as essential functions in bacterial cells are altered or impaired (81). This cost is 
variable and influences the ability of bacteria to maintain or change the rate of resistance 
(82-84). Fitness costs can be overcome by compensatory mutations, true reversion and 
other mechanisms and may differ between in vitro and in vivo studies making it difficult to 
study the real fitness cost on resistance. 
At the molecular level, bacterial resistance is caused by two different mechanisms: 
intrinsic or acquired (85). Intrinsic mechanisms are defined as those mechanisms that allow 
bacteria to resist the antibiotic action as a result of inherited structural or functional 
characteristics (e.g. inability to cross bacterial cell wall). Acquired mechanisms, otherwise, 
are developed by bacteria to by-pass the effective action of the antibiotic. Three big groups 
were established by Blair and co-workers for acquired bacterial resistance mechanisms: 
minimization of antibiotic intracellular concentration by reduced drug permeability or 
increased efflux, target site changes via mutation, overexpression or chemical protection 
and antibiotic inactivation by hydrolysis or steric hindrance. Multiple cases have been 
encountered for all groups and the challenges for all of them are evident.  
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Development of novel antibacterials represent a scientific and economic challenge. 
The lack of new platforms for antibacterial discovery and the increasing costs in the 
discovery pipeline for new compounds make the development process even harder. Few 
new classes of antibacterials have been approved after 1960 (86). Rational drug design of 
molecules with new mechanisms of action have not been successful, mostly by the inability 
to penetrate the bacterial envelope (87). The Lipinski Rule of 5 used as a standard to predict 
oral bioavailability, have no counterpart in antimicrobial discovery. Attempts to adhere to 
these rules most likely have precluded antibiotic discovery as most current approved 
compounds do not obey all the parameters of the Lipinski Rule of 5 (87-89). 
Antibacterial drugs developed to date target the following areas (90):  
i. Inhibition of cell wall biosynthesis – β lactams, polypeptides, 
glycopeptides, phosphonic acid derivatives, ᴅ-alanine analogs 
ii. Interference of cell membrane integrity– lipopeptides, diarylquinolines, 
polymyxins 
iii. Inhibition of protein synthesis – aminoglycosides, chloramphenicols, 
macrolides, ketolides, tetracyclines, fusidane, oxazolidinones, 
streptogramins, monoxycarbolic acid  
iv. Inhibition of nucleic acid biosynthesis – rifamycins, quinolones, 
macrocyclic, nitrofurans, nitroimidazoles 
v. Inhibition of metabolic pathways – sulfadrugs, trimethoprim 
Different approaches has been suggested to tackle the discovery of new class of 
antibacterials and combat antibiotic resistance. Development of new compounds for old 
targets have been suggested (90). This approach will require an intense search for sources 
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where new compounds can be obtained. A different approach could involve chemical 
modifications to already existing compounds (91). It is expected that the risks associated 
with safety and toxicity in derivatives will be lower than the ones present in new classes of 
compounds. The same strategy was used for the development of penicillin derivatives back 
in the 1940s. 
Combination therapies have been also proposed to fight antibiotic resistance (92). 
Currently many oncologic treatments use this approach. The treatment of infections with 
multiple, rather than individual drugs will make it harder for bacteria to develop resistance 
as the probability to develop resistance against both drugs combined will be less than the 
probability of developing resistance against each antibiotic individually. 
Restoration of natural product drug discovery programs is probably one of the most 
promising platforms. Most of the currently used antibiotics were completely or partially 
derived from natural sources with very few exceptions (sulfonamides, quinolones, 
oxazolidinones, nitrofurans) (93). Marine natural products represent a good source for the 
development of new antibiotics as they are rich in secondary metabolite production (94). 
The same is true for plants, which are able to liberate toxins against grazing by animals. 
Marinomycins A-D, four different macrodiolides extracted from ocean microorganisms, 
showed significant antibacterial activities against methicillin-resistant Staphylococcus 
aureus and vancomycin-resistant Enterococcus faceium (95). The discovery of these 
compounds re-emphasize the potential of new sources of natural products for drug 
discovery. 
At last, the development and screening of new targets could also lead to the 
discovery of new compounds. Recently, a group of scientists at Merck Research 
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Laboratories discovered ribocyl, a synthetic analog of flavin mononucleotide (FMN) that 
competes with the natural ligand to inhibit FMN riboswitch-mediated expression and 
inhibit bacterial growth (96). Bacteria, fungi and plants synthesize FMN or obtain it from 
their environment, while humans only acquire it through their diet. The target-specific 
effect obtained in this case could be mimicked to find others able to alter bacterial 
metabolism. Most importantly this also represent an example of how the space of 
antibacterial targets could be expanded to account for new candidates, as non-coding 
RNAs, to combat infections. 
 
1.2.2 Antifungal targeting, resistance and development  
Fungal pathogens are one of the leading causes of infectious diseases within the 
immunocompromised population. Unfortunately, analogous to antibacterials, resistance 
against antifungals have also been observed. The antibiotic resistance handbook published 
by the CDC in 2013, focused mainly on bacterial infections, also includes Candida as a 
serious threat due to the existence of numerous drug-resistant strains. Information on fungal 
infections, mechanisms of resistance and drug development is limited when compared with 
the amount of information available for bacterial infections. For this reason information on 
bacterial resistance, antibacterial targets, mechanisms of resistance and new antibacterial 
discovery schemes were covered first in this literature survey, as comparisons between 
bacterial and fungal antimicrobials have been performed, and are not uncommon due to the 
disparity of available information. 
Similar to bacteria, anti-fungal development started in the 1930s with the 
introduction of griseofulvin, the first oral antifungal drug (97). Griseofulvin was isolated 
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from Penicillium griseofulvin and used to treat skin, hair and nail infections caused mainly 
by Trichophytons. Posterior to griseofulvin, several classes of antifungals were developed 
(i.e. polyenes, flucytosine, echinocandin, imidazole, triazoles, allylamines, etc.) leading to 
the golden era of antifungal discovery between the 1950s and 1980s. An increasing concern 
of fungal diseases to public health has also become evident. Drug-resistant strains continue 
to emerge and very few antifungals have made it to the market since the 1980s. 
Analogous to bacteria, antifungal resistance can be intrinsic or acquired.  However, 
a third class of antifungal resistance, described as clinical resistance, has also been 
observed (98-99). Clinical resistance has been identified in patients with latent or 
progressive infections, in which an isolate of the fungi demonstrates susceptibility towards 
anti-fungal drugs in laboratory tests in vitro. Successful responses to antimicrobial 
therapies are not exclusively pathogen dependent and the host immune system along with 
the drug pharmacodynamics and pharmacokinetic profiles, location of infection, duration 
of the treatment, among others may contribute to the resistance acquisition, especially with 
fungi (100). Similar to bacteria, acquired resistance can be obtained through increased 
efflux, target-site alterations, up-regulation of target enzymes or development of by-pass 
pathways (99-100). Still, decreased cell permeability, drug modifications or combinations 
of these mechanisms have not been identified as mechanisms of resistance against 
antifungals (101). 
Since both, yeast and human, are eukaryotic organisms closely related in the 
phylogenetic tree of life it is a challenge to design compounds with the desired specificity 
and pharmacological profiles. Antifungals developed to date target the following areas (90, 
102): 
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i. Disruption of cell membrane – polyenes 
ii. Inhibition of cell membrane biosynthesis pathways – azoles, allylamines, 
thiocarbamates 
iii. Inhibition of cell wall biosynthesis pathways – echinocandins 
iv. Inhibition of nucleotides synthesis – pyrimidine analogues 
v. Cells – hydroxypyridones, benzofurans, phenyl ethers, sesquiterpenes 
Comparison between antibacterial and antifungal drug targets revealed that many 
antibacterials possess no antifungals analogues. Inhibition of protein synthesis and 
metabolic pathways in bacteria have no counterpart in fungi. The structural and sequence 
resemblance between fungal and human ribosomes have minimized the efforts of scientists 
to screen and develop drugs against these targets. Sordarins constitute the only known 
exception of anti-fungals developed to inhibit ribosomal translation by interacting with 
elongation factor 2 (EF-2) (103). Still, there is no evidence in the literature of drug 
approval. 
Different strategies have been proposed to overcome antifungal resistance. Natural 
products and its derivatives represent a good source for antifungal discovery. Similar to 
antibacterials, the majority of antifungals have been derived from nature with very few 
exceptions (i.e. azoles, allylamines). Fitness tests profiling allowed the discovery of a 
variety of natural products with diverse targets: biosynthesis of sphingolipids, fatty acids 
and proteins, 3’ mRNA processing, ribosome biogenesis, nuclear export, protein 
translocation, etc. that could be developed into potential antifungals (104). Identification 
of new, target-specific sites have also been suggested. Several groups have worked 
successfully to screen and identify genes specific to C. albicans growth and survival for 
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drug target development (105-108). Every living cell require amino acids in order to 
maintain its function and methionine and threonine biosynthesis have emerged as 
exploitable pathways (109). This approach most likely can be applied to the development 
of new antibacterials as well. 
Increased anti-fungal dose intensity, development of new drug delivery systems to 
improve the therapeutic index of existing antifungals, combination therapies and surgery 
for sequestered lesions emerge as additional proposals (110). Detailed comparison of data 
between antibacterial and antifungals operating mechanisms will provide more insight in 
the development of novel drug discovery platforms and how to overcome the mechanisms 
of resistance. 
 
1.3 Thesis overview 
This thesis studies the stability, structure and function of rRNA expansion segments 
in eukaryotic organisms and its role as antifungal targets. Chapter 2 investigates the role of 
S. cerevisiae ES7 in the ribosome and identifies direct ES7-binding partners through RNA-
protein pull-down experiments. Chapter 3 characterizes human ES7 and compares the 
functions of various human ESs across different cellular environments. This chapter also 
investigates the existence of G-quadruplexes in the human ribosome. Chapter 4 examines 
C. albicans ES7 as a target for antimicrobials. Chapter 5 provides the overall conclusions 








The core function of the ribosome is to read mRNA and synthesize coded protein. 
In addition, ribosomes facilitate protein folding, protein degradation, stress response and 
mRNA surveillance (111-113). The increased size of ribosomal RNAs (rRNAs) in complex 
organisms appears to confer increased functionality to the ribosome (4). Many auxiliary 
functions of large ribosomes are yet to be characterized. However, auxiliary functions 
correlate with rRNA size, which follows well-defined patterns: 
(i) All cytoplasmic ribosomes contain a “common core” of rRNA, which is 
reasonably approximated in structure by prokaryotic rRNA (Figure 2.1). 
(ii) Expansion of rRNA beyond the common core is focused at few specific regions 
on the ribosome called “expansion segments” (ESs) (3, 21, 25, 32-33).  
(iii) ESs are located on the surface of the ribosome and are excluded from the 
ribosome interior and from core functional centers such as the peptidyl 
transferase center, the decoding center, the subunit interface, and tRNA binding 
sites (114). 
(iv) Size variation is significantly greater in eukaryotes than prokaryotes and in 
large subunit (LSU) rRNAs than in small subunit (SSU) rRNAs (3).  
(v) rRNA size increases from bacteria/archaea to protists to metazoan and is 
greatest in mammals (4, 21).  
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(vi) rRNA size correlates with organismal complexity (4). 
  
 
Figure 2.1 The LSU rRNA of S. cerevisiae with highlighted expansion segments. A) 
Secondary structure and B) three dimensional structure of LSU rRNA. Common core 
rRNA, which is common to all cytoplasmic ribosomes, is dark gray. Expansions of S. 
cerevisiae rRNA from the common core are green, except for expansion segment 7 (ES7) 
which is pink and enclosed in a shaded box in panel A. For panel B, the top shows the back 
view of the LSU, and the bottom shows the front (interfacial) view. Locations of structural 
hallmarks such as the peptidyl transferase center, the central protuberance, stalk and tunnel 
exit are indicated. Thick dashed lines in panel A represent RNA that is not observed in the 
three dimensional structure (114) and is absent in panel B. 
 
Here we investigate the functions of expansion segment 7 (ES7, Figure 2.1) of 
Saccharomyces cerevisiae. ES7 is an extension of Helix 25 of the prokaryotic ribosome 
and is among the largest expansion segments of the LSU and the ribosome as a whole. ES7 
is one of the most variable regions of eukaryotic rRNA. It is 210 nucleotides (nts) in S. 
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cerevisiae (Figure 2.2), 341 nts in Drosophila melanogaster, 800 nts in Gallus gallus and 
876 nts in Homo sapiens. The locations of ESs on the surface of the ribosome were 
established by Dervan and coworkers (50) and confirmed by three-dimensional structure 
determination (reviewed in reference 21).  
The ribosome has grown in size and complexity within certain branches of the 
eukaryotic tree. The LSU rRNA of S. cerevisiae is 3554 nts, while that of D. melanogaster 
is 4078 nts, G. gallus is 4725 nts and H. sapiens is 5227 nts. It has been proposed that ESs 
are involved in ribosomal regulation, packaging, turnover and biogenesis (60, 115-116). In 
trypanosomes, ESs of the small ribosomal subunit contribute to a ‘turret-like’ structure, 




Figure 2.2 ES7 rRNA interacts with ribosomal proteins in the assembled ribosome. A) 
Secondary structure and B) three dimensional structure of S. cerevisiae ES7. Interactions 
of ribosomal proteins with ES7 are mapped on to the A) secondary and B) three- 
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dimensional structures. In panel A, nucleotides are colored by the protein with which they 
interact. Nucleotides not present in the three dimensional structure are shown in gray. In 
panel B, amino acids interacting with ES7 rRNA are colored by the proteins to which they 
belong. Coordinates are from PDB entry 4V88. 
 
We characterized the secondary structure and protein binding capabilities of ES7. 
The results are consistent with a model in which expansion segments of eukaryotic 
ribosomes are docking sites for protein factors that are auxiliary to core ribosomal 
functions. These factors include aminoacyl tRNA synthetases (aaRSs), quality control 
proteins and chaperones.  
 
2.2 Materials & Methods 
2.2.1 S. cerevisiae ES7 DNA and RNA 
The DNA encoding S. cerevisiae ES7 was amplified from yeast genomic DNA. 
The T7 promoter and restriction sites for EcoRI (5’ end) and HindIII (3’ end) were added 
via PCR. The DNA was inserted into a previously restricted, dephosphorylated pUC19 
plasmid. Ligated plasmid was transformed into DH5α competent cells and colonies were 
selected based on X-gal Blue-White screening (Thermo Scientific). Primer sequences are 
shown in Table A.1.  
 The Weeks cassette (118) was incorporated onto the 3’ end of ES7 to allow SHAPE 
mapping without losing information from ES7 termini using the Q5® Site-directed 
Mutagenesis Kit (New England BioLabs). Primer information is described in Table A.2. 
Primer synthesis and DNA sequencing were performed by Eurofins-MWG Operon. 
2.2.1.1 In vitro RNA synthesis 
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S. cerevisiae ES7 RNAs were transcribed (HiScribe™ T7 High Yield RNA 
Synthesis Kit, New England BioLabs) with the following modifications to the 
manufacturer’s protocol. pUC19 containing the S. cerevisiae ES7 gene was linearized at 
the 3’ end with HindIII. In each 20 µL transcription reaction, 500 ng of DNA template 
were used. The DNA was transcribed overnight at 37 °C followed by incubation with 
TURBO DNase (Ambion) at 37 °C for 15 min. A 1:10 dilution of a 5 M ammonium acetate 
solution (pH 5.6) and 2.5 vol of 100% ethanol were added to the reaction mixture, which 
was then incubated at -20 °C for 1 h and centrifuged at 15,600g for 10 min at 4 °C. Pellets 
were washed three times with 80% ethanol before drying via Speedvac. RNA was 
resuspended in nuclease-free water and purified from unincorporated nucleotides with an 
illustra NAP 5 column (GE Healthcare). RNA yields were quantified by UV absorbance. 
RNA purity and integrity were verified by 6% acrylamide (29:1 acryl:bisacryl), 8 M urea 
gel with TBE buffer. 
 
2.2.2 SHAPE reactions 
Selective 2’-Hydroxyl Acylation Analyzed by Primer Extension (SHAPE) methods 
were adapted from published protocols (118-119). In vitro-transcribed RNA in nuclease-
free water was added to folding buffer [final concentrations: 200 mM NaOAc, 50 mM Na-
HEPES (pH 8.0) and 1 mM 1,2-trans- cyclohexane-N,N,N'N'-diaminetetraacetic acid or 5 
mM of MgCl2] to obtain 400 nM RNA in 80 µL. RNAs were annealed by cooling from 75 
°C to 25 °C at 1 °C/min. Data were collected in 200 mM Na+ and no Mg2+ to analyze 
secondary structure (120-122). RNA tertiary interactions were characterized in the 
presence of Mg2+ ions. 
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2.2.2.1 Benzoyl cyanide reaction 
Chemical modification of ES7 RNA was performed with a 10X dilution of a 1000 
mM benzoyl cyanide (Sigma) stock prepared in dimethyl sulfoxide (DMSO) into 36 µL of 
annealed RNA. Control reactions contained DMSO only. Reactions were carried out for 
~1-2 min at room temperature (123). 
 Benzoyl cyanide-modified RNA was purified from reaction mixtures by 
precipitation in ammonium acetate [1:10 dilution, 3 M (pH 5.2)] and ethanol (2.5 vol) at -
20 °C for ~15 min. Reaction mixtures were centrifuged at 15,600g at 4 °C for 10 min and 
the pellet washed once with 80% ethanol before drying via Speedvac. Pellets were re-
suspended in 22 µL 1X TE buffer [10 mM Tris-Cl, 1mM EDTA (pH 8.0)]. Recovery after 
purification was > 40%. 
2.2.2.2 Reverse transcription of benzoyl cyanide-modified S. cerevisiae ES7 RNA 
A single [6-FAM]-labeled primer (Table A.3) provided complete SHAPE reads on 
ES7 of S. cerevisiae (124). Modified RNA (20 µL) was added to 40 pmol primer in reverse 
transcription (RT) buffer to yield 1X First-Strand Buffer (Invitrogen), 2 mM DTT and 625 
µM of each deoxynucleotide (dNTP) in 50 µL. Primer annealing was performed stepwise: 
95 °C for 30 sec, 65 °C for 3 min, 60 °C for 3 min and 4 °C for 10 min. SuperScript III 
Reverse Transcriptase (Invitrogen) was used in RT reactions. RT mixtures were pre-
incubated at 52 °C for 2 min before addition of 1 µL (200 U) of RT enzyme and reaction 
was allowed to proceed for 2 h at 52 °C. RT enzyme was inactivated at 70 °C for 15 min. 
Reverse transcription reactions were also performed on un-modified RNAs (DMSO only) 
at the conditions used for modified RNA samples. 
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RNA was sequenced by RT/chain termination using dideoxynucleotides (ddNTPs) 
at a ratio of 1:1 ddNTP to dNTP. Ten pmol of ES7 RNA in TE buffer and 40 pmol of 
primer were used for sequencing reactions. A reaction without ddNTPs identified natural 
polymerase fall-off peaks. 
2.2.2.3 Capillary electrophoresis of RT reaction products  
Analysis of RT reaction productions was performed as described previously (124). 
2.2.2.4 SHAPE data processing 
SHAPE data were processed as described (125). SHAPE data were mapped onto 
secondary structures with the program RiboVision (126). 
 
2.2.3 RNA folding/unfolding 
Melting curves for ES7 RNA were determined by absorbance at 260 nm as a 
function of temperature with a thermostated Varian Cary-1E UV spectrophotometer. RNA 
was concentrated by Speedvac to at least 1 µg/µL and added to melting buffer [180 mM 
NaCl, 20 mM Tris-HEPES (pH 8.0)] to reach an initial absorbance of 0.30-0.33 at 260 nm. 
Samples were heated from 15 °C to 95 °C at 3 °C/min in the spectrophotometer to unfold 
the RNA. Melting transitions were obtained by repeated heating and cooling at 0.5 °C/min. 
Due to the RNA size the temperature ramp was less than 1 °C/min, which is commonly 
used for melting short duplexes (127). Superimposition of heating and cooling curves was 
used to confirm equilibrium during melting. Thermodynamic model information as well as 
information on fitting and parameter estimation are described in Appendix A. 
 
2.2.4 Pull-down assays and LC-MS/MS analysis 
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The DNA anchor was the same sequence as the SHAPE primer, modified with a 
biotin label on the 5’ end (Table A.3). ES7 RNA (1.3 µM) was annealed to 2 µM of the 
DNA anchor in melting buffer with the annealing conditions described for SHAPE 
experiments. SoftLink™ Soft Release Avidin Resin (Promega) was washed three times 
with lysis buffer [0.1% (w/v) sodium deoxycholate, 100 mM NaCl, 1 mM EDTA, 50 mM 
Tris-Cl (pH 8.0) and 1X protease inhibitor cocktail containing 1 mM AEBSF and 1.54 mM 
Aprotonin] also containing 10 U of RNAse inhibitor, 5 mg/mL of heparin (Fisher 
Scientific) and 0.5 mg/mL of yeast tRNA (Roche) at 4 °C. Posteriorly, the RNA-biotin 
assembly was shaken gently at room temperature with 10 µL of equilibrated Avidin resin 
to promote the attachment of ES7 to the resin.  
Pull-down assays were performed with S. cerevisiae cell lysates. One feature of 
these experiments that distinguishes them from conventional pull down assays is the high 
abundance of the competing rRNA within the lysate. It seems likely that intrinsic 
competition from endogenous rRNA might attenuate non-specific binding.  
A starter culture of S. cerevisiae was grown in yeast extract-peptone-dextrose 
(YPD) media overnight at 30 °C and used to inoculate a 50 mL culture. Cells were 
harvested when they reached an optical density at 600 nm (OD600) of ~1.0 by pelleting at 
770g and 4° C for 15 min. Pellets were stored at -80 °C until use. Cells were resuspended 
in lysis buffer and 0.5 mm Zirconia/Silica beads (BioSpec) were added. Cell lysis was 
performed on a Mini BeadBeater 16 (BioSpec) with three 30 sec cycles and interleaved by 
2 min of incubation on ice. Lysates were separated from beads by centrifugation at 1000g 
for 3 min, vortexed and centrifuged at 15,000g for 10 min. The supernatant was collected 
and used for pull-down experiments.   
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 To assay for non-specific protein binding to Avidin or the biotinylated DNA 
anchor, three parallel experiments were performed, that is, three samples were incubated 
with the cell lysate: 1) Avidin-biotin primer-RNA, 2) Avidin only, and 3) Avidin-biotin 
primer complex. One hundred twenty µL of cell lysate were added to each reaction and 
incubated for one hour at room temperature with end-over-end rotation. Following 
incubation, samples were transferred to 30 µm polyethylene spin columns and washed 
three times with 200 µL of lysis buffer. Digestion buffer containing 50 mM HEPES (pH 
7.5), 0.1 M urea and 5% acetonitrile was added to the samples and digestion was carried 
out overnight at 31 °C with Lys-C at a ~1:200 Lys-C:protein ratio. Flow-through digests 
were collected. Avidin beads on spin columns were washed twice with a solution 
containing 75% acetonitrile and 0.5% acetic acid, and all flow-through was collected and 
combined for each sample. Acetonitrile was removed by evaporation and the peptides were 
purified with the stage tip method (128) and dried again. Purified samples were dissolved 
in 5% acetonitrile and 1% formic acid for liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Further details on LC-MS/MS runs and data analysis are found 
in Appendix A.  
 
2.2.5 EMSA 
2.2.5.1 Cloning of aaRSs  
 The cDNA for S. cerevisiae aspartyl-tRNA synthetase (AspRS), lysil-tRNA 
synthetase (LysRS) and tyrosyl-tRNA synthetase (TysRS) was obtained from DNASU 
plasmid repository (129). Synthetase DNA was amplified by PCR to add NdeI and XhoI 
restriction sites at the 5’ and 3’ ends of the corresponding genes and cloned into pET21b 
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(Novagen) with a C-terminal 6x histidine tag. Primer sequences are described in Table A.4. 
E. coli BL21 (DE3) transformants were selected based on ampicillin resistance (50 μg/mL) 
and screened for insert by colony PCR. 
2.2.5.2 aaRSs expression and purification 
Three mL starter cultures of E.coli BL21 (DE3) transformed cells were incubated 
overnight at 37 °C with 50 μg/mL ampicillin. These cultures were used to inoculate (1% 
v/v) 100 mL cultures in a shaking incubator at 37 °C until OD600 reached 0.5 – 0.7. 
Expression was induced by addition of 0.5 mM final concentration of isopropyl β-D-1-
thiogalactopyranoside (IPTG) and cultures were incubated for 4 h at 37 °C. Cells were 
harvested by spinning at 4 °C and 3900g for 15 min. Pellets were stored at -80 °C until use. 
 Protein purification was carried out by standard immobilized metal affinity 
chromatography (IMAC). Cell pellets were resuspended in 5 mL of 50 mM sodium 
phosphate, 300 mM NaCl, and 20 mM imidazole (pH 8.0). Cell lysis was performed in ice 
water by sonication with QSonica Q125 at 50% amplitude for 30 sec nine times with 30 
sec intervals followed by centrifugation in a Sorvall RC 5Bplus centrifuge at 4 °C, 23,426g 
for 30 min. Clarified cell lysate was bound to 1 mL of Ni-NTA resin with gentle rocking 
at 4 °C for 45 min, and then purified with column chromatography. The resin was washed 
twice with five column volumes (CVs) of 50 mM sodium phosphate (pH 8.0), 300 mM 
NaCl and 50 mM imidazole. Protein was eluted with 0.5 CVs of 50 mM sodium phosphate 
(pH 8.0), 300 mM NaCl and 250 mM imidazole. Protein concentration was measured by 
BCA (130). Active fractions were concentrated and stored in 50% (v/v) glycerol. Protein 
purity and integrity was analyzed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). 
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2.2.5.3 ES7 rRNA/aaRSs interactions 
RNA-protein interactions were characterized by EMSA as described previously 
(119) with the following modifications. A 10 µM solution of ES7 RNA was prepared in 20 
mM Tris-HEPES (pH 8.0) and annealed by cooling from 90°C to 25 °C at 2°C/min. aaRSs 
were introduced at varying concentrations (0.25 µM-10 µM final) and incubated with 1 
µM of ES7 RNA (final concentration) for 20 min at room temperature. Multi-protein 
EMSA was performed with fixed RNA (4 µM) and fixed protein concentration (10 µM 
LysRS and 10 µM TyrRS) in 20 mM Tris-HEPES (pH 8.0). RNA-protein incubation was 
also performed for 20 min at room temperature. RNA-protein interactions were analyzed 
on 5% native-PAGE with 3% glycerol. Gels were visualized using a two-color fluorescent 
dye protocol in a Typhoon FLA 9500 (GE Healthcare) (131). In a two-color fluorescent 
EMSA, uncomplexed nucleic acid is green, free protein is red and the nucleic acid protein 
complexes are yellow, although slight leaking between channels of the Typhoon imager 




2.3.1 Protein binding to S. cerevisiae ES7 
 S. cerevisiae cell lysates were screened for proteins with affinity for ES7 using pull-
down assays. Mass spectrometry (MS) was used to identify ES7-associated proteins 
extracted from the lysates. During exponential growth of S. cerevisiae, 36 proteins (Table 
A.6) were seen to interact with ES7. Our assay identifies primary proteins that interact 
directly with ES7 in addition to secondary proteins that bind to the primary proteins.  
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 As an illustration of the process used here for identifying ES7-associated proteins, 
a tandem mass spectrum corresponding to a peptide from lysyl tRNA synthetase (LysRS) 
is shown in Figure A.1. We attached isolated ES7 to beads, incubated the beads with cell 
lysates, washed the beads to remove non-specific and weakly associated proteins, and 
proteolytically digested the ES7-associated proteins. The peptide ELELNFSRPWK was 
identified with an XCorr of 3.0, and a mass accuracy of -0.69 ppm. XCorr values represent 
the correlation between tandem mass spectra recorded in our experiment and the 
corresponding theoretic spectra of peptides in the database. The higher the XCorr, the 
greater the confidence in peptide identification. Similarly, mass accuracies determine the 
extent to which theoretical masses match observed masses of peptides in our experiments. 
Mass accuracies of less than 3 ppm indicate high confidence in peptide identification.  
 Many of the proteins seen here to associate with ES7 have been shown previously 
to bind to the ribosome. Of the 36 ES7-associated proteins identified here, 25 were 
identified by Link as components of intact translation complexes (132). These proteins 
include Aspartyl tRNA synthetase (AspRS), Translation Machinery-Associated Protein 10 
(TMA10), Ribosome biogenesis protein ERB1 and ATP-dependent RNA helicase MAK5. 
Of these, 12 of them were identified as mRNA-binding proteins (mRBPs) by Hentze (133). 
Nine proteins that associate with ES7 in this work were found previously to associate with 
both intact ribosomes and with mRNA (132-133). Those nine are (i) protein transport factor 
SEC1, (ii) MAK21, which is involved in maturation and export of pre-LSU particles, (iii) 
fimbrin, which is an actin-bundling protein involved in cytoskeleton organization and 
maintenance, (iv) HXK1, which catalyzes hexose phosphorylation, (v) NAD(+) salvage 
pathway component, nicotinamidase, (vi) transcription elongation factor SPT6, (vii) 
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AspRS, (viii) 40S ribosomal protein S30, and (iv) protein PBI2, inhibitor of vacuolar 
protein B. 
 Seven aminoacyl tRNA synthetases (aaRSs) were identified here in association 
with ES7. AspRS and tyrosyl tRNA synthetase (TyrRS) were found in each of the replicate 
experiments. Cumulatively Ala-, Arg-, Asn-, Asp-, Leu-, Lys- and TyrRS were observed 
in at least one experiment. Our observations are consistent with Link et al., (132) who 
observed Ala-, Asn-, Asp-, Leu- and LysRS bound to intact ribosomes. Asp-, Leu- and 
LysRS associate more tightly with the intact ribosome than AlaRS and AsnRS. The binding 
of AspRS, TyrRS and LysRS to ES7 is confirmed here by in vitro binding assays (below).  
 A total of six proteins known to localize in the nucleolus (134) are observed here 
to associate with ES7. Nucleolar proteins that associate with ES7 include (i) MAK5, (ii) 
MAK21, (iii) ERB1, (iv) Ribosome biogenesis ATPase RIX7, (v) DNA-directed RNA 
polymerase I subunit RPA49 and (vi) RNA 3'-terminal phosphate cyclase-like protein 
RCL1.  
 Clustering of ES7-associated proteins by biological process was performed using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) (135-136). 
Four clusters are highly enriched (Figure 2.3), including (i) response to abiotic stimulus 
such as temperature, (ii) ribosomal LSU biogenesis, (iii) protein transport and localization, 
and (iv) transcription elongation. For this analysis, if multiple clusters contained identical 
proteins, only the cluster with the lowest P-value was retained. The two most intense 
clusters correspond to response to abiotic stimulus (P = 5.3x10-3) and ribosomal LSU 
biogenesis (P = 1.03x10-2). Clusters with P-values lower than 0.05 are considered to be 
highly enriched and thus specifically associated with the corresponding biological process. 
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With DAVID we were unable to cluster all 36 ES7-associated proteins because the 
functional annotation for the S. cerevisiae proteome is not fully finalized in the database. 
Of the 36 ES7-associated proteins, 12 were not clustered. Six mitochondrial proteins 
observed were assumed to be artifacts and were excluded from the analysis. 
 For comparison, we clustered Hentze’s mRBPs with the same methods used here 
for ES7-associated proteins, and observed some of the same clusters. Clusters common to 
mRBPs and ES7-associated proteins include (i) response to abiotic stimulus and (ii) protein 
transport and localization. ES7-associated proteins were also clustered based on molecular 
function with DAVID (Figure 2.3). The results demonstrate that ES7-associated proteins 
are important in (i) nucleotide binding and (ii) catalytic activity. Both of these clusters are 




Figure 2.3 Clustering of S. cerevisiae ES7 RNA-proteins identified in this work: based on 
biological process and molecular function. A) Clusters were organized based on their P-
values. A greater –log(P) corresponds to higher statistical significance of a particular group 
of proteins. B) List of genes included in each cluster.   
 
2.3.2 S. cerevisiae ES7 forming complexes with tRNA synthetases in vitro 
To assess the validity of the results of the pull-down experiments, and to determine 
if some of the associations are direct or are mediated by other proteins, we selected three 
ES7-associated proteins and assayed their affinities for ES7 in vitro. The affinities of Asp-
, Lys- and TyrRS for ES7 were assayed by Electrophoretic Mobility Shift Assay (EMSA). 
The results (Figure 2.4) demonstrate that Asp-, Lys- and TyrRS bind tightly to ES7, and 
suggest that the interaction we detect is direct and not mediated by other proteins. One µM 
of rRNA and 1 µM of protein produce a single shifted rRNA band. It is probable that aaRS 
proteins bind to ES7 rRNA with 1:1 stoichiometry. Control experiments show that the 




Figure 2.4 EMSA of S. cerevisiae ES7 RNA with aaRSs. Binding of ES7 to A) AspRS, 
B) LysRS, C) TyrRS and D) LysRS and TyrRS is shown in vitro. RNA, protein and RNA-
protein complexes were visualized by two color EMSA in a native gel. Binding reactions 
for panels A-C were performed with 1 μM RNA and various concentrations of protein. 
Lane 1 contains 10 μM of protein and no RNA. Lane 2 consists of 1 μM RNA only. Lanes 
3-10 contain 1 μM RNA and increasing protein concentration: lane 3 – 0.25 μM protein, 
lane 4 – 0.50 μM, lane 5 – 1 μM, lane 6 – 2 μM, lane 7 – 4 μM, lane 8 – 6 μM, lane 9 – 8 
μM and lane 10 – 10 μM. Binding reactions for panel D were performed with 4 μM RNA 
and 10 μM of each protein. Lane 1 contains 10 μM of TyrRS, Lane 2 contains 10 μM of 
LysRS and Lane 3 contains 10 μM of TyrRS and 10 μM of LysRS, as controls. Lanes 4 – 
7 contain 4 μM RNA and various aaRSs: lane 4 – no protein, lane 5 – 10 μM TyrRS, lane 
6 – 10 μM LysRS and lane 7 – 10 μM TyrRS and 10 μM LysRS.  
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For these 1:1 complexes, gels were quantitated and dissociation constants, Kd’s, 
were estimated to be approximately 100 nM for LysRS and 1 µM for Asp- and TyrRS. The 
affinities of these aaRS proteins for ES7 are roughly equivalent to the affinities observed 
elsewhere for ribosomal proteins for cognate rRNA (137-138). Kd’s in the low micromolar 
to nanomolar ranges have been observed for ribosomal proteins uL1, uL2, uL3 and uL6 
with rRNA. 
 Multi-protein EMSA experiments do not provide evidence of simultaneous binding 
of multiple aaRSs to ES7 (Figure 2.4D, Figure A.3). LysRS and TyrRS were selected for 
this assay based on the differential migration of the free proteins in native-PAGE. A fixed 
amount of ES7 RNA was incubated with TyrRS, LysRS and a combination of TyrRS and 
LysRS. The mobilities of LysRS and TyrRS alone differ from the mobility of the ES7-
LysRS and ES7-TyrRS complexes. Incubation of ES7 simultaneously with TyrRS and 
LysRS showed at least two distinct bands that correspond to ES7-LysRS and ES7-TyrRS 
complexes. Bands suggesting the formation of additional ES-aaRS complexes could not be 
observed. The data does not support formation of the ES7-LysRS-TyrRS complex. 
 
2.3.3 Secondary structure of ES7 
SHAPE footprinting (139-140), computational folding (141) and phylogenetic data 
were used to determine the secondary structure of isolated S. cerevisiae ES7, which is seen 
to be the same as the ES7 secondary structure in the Yusupov three-dimensional structure 
(17) and the secondary structure of purified ribosomes determined by Dinman (142). 
SHAPE monitors relative reactivity of 2’-oxygens to an electrophile, indicating extent of 
local flexibility. Nucleotides in unpaired loops and bulges and in non-canonical base pairs 
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show elevated SHAPE reactivity while canonical helical regions show depressed SHAPE 
reactivity. A direct comparison of the SHAPE reactivity of isolated ES7 to that of Dinman’s 
ES7 secondary structure demonstrates that the secondary structure of isolated ES7 in vitro 
is the same as in intact ribosomes. 
SHAPE reactivities were determined for all nucleotides of isolated S. cerevisiae 
ES7 (Figure 2.5A). Nucleotides were clustered into three groups based on their SHAPE 
reactivity, after background subtraction and normalization. Positions of low SHAPE 
reactivity (<0.4) are located in helical regions in the secondary structure, whereas moderate 
and highly reactive SHAPE positions (>0.4) are concentrated in bulges, loops and RNA 





Figure 2.5 SHAPE reactivities of isolated S. cerevisiae ES7 rRNA. SHAPE reactivities 
were determined in presence of A) Na+ or B) Na+ and Mg2+. Orange or red nucleotides 
show moderate to high SHAPE reactivity. Ivory or white nucleotides show low or no 
SHAPE reactivity. C) Mg2+ induces changes in SHAPE reactivity. Nucleotides in red show 
increased reactivity in the presence of Mg2+. Nucleotides in blue show decreased reactivity. 
These figures were generated with RiboVision. All samples contained 200 mM NaOAc, 
50 mM Na-HEPES (pH 8.0). 
 
2.3.4 Tertiary structure of ES7 
Changes in SHAPE reactivity suggest that Mg2+ induces formation of tertiary 
interactions in isolated ES7. Previously, the Mg2+ dependence of SHAPE reactivity was 
determined for a variety of RNAs including tRNA (124), RNase P (123), Domain III (125) 
and the intact LSU rRNA of Thermus thermophilus (Timothy K. Lenz, Nicholas Hud and 
Loren Williams, unpublished observations). The data were interpreted to indicate 
formation of tertiary interactions upon addition of Mg2+. We have used this comparative 
method to demonstrate specific inter-domain, intra-domain and subunit folding of LSU 
rRNA caused by addition of Mg2+ (119, 125). 
SHAPE data obtained in the presence of Na+ alone (Figure 2.5A) was subtracted 
from that obtained in the presence of Na+ and Mg2+ (Figure 2.5B). The heat map obtained 
by this method (Figure 2.5C) identifies nucleotides that increase or decrease in reactivity 
upon addition of Mg2+. It can be seen that canonical helical regions are invariant to the 
addition of Mg2+, consistent with the expectation that secondary structure is maintained 
upon formation of tertiary structure. Changes in reactivity are focused on loops and non-
helical regions, which are expected to be involved in tertiary interactions. The results 




2.3.5 Thermal folding/unfolding of S. cerevisiae ES7 
Isolated ES7 is well-behaved in solution. The number of transitions in the unfolding 
process provides information on the architecture of ES7. Thermal melts show that the 
folded structure is stable at room temperature and that folding and unfolding are reversible. 
Thermodynamic parameters were obtained from the melting curves by non-linear fitting to 
a multi-state model with independent transitions (Figure A.4) (143). An estimate of the 
number of melting transitions and the thermodynamic parameters associated with these 
transitions is obtained from the melting profile, which is the derivative of the fraction 
unfolded (dϴ/dT) as a function of temperature (Figure 2.6). The best fit to the melting 
profile of ES7 was obtained with a four transition model (Figure 2.6). A three-transition 
unfolding model gives significantly worse statistics of fit. However, unfolding models with 
additional transitions cannot be excluded by the methods used here and, in fact, are 
probable for such a large RNA.  
Melting profiles were fit and deconvoluted to obtain estimates of thermodynamic 
parameters for each of the four transitions. The melting temperatures (Tm,n) of the 
transitions are Tm,1 = 51°C, Tm,2 = 64°C, Tm,3 = 75°C and Tm,4 = 83°C in 180 mM NaCl. 
The highest temperature transition has a relatively small hyperchromicity but was retained 
in the model because it is reproducible and observed in the thermal melting of isolated ES7 
rRNA from a closely related fungi (unpublished observations). In this method, uncertainty 
arises because enthalpies can correlate with hyperchromicities (143). The Tm’s are constant 
with varying RNA concentrations (unpublished observations) indicating that the transitions 
are unimolecular. Since ES7 rRNA is large and is subject to degradation, Mg2+ was 
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excluded from melting buffers to prevent in-line cleavage (144). Additional information 
on thermodynamic models and parameter estimation are provided in Appendix A. 
 
Figure 2.6 Melting profile of S. cerevisiae ES7 rRNA. The derivative of fraction unfolded 
at 260 nm with respect to temperature was computed. The derivative was fit to a non-
sequential, independent transition model with IGOR Pro. The enthalpy (ΔHn), melting 
temperature (Tm,n) and the relative hyperchromicity (An) were estimated for each transition, 




Mammals have the largest known rRNAs. Metazoans have larger rRNAs than 
protists, which have larger rRNAs that prokaryotes. We suggest that the breadth of 
ribosomal function is related to the size of the rRNA (4) and that eukaryotic ribosomes 
facilitate functions auxiliary to translation. One of the foci of rRNA expansion is ES7. By 
determining which proteins associate with ES7 we can deduce at least some of its 
contributions to function.  
At least 36 proteins in cell lysates bind here to isolated ES7 rRNA of S. cerevisiae 
directly or through intermediates. Of these ES7-associated proteins, 25 were previously 
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identified by Link in association with intact ribosomes (132). It appears we have identified 
the subset of Link’s proteins that bind to ES7 rRNA as opposed to other regions of the 
ribosome. Of these ES7-associated proteins observed here, 12 were also identified as 
mRBPs by Hentze (133). Some proteins identified here may bind at multiple sites on the 
ribosome. Six of the ES7-associated proteins reside in the nucleolus consistent with roles 
of ES7 in ribosome biogenesis (145).  
ES7-associated proteins were clustered with DAVID (135-136) into four groups 
based on biological process, (i) response to abiotic stimulus such as temperature, (ii) LSU 
biogenesis, (iii) protein transport and localization, and (iv) transcription elongation (Figure 
2.3). Clustering based on molecular function shows ES7-associated proteins are important 
in nucleotide binding and catalytic activity. 
aaRSs. aaRSs couple amino acids with their cognate tRNAs, establishing the 
relationship of nucleotide triplets with amino acids (i.e., the genetic code). Cumulatively 
seven synthetases, Ala-, Arg-, Asp-, Asn-, Leu-, Lys- and TyrRS were observed in at least 
one experiment. ES7 may be a focus of aaRS association on the ribosome. Previously, 16 
aaRSs were observed to associate with intact ribosomes in S. cerevisiae (132). ES7 may be 
an ancestor or proxy of large multi-aaRS complexes in other systems, maintaining close 
association of synthetases with each other and with the translational machinery. In S. 
cerevisiae, only two aaRSs are found in multi-synthetase complex (146). These two aaRSs 
are not observed here to associate with ES7. Half of the ES7-associated aaRSs in S. 
cerevisiae correspond with those observed previously in the human multi-aaRS complex 
(147). Yeast two-hybrid studies in archaea suggest that EF-1α associates with LeuRS and 
contributes to the overall translation efficiency by promoting aminoacylation (148). Our 
47 
work complements these findings. ES7 could act as a hub for tRNA aminoacylation and 
for improving translation efficiency.  
Affinity and specificity of AspRS, TyrRS and LysRS for ES7 were confirmed by 
in vitro binding assays. AspRS and TyrRS were observed in each of the replica experiments 
and appear to be the most robust ES7 binders. The affinities and specificities of Asp-, Lys- 
and TyrRS for ES7 were assayed by EMSA. The data suggest that these aaRS proteins bind 
to ES7 rRNA with 1:1 stoichiometry. Their affinities for ES7 are greater than for a different 
rRNA fragment (Figure A.2). The results also suggest that these three aaRSs bind directly 
to ES7 supporting the hypothesis that ES7 in S. cerevisiae might promote close association 
of aaRSs with each other and with the ribosome. Based on the direct association of ES7 to 
Asp-, Lys- and TyrRS it seems likely that additional aaRSs might bind to ES7 in vivo and 
may form stable RNA-protein complexes. Multi-protein EMSA does not provide evidence 
for simultaneous association of ES7 with multiple aaRSs. 
Observations of RNA-protein association in pull down experiments must account 
for specificity. A complex observed experimentally might not be relevant in vivo because 
of competition from other factors. Several measures were taken to control non-specific 
RNA-protein binding. For a subset of the ES7-associated proteins we have directly 
confirmed high affinities in vitro (Figures 2.4, A.2 and A.3). ES7 has 26,000 Å2 of 
accessible surface area when stripped of ribosomal proteins and 20,000 Å2 of accessible 
surface area in the assembled ribosome. Therefore ES7 provides ample surface area for 
association with non-ribosomal proteins. Considering that rRNA accounts for over 80% of 
cellular RNA (149), competition from other RNAs seems unlikely, and the proteins 
detected here must be considered highly probable ES7 binding partners in vivo.  However, 
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binding of proteins could be transient and might depend upon the stage cell cycle and on 
external cell environment. We expect that the majority of the proteins identified in this 
study are representative of the proteins that bind to ES7 in vivo during log phase, although 
we cannot exclude additional binding partners. 
Ribosomal proteins. Although some nucleolar proteins were identified, it seems 
likely that nucleoli and intact nuclei were depleted prior to the assay. None of the ES7-
associated proteins found here are ribosomal proteins. ES7 rRNA does contact multiple 
ribosomal proteins in the assembled ribosome (Figure 2.2). rProtein uL4 makes the most 
extensive contacts with ES7 in vivo, yet is not observed in our assay. It is possible that uL4 
in the cytoplasm is tied up in association with ribosomes, and that the amount of free uL4, 
not associated with assembled LSU, is sufficiently small that it cannot be detected in our 
assay. 
ES7 folding. Our footprinting and folding/unfolding experiments along with 
computational studies indicate that isolated ES7 folds to a native-like secondary structure, 
consistent with the secondary structure inferred for intact S. cerevisiae ribosomes (17, 142). 
In the presence of Mg2+, isolated ES7 forms tertiary interactions. The thermal melting 
shows that folded ES7 is highly stable and that the multistate folding/unfolding process is 
reversible. Combined, the results provide experimental confirmation of the secondary 
structure of S. cerevisiae ES7, and suggest that our experiments employed a native-like 






We hypothesize that expansion segments could be sites of functional interactions 
with other macromolecules given their proximity to the ribosome surface. ES7 is the largest 
expansion segment and the most variable region of rRNA over phylogeny. We performed 
in vitro characterization of S. cerevisiae ES7 by measuring its stability, and its interactions 
with cellular proteins. The results here support our hypothesis. Here, we demonstrate that 
Asp-, Lys- and TyrRS bind directly to S. cerevisiae ES7. aaRSs charge amino acids with 
their cognate tRNAs catalyzing the first reaction needed for protein synthesis (150). 





3ELONGATED EXPANSION SEGMENTS EXTEND THE 
CAPABILITIES OF HUMAN RIBOSOMES 
 
3.1 Introduction 
Secondary and three-dimensional structures of rRNA in the ribosomal common 
core are universally conserved in all living systems (4, 19, 22), as are mechanisms of 
mRNA decoding and aminoacyl transfer. By contrast, translation initiation, termination 
and regulation, quality control, and ribosome biogenesis are accomplished by diverse 
structures and mechanisms (111, 151-157). In many cases, variability in ribosomal function 
appears to be related to specific differences in ribosomal structure beyond the common 
core. Relative ribosomal size is a predictor of differential ribosomal function. 
The prokaryotic ribosome is a reasonable approximation of the common core. With 
a surface patchwork of rRNA and ribosomal proteins (rProteins) (16, 158), the common 
core is universal to all cytoplasmic ribosomes. Larger and more complex ribosomes are 
found in eukaryotes due to rRNA expansion segments (ESs) (2-3, 32) that emerge at the 
surface of the common core (Figure 3.1A). Eukaryotic ESs and eukaryote-specific 
rProteins encase much of the common core, forming a secondary eukaryotic rRNA–
rProtein shell (21, 159-160). Sizes and secondary structures of ES7 in various organisms 
are shown in Figure 3.1B. 
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Figure 3.1 ESs from the human ribosome are the biggest ones in nature.A) Schematic 
diagram of the human LSU, showing the relative sizes of the common core (dark green) 
and the eukaryotic shell (light green). Human ES7 (magenta) and ES27 (blue), which 
contain the longest ESs are shown. The lengths of ES7 and ES27 are correctly proportioned 
relative to the size of the common core and eukaryotic shell. Human ES7 contains two 
primary tentacles (ES7a and ES7b) which are both estimated to be ~325 Å in length (~125 
bp). Human ES27 contains two tentacles (ES27a and ES27b) which are estimated to be 
~450 Å and ~350 Å in length (ES27a, ~180 bp; ES27b, ~145 bp). This schematic is not 
intended to accurately indicate ES/tentacle conformation. B) Secondary structures of Helix 
25/ES7 from throughout the phylogenetic tree. Each of these secondary structures has been 
experimentally determined by diffraction methods or chemical footprinting.  
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In protists, ESs are important for ribosome biogenesis (115-116), rRNA processing 
and stabilization (47, 60), translation initiation (68) and recruitment of non-ribosomal 
factors such as chaperones, enzymes or signal recognition particles (69-70). ESs can be 
described as docking regions for proteins that enhance and extend ribosomal function 
(161). Previously we characterized the secondary structure and protein binding capabilities 
of ES7 of S. cerevisiae (shown in Figure 3.1B) and suggested that ES7 confers auxiliary 
functionality to the ribosome. In S. cerevisiae, ES7-associated proteins include aminoacyl 
tRNA synthetases (aaRSs), quality control proteins and chaperones.  
ESs of metazoan ribosomes contain characteristic rRNA ‘tentacles’, which are long 
unbranched helical structures that attach to the surface of the eukaryotic LSU (20, 162) 
(Figure 3.1). Tentacles are laden with defects such as bulges and mismatches. Except at 
their attachment sites, rRNA tentacles are not tightly integrated with the ribosomal surface 
and appear to be dynamic and positionally disordered. These properties preclude their 
observation by structure determination by X-ray diffraction and cryo-EM. The lengths, 
dynamics, nucleotide compositions and lack of helical branching of human rRNA tentacles 
are anomalous among known ESs. Human ESs (and its tentacles) are highly enriched in C 
and G (approximately 85% CG content). 
Here we investigate the functions of the largest ESs of the human ribosome (Figure 
3.1 and 3.2), which is the largest ribosome known in nature (4), with the longest tentacles. 
Our results reveal association with ESs of a variety of critical proteins and assemblies, 
including the ubiquitin-proteasome system (UPS). The UPS directly associates with rRNA 
ESs. The results suggest that protein synthesis in humans is physically coupled with protein 
degradation. Human ESs are also associated with a variety of other functional elements, 
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including those involved in metabolism, transcription, translation, mRNA stability and 
regulation, and cell structure.  
The distribution of ES-associated proteins appears to depend on cell line. We 
observe differences in protein-ES association in a non-carcinoma cell line and in a 
carcinoma cell line. In addition, the distribution of ES-associated proteins appears to 
depend on the identity of the ES, suggesting specific rRNA structures and sequences could 
be important determinants of protein association. We have characterized the stability, 
secondary structure and folding of isolated ES7. We note that the tentacles of ES7 contain 
putative G-quadruplex forming sequences and that in our experiments ES7 is seen to 




Figure 3.2 Human LSU rRNA with highlighted expansion segments. A) Secondary 
structure is shown. B) Three-dimensional structure with front view (SSU interface) and C) 
three-dimensional structure with back view (solvent accessible region) of the LSU are 
shown. Common core rRNA, which is contained in all cytoplasmic ribosomes, is gray. ES7 
(magenta) and ES27 (blue) are enclosed in shaded boxes. Dashed lines on the ESs in panel 
A indicate segments of tentacles that are not observed by three-dimensional structure 
determination and which are absent from panels B and C. Other ESs are shown in green. 
The images in panel B and C are upside down relative to the conventional ribosome 
representation so that they are oriented in accordance with the secondary structure in panel 
A. These images are made from PDB entry 4UG0. Ribosomal proteins are omitted for 
clarity. 
 
3.2 Materials & Methods 
3.2.1 Human ES7 and ES27 sequences 
ES7 corresponds to nucleotides (nts) 436 to 1311 of the LSU rRNA (Figure 3.2). 
ES27 corresponds to nts 2903 to 3591 (Figure 3.2). Tentacles ES27a and ES27b are 
composed of nts 2914 to 3279 (ES27a) and nts 3285 to 3582 (ES27b).  
3.2.1.1 Plasmid construction 
The genes encoding human ES7, ES27, ES27a and ES27b (Table B.1) in pUC57-
Kan resistant plasmids were purchased from Genewiz. All constructs were confirmed by 
sequencing (Eurofins MWG Operon). Each construct contains the T7 promoter and 
restriction sites for EcoRI (5’ end) and HindIII (3’ end). Once expressed, the RNA contains 
a 3’ single stranded region that acts as a primer binding site for SHAPE reverse 
transcription (RT) reactions and as a complement to a biotin-linked DNA oligomer for 
anchoring the RNA to beads in RNA-protein pull-down experiments. The appended 3’ 
single-stranded RNA, taken from Weeks (124), allowed unobstructed SHAPE mapping of 
the complete ES7 sequence. ES27 was appended to a seven nucleotide base pair clamp (5’ 
CAAGTAC 3’) designed to promote correct secondary structure at the terminus. The high 
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CG content of all the sequences used in this work makes the RNA and DNA difficult to 
manipulate via molecular biology techniques.  
Gq1ES7 and Gq2ES7 (Table B.2), which contain putative G-quadruplex forming 
sequences, were cloned into pUC19 and overexpressed as RNA. Restriction digests and 
purifications were performed by standard procedures. Restricted DNA was inserted into 
previously restricted, dephosphorylated pUC19 plasmid. 
3.2.1.2 In-vitro RNA synthesis 
RNAs were produced by transcription (HiScribe™ T7 High Yield RNA Synthesis 
Kit, New England BioLabs) as described (161). RNA purity and integrity were verified by 
8 M Urea gel in TBE buffer with 5% acrylamide for human RNAs and 12% acrylamide for 
the shorter putative G-quadruplex RNAs. 
 
3.2.2 SHAPE 
SHAPE was adapted from published protocols (118-119). In vitro-transcribed RNA 
(400 nM) in nuclease-free water was dissolved in 200 mM NaOAc, 50 mM Na-HEPES 
(pH 8.0) and 1 mM 1,2-trans-cyclohexane-N,N,N'N'-diaminetetraacetic acid or 5 mM 
Mg2+. RNAs were annealed by slow cooling from 75 °C to 25 °C at 1 °C/min. SHAPE 
reactions were conducted in 200 mM Na+ and the absence of Mg2+ for secondary structure 
determination. Tertiary interactions and divalent binding sites were characterized by 
changes on SHAPE reactivity upon addition of Mg2+. 
3.2.2.1 Benzoyl cyanide modification 
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Chemical modification of human ES7 rRNA and subsequent RNA purification 
were performed as described (161) except that benzoyl cyanide concentration was 
decreased by half (500 mM) to promote longer reads of the reverse transcriptase.  
3.2.2.2 Reverse transcription of benzoyl cyanide-modified human ES7 RNA 
Reverse transcription using [6-FAM]-labeled primers and Maxima Reverse 
Transcriptase (Thermo Fisher Scientific) provided SHAPE data on 91% of ES7. Modified 
RNA was added independently to 40 pmol of primer 1, 80 pmol of primer 2 or 60 pmol of 
primer 3 and RT buffer to yield 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 
mM DTT and 625 µM of each dNTP in 50 µL.  
Primers were annealed to modified RNA following a stepwise incubation procedure 
at 95 °C for 1 min, 60 °C for 5 min, 55 °C for 5 min and 4 °C for 10 min in a thermocycler. 
Primer sequences are shown in Table B.3. RT mixtures were pre-incubated at 52 °C for 2 
min before addition of 200 U of reverse transcriptase. RT reactions were run for 2 h at 52 
°C and were quenched by stepping the temperature to 85 °C for 5 min. Control RT reactions 
were performed in un-modified RNAs. 
RNA sequencing reactions used dideoxynucleotides (ddNTPs) with modified 
ddNTP to dNTP ratios that were established empirically to account for the high CG content 
of these rRNAs. For primer 1 the reaction ratios were 1:8 ddNTP to dNTP for guanosine 
and cytosine and 1:1 for thymidine and adenosine. For primers 2 and 3 the ratios were 1:15 
ddNTP to dNTP for G and C and 1:1 for T and A. Ten pmol of human ES7 RNA in TE 
buffer and 40 pmol of primer 1, 80 pmol of primer 2 or 60 pmol of primer 3 were used in 
sequencing reactions. Reactions lacking ddNTPs were run as controls. RT reactions were 
analyzed by capillary electrophoresis as described elsewhere (119). 
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3.2.2.3 SHAPE data processing 
SHAPE reactivities were obtained after background subtraction and normalization. 
Nucleotides were clustered by SHAPE reactivity. Unreactive nucleotides (<0.4) are 
confined to helical regions in the secondary structure. Moderately (0.4-0.8) and highly 
reactive nucleotides (>0.8) are concentrated in bulges, loops and helical defects. SHAPE 
data were processed as described (125) and were mapped onto secondary structures with 
RiboVision v.1.15 (126). 
 
3.2.3 RNA folding/unfolding 
Thermal melting of rRNA fragments was conducted by monitoring UV absorbance 
at 260 nm as temperature was varied in a thermostated Varian Cary-1E UV 
spectrophotometer. Melting solutions contained 0.3 ODs of RNA, 18 mM of monovalent 
cation (Li+, Na+, K+, Rb+ or Cs+) and 20 mM Tris-HEPES (pH 8.0). 
Samples were initially heated from 15 °C to 95 °C at 3 °C/min to unfold the RNA. 
Equilibrium folding and unfolding reactions were conducted by cooling or heating at 0.5 
°C/min. Superimposition of heating and cooling curves was used to confirm equilibrium 
during melting. A slow temperature ramp (0.5 °C/min) was used to accommodate the large 
RNA. Fitting of melting data to models was performed as described (161). The normalized 
absorbance vs. temperature data were subject to binomial smoothing before and after 
differentiation in the program IGOR Pro.   
 
3.2.4 Circular dichroism spectroscopy 
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Samples were prepared at 1 µM strand concentration in 100 mM monovalent cation 
(Li+, Na+ or K+) and 10 mM Tris-Cl (pH 7.5). Samples were annealed with a linear gradient 
from 90 °C to 25 °C at 1 °C/min in a thermocycler. CD spectra in 1 cm cuvettes were 
acquired at 20 °C on a Jasco J-810 spectropolarimeter with a Peltier temperature controller. 
Data from 200-320 nm was acquired at a rate of 100 nm/min with 1 sec response, a 
bandwidth of 4 nm, and averaged over four measurements. The buffer spectrum was 
subtracted. Smoothing was performed with the program Origin 9.1. 
 
3.2.5 Pull-down assays and LC-MS/MS analysis 
A sequence equivalent to primer 1, but linked to biotin at the 5’end, served as a 
DNA anchor (Table B.4). Ten µg of rRNA (ES7, ES27 or ES27b), appended to the RNA 
complement of the DNA anchor, were hybridized with 1.20 µg of the DNA anchor. DNA-
RNA hybridization was performed in 180 mM NaCl and 20mM Tris-HEPES (pH 8.0), 
mimicking the annealing conditions used for SHAPE RT. SoftLink™ Soft Release Avidin 
Resin (Promega) was equilibrated three times with lysis buffer [10 mM HEPES (pH 8.0), 
10 mM KCl, 1.5 mM MgCl2 and 1x protease arrest from G-Biosciences] containing 10 U 
of RNAse inhibitor, 5 mg/mL of heparin and 0.5 mg/mL of yeast tRNA (Roche) at 4 °C. 
The hybrid complex was shaken gently at room temperature with 10 µL of Avidin resin 
previously equilibrated in the lysis buffer. Attachment of RNA to beads was confirmed by 
electrophoresis. 
Pull-down experiments were performed with cell lysates from HEK293T and 
MDA-MB-231 with RNAs corresponding in sequence to human ES7, ES27 or ES27b. 
HEK293T and MDA-MB-231 were grown in Dulbecco’s Modified Eagle’s Medium, 
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supplemented with 10% fetal bovine serum and harvested at 90% confluency. Pellets were 
washed once with phosphate buffered saline and stored at -80 °C. Cells were resuspended 
in lysis buffer with 0.5 mm Zirconia/Silica beads (BioSpec) and lysed with a Mini 
BeadBeater 16 with three 30 sec cycles interleaved with 2 min on ice. Lysates were 
separated from beads by centrifugation at 1000xg for 3 min in a new micro-centrifuge tube, 
vortexed and centrifuged at 15,000xg for 10 min. Supernatants were collected and used for 
pull-down experiments. RNA-protein incubation was performed for 1 h with slow 
vortexing at room temperature. Description of controls to assess for non-specific RNA-
protein binding, protein digestion, LC-MS/MS runs and data analysis can be found 
elsewhere (161). All MS/MS spectra were searched against the UniProt Human Database 
(Homo sapiens) downloaded in February 2014. 
 
3.3 Results 
3.3.1 Pull-down assays and LC-MS/MS analysis 
Protein binding to human rRNA expansion segments 
The goal here is to characterize protein interactions of ES rRNAs in human cells. 
Cell lysates were screened to determine which proteins associate with ES7 and ES27. We 
investigated a non-carcinoma cell line (HEK293T) and a highly metastatic carcinoma cell 
line (MDA-MB-231) to determine whether protein-rRNA interactions might vary with cell 
line. The assay used here does not distinguish between primary proteins, which bind 
directly to ES rRNAs, and secondary proteins, which bind to primary proteins. Some of 
the proteins observed here in association with ESs are known to interact with each other in 
vivo suggesting secondary association in our experiments. 
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Isolated ESs, or isolated fragments of ESs, were attached to beads, incubated with 
cell lysates and washed to remove non-specific and loosely associated proteins. ES-
associated proteins were proteolytically digested and the resulting peptides identified by 
LC-MS/MS and analyzed by tandem mass spectra. Clustering of these proteins based on 
biological process and/or molecular function was performed using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID) (135-136). 
For each rRNA fragment, four replica experiments were performed with each cell 
line. The proteins detected were partitioned into Group I and II. Group I contains proteins 
observed in all four-replica experiments. Proteins in Group I are identified with the greatest 
confidence. Group II contains proteins observed in two or three of the four replica 
experiments. Group II appears to contain proteins that bind to the ESs less directly, with 
lower affinity, or more transiently, than Group I proteins. Groups associated with 
HEK293T cells are indicated with a subscript H (i.e. Group IH). Groups associated with 
MDA-MB-231 cells are indicated with a subscript M (i.e. Group IM). 
Human ESs are CG-rich. ES7 and ES27 contain sequences suggesting the 
possibility of G-quadruplex formation (see below). Therefore, proteins observed here to 
bind to human ESs were evaluated for known affinity towards G-quadruplexes.  
ES7-associated proteins 
Many important proteins bind to ES7. The ubiquitin-proteasome system (UPS), 
including the ubiquitin-proteasome complex (UPC) and ubiquitin-like proteins (UBLs) 
associate with ES7 rRNA primarily in HEK293T cells and to a lesser extent in MDA-MB-
231 cells. Proteins involved with cell-cycle regulation and division, mRNA stability and 
mRNA processing also associate with ES7 rRNA.  
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ES7-associated proteins in HEK293T cells 
Human ES7 associates with multiple members of the UPS in HEK293T cells. Nine 
of the fifteen Group IES7,H
 proteins are known to be involved in ubiquitination or 
sumoylation processes (Table B.6). Group IIES7,H contains eleven additional proteins with 
known involvement in the UPS (Table B.7).  
Group IES7,H contains three E1-like enzymes, which are SUMO-activating enzyme 
subunit 2 (SAE2), NEDD8-activating enzyme E1 regulatory subunit (ULA1) and 
Ubiquitin-like modifier-activating enzyme 5 (UBA5). This Group also contains Ubiquitin-
conjugating enzyme E2O (UBE2O), which is a hybrid between E2/E3 enzymatic activities. 
Group IES7,H contains several proteins that are known to bind to deubiquitinating enzymes 
(163). These proteins are Transcription elongation factor A protein-like 4 (TCAL4), 
Ankyrin repeat domain-containing protein 17 (ANR17) and Nucleoside diphosphate kinase 
A (NME1) (163). Group IES7,H, in addition, contains CD2 antigen cytoplasmic tail-binding 
protein 2 (CD2B2) and Neurofilament light polypeptide (NFL). CD2B2 is a protein-
binding partner for E3-ligase NEDD4 (164) and NFL interacts with E3 SUMO-protein 
ligase PIAS4 (165).  
Three Group IES7,H
 proteins are distinguished by their roles in transcriptional or 
translational regulation; these include CD2B2, ERF1, and TCAL4. Some of these proteins 
were previously identified as binding partners for ubiquitination-related processes. TCAL4 
is involved in transcriptional regulation (166), CD2B2 helps to regulate pre-mRNA 
splicing (167) and ERF1 recognizes the three in-frame stop codons in human mRNA and 
induces termination of protein biosynthesis (168). 
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Group IIES7,H (Table B.7) includes ribosomal proteins eL6 and eL33, which are 
binding partners of ES7 in the assembled ribosome in vivo. Additional members of Group 
IIES7,H include DICER, three Ras-related proteins, eukaryotic initiation factor 4E (EIF4E) 
and associated components, and Fragile X mental retardation protein (FMR1). A complex 
formed by FMR1, EIF4E and additional proteins inhibits translation ignition in neurons 
(169). FMR1 is known to bind G-quadruplexes (170-171). Only two aminoacyl tRNA 
synthetases (SerRS and AsnRS) were identified in Group IIES7,H in contrast to the previous 
observation of seven ES7-associated aaRSs in S. cerevisiae (161).  
ES7-associated proteins in MDA-MB-231 cells 
Proteins involved with the UPS appear to associate less extensively with ES7 in 
MDA-MB-231 cells in comparison to HEK293T cells. Group IES7,M contains nine proteins, 
none of which are involved in the UPS (Table B.8). Around half of Group IES7,M proteins 
are involved in mRNA stability, nucleo-cytoplasmic trafficking and mRNA decay. These 
proteins include Polyadenylate-binding protein 2 (PABP2), DnaJ homolog subfamily C 
member 8 (DNJC8), Protein quaking (QKI) and Superkiller viralicidic activity 2-like 2 
(SK2L2). Ras-related protein Rab-7a is also found within Group IES7,M. Two additional 
members of the Ras protein family are contained in Group IIES7,M.  
SAE2, ULA1, UBA5 and Phosphoglucomutase-2 (PGM2) were found in both 
Group IIES7,M and Group IES7,H. Ribosomal proteins uL13 and eL28, known binding 
partners of ES7 in the assembled ribosome in vivo, FMR1 and twelve UPSs were also 
identified in Group IIES7,M (Table B.9).  
Clustering of ES7-associated proteins 
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Clustering of ES-associated proteins was performed based on molecular function 
and biological process using DAVID (Figure 3.3). Group IES7,H shows four biological 
process clusters. These clusters are i) protein catabolic processes, ii) metabolic processes, 
iii) ribonucleoside triphosphate biosynthetic processes and iv) cellular response to stress. 
Clustering by molecular function gives only a single cluster, which is ligase.  
Group IES7,M shows three biological process clusters, i) RNA processing, ii) gene 
expression and iii) cellular process. Clustering Group IES7,M by molecular function gives 
only a single cluster, which is protein binding. As described previously (161), if an identical 




Figure 3.3 Clustering of human ES7- and ES27-associated proteins obtained from pull-
down experiments with HEK293T and MDA-MB-231 cells based on biological process 
and molecular function. Clusters are listed in order of their P-values. A greater –log(P) 
corresponds to higher statistical significance. Clustering of proteins of A) Group IES7,H, B) 
Group IES7,M, C) Group IES27,H, and D) Group IES27,M. Clusters by biological process were 




Human ES27 appears to be a hub for RNA binding proteins known to be involved 
in transcription, translation and protein folding. The interactions of ES27 with UPS 
components are attenuated compared to the UPS interactions with ES7. 
ES27-associated proteins in HEK293T cells 
 Group IES27,H contains sixteen proteins (Table B.10). Seven Group IES27,H proteins 
are related to regulation of RNA transcription and protein translation. These include RNA-
binding protein Musashi homolog 1 and 2 (MSI1H and MSI2H), putative ATP-dependent 
RNA helicase DDX11-like protein 8 (D11L8), B-cell CLL/lymphoma 9-like protein 
(BCL9L), Zinc finger CCCH-type antiviral protein 1 (ZCCHV), Phenylalanine tRNA 
ligase (SYFB) and Transcription intermediary factor 1-alpha (TIF1A). Only two Group 
IES27,H proteins are involved in the UPS. These are ubiquitin carboxyl-terminal hydrolase 7 
(UBP7) and TIF1A, which has dual functionality and is involved in both transcription and 
protein degradation (172-174). The rest of Group IES27,H
 is comprised of proteins with a 
broad array of functions in metabolism. These proteins include ADP-ribosylation factor 
GTPase-activating protein 2 (ARFG2), which plays a role in COPI vesicle formation (175) 
and Importin subunit alpha-5 (IMA5), which is involved in nucleo-cytoplasmic protein 
export (176-177). 
 Like Group IES27,H, Group IIES27,H
 contains proteins involved in cellular 
organization and RNA processing and metabolism (Table B.11). Group IIES27,H contains 
twenty UPS-associated proteins. Group IIES27,H also contains Eukaryotic translation 
initiation factor 4E transporter (4ET) and Translation initiation factor eIF-2B subunit 
gamma (EI2BG). Several translation initiation factors are also contained in Group IIES27,M 
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(below). Other proteins in Group IIES27,H
 include DICER, Ribosomal biogenesis protein 
LAS1L, two Ras-related proteins and several proteins involved in RNA splicing. 
Consistent with results with ES7 and HEK293T cells, few aaRSs were identified here 
(AlaRS, PheRS and GlyRS). FMR1 was not observed either in Group IES27,H or Group 
IIES27,H. 
Here ES27 was cleaved into two fragments, corresponding to ES27a and ES27b 
(Figure 3.1 and 3.2), each of which contains a single tentacle, in an attempt to determine 
the locus of RNA-protein interactions within ES27. However, isolated ES27a is poorly 
behaved and did not tend to fold properly. Therefore, pull-down experiments were 
conducted with ES27b only. Further information is provided in Appendix B.  
ES27-associated proteins in MDA-MB-231 cells 
Group IES27,M
 contains seven proteins (Table B.12). Two of these, Splicing factor 1 
(SF01) and protein SON (SON) are involved in pre-mRNA splicing (178-179). Other two 
proteins, Transcription factor BTF3 (180) and Eukaryotic translation initiation factor 3 
subunit J (EIF3J), are involved in transcription and translation (181). Several subunits of 
the eukaryotic translation initiation factor 3 (eIF3) complex were identified in Group 
IIES27,M, including subunits B, D and E. eIF3 is known as a binding partner for members of 
the eukaryotic translation initiation factor 4 (eIF4) complex (182). Two members of the 
eIF4 complex, eIF4E2 and eIF4G2, were identified in Group IIES27,M. Our experiments do 
not distinguish whether the binding of eIF4 to ES27 is direct or mediated through 
intermediate protein factors. Similarly, Group IIES27,M contains Eukaryotic translation 
initiation factor 2 subunit 2 (IFB2) and Eukaryotic translation initiation factor 5B (IF2P). 
Fragile X mental retardation syndrome-related protein 1 (FXR1) which associates directly 
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with FMR1 (183) also forms part of Group IIES27,M. FMR1 was identified in Group IIES7,H 
and Group IIES7,M (above).  
It has been suggested that eIF3 interacts with proteins in the proteasome core 
particle (181, 184). Ten UPS- or UBL-associated proteins are contained in Group IIES27,M 
(Table B.13). Other proteins with affinities for the UPS in Group IIES27,M include SF01, 
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRPC), Peptidyl-prolyl cis-trans 
isomerase B (PPIB) and Septin-9 (SEPT9). SAE2, ULA1 and FRX1 identified in 
association with ES7 (above) are also contained in Group IIES27,M. 
Clustering of ES27-associated proteins 
Group IES27,H and Group IES27,M (Figure 3.3C and 3.3D) failed to cluster by 
biological process due to the small number of proteins identified. Molecular function of 
HEK293T proteins yielded two clusters, i) poly-pyrimidine tract binding and ii) RNA 
binding. Clustering of MDA-MB-231 proteins yielded a single group, which is protein 
binding.     
 
3.3.2 Secondary structure of human ES7 
The secondary structure of isolated human ES7 was characterized by SHAPE 
footprinting (139-140) in conjunction with computational folding (141) and secondary 
structure homology modeling. SHAPE provides a powerful test for secondary structural 
models. Nucleotides that are paired within helices are mostly unreactive, whereas 
nucleotides in bulges, loops, mismatches and other unpaired regions are reactive (Figure 
3.4A). Ultimately, approximately 91% of nucleotides were characterized, showing SHAPE 
reactivities consistent with the secondary structure of Beckman and coworkers (19), 
67 
confirming the validity of their secondary structure model (Figure 3.4A). Metazoan ESs 
are characterized by high CG content, which pose special problems to biophysical 
characterization, including SHAPE characterization. CG-rich RNA can be difficult to 
synthesize and here required iterative rounds of primer design, synthesis and testing. 
 
3.3.3 Magnesium-dependent interactions of human ES7 
The Mg2+-dependence of the SHAPE reactivity of human ES7 suggests changes in 
conformation and molecular interactions upon addition of Mg2+ ions (Figure 3.4B). SHAPE 
reactivity in Na+ alone was subtracted from reactivity in the presence of Na+ and Mg2+. The 
resulting heat map (Figure 3.4C) indicates that helical regions are generally invariant to 
addition of Mg2+ ions. The Mg2+-dependence of the SHAPE reactivity correlates with 
locations of helical defects. Nucleotides with high intrinsic SHAPE reactivity in the 
presence of Na+ only are more likely to interact with Mg2+ ions, indicated by either 
increases or decreases in SHAPE reactivity. This pattern of Mg2+ ion dependence on 




Figure 3.4 SHAPE reactivities of isolated human ES7 rRNA. SHAPE reactivities in the 
presence of A) Na+ alone, or B) Na+ and Mg2+ are mapped onto the ES7 secondary 
structure. Orange or red indicates nucleotides with moderate to high SHAPE reactivity. 
White indicates low SHAPE reactivity. No SHAPE data could be obtained for regions in 
gray. C) Mg2+-induced changes in SHAPE reactivity mapped onto human ES7 rRNA 
secondary structure. Positions with positive values (red) indicate increased reactivity upon 
addition of Mg2+. Positions with negative values (blue) indicate decreased reactivity. 
  
3.3.4 Thermal unfolding of human ES7 
Human ES7 is extremely stable because of its high CG content. In low salt 
conditions the unfolding transition temperatures are accessible (Figure 3.5, Table B.5). The 
unfolding of human ES7 proceeds in a sequential multi-state process (Figure B.1) as 
observed previously for ES7 of S. cerevisiae (161) and other large RNAs (143, 187). 
Distinct unfolding transitions are consistent with the proposed ES7 secondary structure, 
which contains resolved secondary structural elements.  
The best fit of the human ES7 unfolding data to a melting model suggests seven 
distinct transitions (Figure 3.5) in the presence of Na+ ions. Thermodynamic parameters 
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for melting were estimated by fitting the unfolding data to a multiple state model with 
independent transitions as described previously (161, 187). Derivative plots of melting 
profiles were baseline corrected, fit to multiple melting transition models, and analyzed for 
component transitions using IGOR Pro. The most probable model is assumed to be the 
simplest model, with the fewest transitions, that yielded good fit of model to data. More 
complex folding models, with greater numbers of transitions, cannot be excluded by the 
methods used here.  
 
 
Figure 3.5 Melting profile of human ES7 rRNA. The derivative of fraction unfolded with 
respect to temperature was computed in NaCl at 260 nm. The derivative was fit to a non-
sequential, independent transition model with IGOR Pro. The enthalpy (Hn), melting 
temperature (Tm,n) and the relative hyperchromicity (An) were estimated for each transition, 
n. The observed derivative is red, the fit is dotted blue and the estimated melting 
temperature for each transition is highlighted with dotted gray lines. Data were obtained at 
18 mM NaCl and 20 mM Tris-HEPES (pH 8.0). 
 
The melting temperatures, Tm,n, (where n indicates the transition number) of ES7 at 
18 mM Na+ were estimated as 37, 50, 61, 71, 75, 79 and 85 °C (Figure 3.5). The Tm,n’s are 
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independent of RNA concentration, indicating that the unfolding is unimolecular and that 
the rRNA does not self-associate before or during the unfolding process under the 
conditions of the experiments. Superimposition of repeated RNA folding and unfolding 
curves confirms that the rRNA is effectively at equilibrium during unfolding and that the 
processes are reversible. Tm,n estimations in the presence of different ions were also 
performed (Appendix B, Figure B.2, Table B.5). In general, there is no evidence of 
monovalent ion-specific interaction with particular areas of ES7, instead there is a 
comprehensive ion-dependence in ES7 as evidenced by the complete shifting of the 
melting curves. 
 
3.3.5 Putative G-quadruplexes in human rRNA expansion segments 
The sequence of human ES7 rRNA suggests potential G-quadruplex formation. 
Two segments of ES7 contain G3+N1-7G3+N1-7G3+N1-7G3+ motifs (where N is any 
nucleotide). Probabilities of G-quadruplex formation can be estimated with QGRS Mapper 
(188), where sequences are ranked by their ‘G-score’. G-scores provide rough estimates of 
probabilities of forming G-quadruplexes based on number of possible guanine tetrads, 
length of loops, and length uniformity within loops. Higher G-scores indicate more 
probable G-quadruplex formation.  
One segment of ES7 (Gq1ES7, nts 583-652), contains ten tandem G-tracts ranging 
from three to five nucleotides. Within Gq1ES7, the sequence 5’ 
GGGGCCGGGGGUGGGGUCGGCGGGG 3’ (nts 623-647) gives a G-score of 60 and 
the sequence 5’ GGGUGCGGGGGUGGGCGGG 3’ (nts 603- 621) gives a G-score of 40. 
A second segment of ES7 (Gq2ES7) contains the sequence 5’ 
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GGGAGGGCGCGCGGGUCGGGG 3’ (nts 829- 849) which gives a G-score of 38. 
Gq1ES7 and Gq2ES7 have G-scores similar to those of established RNA G-quadruplex 
forming sequences. MT3-MMP, in the 5’-UTR of the mRNA of MMP16, and ARPC2, in 
the 5’-UTR of the mRNA of ARPC2 (189), gives a G-score of around 40. However in ES7, 
the complementary strand, which is absent in mRNAs, would probably decrease the 
possibility of G-quadruplex formation. In addition, G-quadruplexes in DNA and more so 
in RNA are complex, polymorphic and cannot be predicted with certainty. 
Experimental investigation of G-quadruplexes 
We synthesized Gq1ES7 and Gq2ES7 along with controls C1ES7 and C2ES7. C1ES7 is 
analogous to Gq1ES7 in sequence composition and length, except that the G-tracts are 
disrupted. C2ES7 is analogous to Gq2ES7, also with disrupted G-tracts. These two control 
sequences give G-scores of 0 (Table B.2). 
The CD spectra of Gq1ES7 and Gq2ES7 are similar to spectra of known RNA G-
quadruplexes (189-193). Cation dependencies of the CD spectra of Gq1ES7 and Gq2ES7 are 
also consistent with G-quadruplex formation. It is known that G-quadruplexes are 
stabilized by monovalent cations in the order K+ > Na+ > Li+ (194). Gq1ES7 gives the same 
CD spectrum in Li+ or Na+, showing a λmax at 267 nm and a λmin at 212 nm. However, in 
K+, the intensity of the Gq1ES7 maximum is increased by 15% relative to Li
+ or Na+ and 
shifts slightly to the blue to a λmax of 265 nm, whereas the intensity of the minimum 
decreases by 35% (Figure 3.6A). The amplitude of the negative band follows the order 
Li+<Na+<K+. The CD spectrum of the control, C1ES7, does not show monovalent cation 
dependence (Figure 3.6A).  
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The CD spectrum of Gq2ES7 shows a distinctive K
+ dependence that is less 
pronounced than for Gq1ES7 (Figure 3.6). Gq2ES7 shows a λmax at 266 nm in Li
+, Na+, and 
K+. This peak increases in intensity by around 14% in the presence of K+. Like that of 
C1ES7, the CD spectrum of C2ES7 does not show cation dependence (Figure 3.6B).  
We searched for additional G-quadruplex forming segments in the sequences of all 
ESs of human LSU. ES27 emerged as the only ES, besides ES7, containing putative G-
quadruplex forming sequences, with two sequences identified. Both sequences are located 
within ES27a. The sequence 5’ GGGGAGAAGGGUCGGGGCGGCAGGG 3’ (nts 3122 
to 3149) gives a G-score of 40 and the sequence 5’ 
GGGCUGGGGCGCGAAGCGGGGCUGGG 3’ (nts 2910 to 2935) gives a G-score of 37. 
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Figure 3.6 CD spectra of putative G-quadruplex forming sequences extracted from human 
ES7 rRNA in the presence of three different monovalent cations. CD spectra of A) Gq1ES7, 
which contains 10 tandem G-tracts (solid lines) and control C1ES7 (dashed lines) and B) 
Gq2ES7, which contains 4 tandem G-tracts (solid lines) and control C2ES7 (dashed lines). 




We believe that human ESs are dynamic and positionally polymorphic docking 
stations for proteins and protein assemblies. A variety of systems that enhance and extend 
translational function appear to be localized by association with ESs. 
 
3.4.1 The ubiquitin-proteasome system 
We observe that many components of the UPS associate with ES7 and ES27. The 
robustness of UPS-ESs association is underscored by observation of interactions of 
multiple UPS components with multiple ESs in multiple cell lines. UPS association with 
ESs appears modestly more extensive in HEK293T cells than in MDA-MB-231 cells. In 
general, the ES-protein associations observed here appear to be particularly reliable 
because competition with non-ES RNAs is intrinsic to these experiments. rRNA accounts 
for over 80% of cellular RNA (149) and is highly abundant during our assays. The proteins 
identified in this study survive that competition and therefore appear representative of 
proteins with affinity for ESs. However, we cannot exclude additional binding partners. 
It is known that many proteins in mammalian cells are co-translationally degraded 
during quality control. Approximately 12-15% of nascent polypeptides are co-
translationally ubiquitinated (195) and 30% of newly synthesized proteins are quickly 
degraded by the proteasome (196-197). Here we observe that the UPS is physically 
associated with the ribosome. Proteins involved in the UPS system bind to human ES7 and 
ES27 rRNA directly or through intermediates. This association suggests that an important 
function of the human ESs is to maintain proximity of the ribosome to the UPS. 
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The UPS targets proteins for degradation (198-200). Ubiquitin is activated by the 
ubiquitin-activating enzyme, E1. In the second step, ubiquitin is conjugated to a ubiquitin-
carrier enzyme or ubiquitin-conjugating enzyme, E2. In the third step, a ubiquitin-protein 
ligase, E3, catalyzes the conjugation of the protein target to ubiquitin.  
E1-like enzymes, like SAE2, ULA1 and UBA5, are shown here to associate with 
human ESs. These ubiquitin-like proteins (UBLs) share high degree of structural similarity 
with ubiquitin and are conjugated to target proteins in mechanisms similar to ubiquitination 
(201). UBLs are involved not only in protein degradation but in a variety of other functions 
(201-202). SAE2 activates SUMO 1, 2 and 3 (small ubiquitin-like modifiers). ULA1, 
which activates NEDD8 (Neural precursor cell expressed, developmentally down-
regulated 8), has high sequence similarity to ubiquitin (60% identity). UBA5 activates 
SUMO2 and ubiquitin fold-modifier-1 (UFM1) (201, 203).  
To our knowledge, there is no previous evidence for direct interactions of the UPS 
with cytoplasmic ribosomes. However, around ten percent of the UPS-proteins identified 
here, across both cell lines and RNAs, were also identified by Baltz in the mRNA-bound 
proteome in HEK293T cells (204). These proteins are exclusively ubiquitination and 
deubiquitination enzymes. UBLs and proteasome components were not identified in the 
mRNA-bound proteome.  
The interdependence and tight linkage of protein synthesis and protein degradation 
might have broad implication in disease and development. The UPS is involved in 
ribosome biogenesis and required for maturation of the 90S pre-ribosome particle (205). 
Many factors involved in proteasome maturation are also involved in ribosome biogenesis 
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and it has been suggested that participation redundancy of these factors could link these 
systems (206). 
 
3.4.2 Other ES-associated proteins 
Many additional proteins appear to associate with ES7 and ES27 in both non-
carcinomic HEK293T cells and breast cancer MDA-MB-231 cells. All of these non-ES 
specific proteins have been shown previously to be directly involved in RNA processing, 
protein synthesis, degradation or modification. These proteins (MSI1H, SAE2, ULA1, 
ZCCHV and Protein phosphatase methylesterase 1 (PPME1)) range in size but uniformly 
contain open twisted α/β domains. ZCCHV, which contains a zinc finger, is an exception. 
Additional factors might assist in regulating protein binding and positioning of human ESs. 
In HEK293T cells, ES7 and ES27 also associate with proteins involved in 
transcriptional and translational regulation. Differences in human ES7 and ES27 protein 
association are most pronounced in MDA-MB-231 cells, where proteins involved in 
mRNA stability, mRNA decay and nucleo-cytoplasmic trafficking prefer association with 
ES7, and proteins involved in pre-mRNA splicing, transcription, and translation prefer 
association with ES27.  
 
3.4.3 Folding of isolated ESs 
The results obtained for human (here) and S. cerevisiae ES7 (161) with SHAPE, 
computational folding, homology modeling and thermal melting suggest that isolated ESs 
fold to native-like structures. By analogy with ES7 we assume that isolated ES27 also folds 
to a native-like state. Our SHAPE results reinforce the role of magnesium in the folding of 
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essentially all large, complex RNAs (120, 207-208). Thermal melting shows that ES7 folds 
to a stable native state via a fully reversible process. The thermodynamic parameters of 
melting displayed mild dependence on monovalent cations (Appendix B). Previous 
experimental structures of the human ribosome do not fully capture the positions and 
orientations of the tentacle regions of the ESs. The tentacles appear to be dynamically 
disordered in solution and statically disordered during structure determination. 
 
3.4.4 G-quadruplexes 
Human rRNA tentacles contain sequences that suggest the potential to form G-
quadruplexes. These sequences possess high scores in QGRS Mapper (188), a program 
designed to predict G-quadruplexes. Experimental support for G quadruplex formation is 
seen in the K+ dependence of CD spectra of a subset of single-stranded ES fragments. 
Finally, proteins with affinity for G-quadruplexes were observed to associate with ES7. 
These proteins include FMR1 and FXR1 (170-171), which are known to associate with the 
human LSU (209). Additional proteins observed here known to bind G-quadruplexes 
include Tropomyosin alpha 4, RNA binding protein 14, EF-hand domain-containing 
protein D2, Serine/arginine-rich splicing factor 1, Serine/arginine-rich splicing factor 9, 
Heterogeneous nuclear ribonucleoproteins and ribosomal proteins uL11, uL30, uS5 and 
eS6 (189, 210). It seems possible that these proteins associate with the LSU via interactions 
with G-quadruplexes in ESs.  
Combined, the results from computation, CD spectroscopy and pull-down 
experiments suggest that human ESs could form G-quadruplexes that interact with specific 
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proteins in vivo. However, the results remain suggestive because we have not 
unequivocally demonstrated the stability of G-quadruplexes in human rRNA. 
 
3.4.5 Clustering 
DAVID (135-136) was used to cluster of ES7- and ES27-associated proteins by 
biological process and by molecular function. Among ES7-associated proteins in 
HEK293T, four clusters were detected by biological process: i) protein catabolic processes, 
ii) metabolic processes, iii) ribonucleoside triphosphate biosynthetic processes and iv) 
cellular response to stress. Ligase was the only detected molecular function cluster (Figure 
3.3A). ES7-associated proteins in MDA-MB-231 clustered by biological process to: i) 
RNA processing, ii) gene expression and iii) cellular process. Protein binding was the only 
molecular function cluster detected (Figure 3.3B). ES27-associated proteins in HEK293T 
clustered by biological process clusters to: i) poly-pyrimidine tract binding and ii) RNA 
binding (Figure 3.3C), while in MDA-MB-231, protein binding was the only cluster 
detected (Figure 3.3D).  
 
3.5 Conclusions 
In previous work we hypothesized that expansion segments could be sites of 
functional interactions with other macromolecules and used ES7 of S. cerevisiae as a model 
(161). This work expands upon that knowledge by investigating the stability and protein 
binding partners of human ESs. Here, we demonstrate that proteins associated with the 
UPS bind to human ESs. In addition, binding of UPS-associated proteins seems to depend 
on cell line, which suggest that protein binding to ESs could also depend on a variety of 
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factors, like the stage of the cell life cycle. It seems likely that ESs could have different 
functions in different organisms. The specificity in sequence and structure of human ESs 
identified unique protein binding partners not identified in yeast ESs and suggest that 
expansion segments could have different roles in protein synthesis or quality control in 












Many antibiotics bind to regions of rRNA that are universal to all organisms. This 
universal rRNA, known as the common core (21-22), contains the A site, the P site, the 
exit tunnel and the peptidyl transfer center (211). These functional centers of the ribosome 
are targeted by macrolides, aminoglycosides, tetracyclines, streptogramins, pleuromutilins, 
chloramphenicol, linezolid and puromycin. Increasing resistance to these antibiotics (212-
213) provides a compelling rationale for seeking new antibiotic targets (214).  
Eukaryotic pathogens, including various fungi, are gaining drug resistance in 
parallel with bacterial pathogens. Mortality caused by eukaryotic pathogens has been 
increasing since the 1980s (215). Unlike those of prokaryotes, eukaryotic ribosomes 
contain large amounts of species-specific rRNA in addition to the common core. 
Eukaryotic rRNA expansion segments (ESs) (3, 21, 25, 32-33, 114) are substantially 
unexplored as drug targets. ESs emerge from the surface of the common core (21) and are 
characterized by idiosyncratic structures and functions that are essential and specific to 
groups of species. ESs are important for ribosome biogenesis (115-116), rRNA processing 
and stabilization (47, 60), translation initiation and recruitment of factors such as 
chaperones, enzymes, aminoacyl tRNA synthetases (aaRSs) and signal recognition 
particles (68-70, 161).  
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Here we investigate ES7 of Candida albicans (ES7CA) as a model for eukaryotic 
drug targets. C. albicans, along with Cryptococcus neoformans, Coccidioides immitis and 
Pneumocystis jiroveci affect immunocompromised populations including AIDS and cancer 
patients, organ-transplant recipients, low-birth-weight infants and individuals with 
inherited diseases (216-217). Candidiasis is the fourth leading cause of healthcare 
associated blood infections in the US, with higher mortality rate than infections caused by 
well-known bacteria including E. coli and Enterobacter species (218). C. albicans and 
several other Candida species show resistance to antimicrobial agents such as fluconazole 
(219-220).  
ES7 of fungi averages around 210 nucleotides in length with conserved GC content 
and secondary structure (Table C.3, Figure C.1). ES7CA is 209 nucleotides with ~55% GC 
content (C. neoformans, 234 nts, ~50% GC; C. immitis, 210 nts, ~60% GC; P. jiroveci, 223 
nts, ~50% GC). By contrast, ES7 of Homo sapiens (ES7HS) is four times larger (876 nts) 
than ES7CA and is different in sequence, composition (~80% GC) and structure.  
Here we use ES7CA to investigate the general utility of ESs as targets for 
chemotherapeutic agents. We demonstrate that isolated ES7CA, like ES7 from human 
(ES7HS) (Chapter 3) and S. cerevisiae (ES7SC) (161), folds reversibly to a native state. 
Aminosugars are a class of compounds well known for their binding to the bacterial 
ribosome. An assay to screen for binding of an amino sugar library (peptidic aminosugars) 
to ES7 was developed. The affinities of peptidic aminosugar (PA) conjugates (Figure 4.1) 
for ES7CA were assessed with fluorescence displacement (FD) assays and differential 
thermal melting studies. Members of the PA library with high binding affinity for ES7CA 
were investigated further to determine the minimum inhibitory concentration (MIC) 
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needed to induce mortality on C. albicans. PAs with the lowest MIC values were tested for 
cytotoxic effects in HEK293T cells. Molecules that bind with high affinity and specificity 
to ES7CA in vitro, in comparison to ES7HS, induce mortality in C. albicans but not in 
HEK293T cells. The results are consistent with the hypothesis that ESs represent useful 
targets for development of new chemotherapeutics directed against eukaryotic pathogens.  
 
 
Figure 4.1 Affinities of a library of peptidic aminosugar (PA) conjugates for ES7CA were 
investigated by a fluorescence displacement (FD) assay. A) Generic structures of peptidic 
aminosugar conjugates. Position 1 is highlighted in blue. Position 2 is highlighted in pink. 
R1 and R2 are amino acid sidechains. B) Schematic diagram of the FD assay showing 
displacement of F-neo (green) by a competitive ligand (PA-conjugates, purple) from a three 
dimensional model of ES7CA. The yellow star indicates fluorescence.   
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4.2 Materials & Methods 
4.2.1 C. albicans and human ES7 DNA and RNA 
 The DNA encoding ES7CA, appended to the T7 promoter and restriction sites for 
EcoRI (5’ end) and HindIII (3’ end), was constructed by recursive PCR (221). The DNA 
was inserted into previously restricted, dephosphorylated pUC19 plasmid. Ligated plasmid 
was transformed into DH5α competent cells and colonies were selected based on X-gal 
Blue-White screening (Thermo Scientific). Oligomer and primer sequences used in the 
recursive PCR are shown in Tables C.1 and C.2. Oligomers, primers and DNA sequencing 
were obtained from Eurofins-MWG Operon. 
 The Weeks cassette (118) was incorporated onto the 3’ end of ES7CA with the Q5® 
Site-Directed Mutagenesis Kit (New England BioLabs) to allow chemical mapping of the 
entire ES7CA. Primer sequences are shown in Table C.4. The ES7HS coding sequence was 
constructed as described previously (in Chapter 3). ES7CA and ES7HS RNAs were 
transcribed using the HiScribe™ T7 High Yield RNA Synthesis Kit (New England 
BioLabs) as described previously (161). 
 
4.2.2 SHAPE 
Selective 2’-Hydroxyl Acylation Analyzed by Primer Extension (SHAPE) methods 
were adapted from published protocols (118-119). SHAPE monitors local nucleotide 
flexibility through reactivity of 2’ oxygens upon addition of an electrophile. Experiments 
and data analysis on ES7CA were performed as described previously (161). Data were 
collected in 200 mM Na+ and no Mg2+ to promote and analyze secondary structure 
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formation (120-122). RNA folding and long-range tertiary interactions were characterized 
in the presence of Mg2+ ions.  
Small-molecule SHAPE was performed by addition of neomycin (Neo) to the 
folding buffer without further changes to the experimental procedure. Since the hydroxyl 
groups of the neomycin ribose might compete for adduct formation with the 2’-hydroxyl 
groups in the RNA ribose, increased Neo was used (10 mM). ES7CA secondary and tertiary 
structures were studied in the presence and the absence of Neo.  
 
4.2.3 Thermal folding/unfolding 
Melting profiles for ES7CA RNAs were determined by monitoring the absorbance 
at 260 nm as a function of temperature with a thermostated Varian Cary-1E UV 
spectrophotometer. RNA was concentrated to reach an initial absorbance of 0.30-0.33. The 
melting buffer consisted of 180 mM NaCl, 20 mM Tris-HEPES (pH 8.0) and Neo at various 
concentrations. Samples were initially heated to 95 °C with a ramp of 3 °C/min. Melting 
transitions were obtained by repeated heating and cooling at 0.5 °C/min. The experimental 
temperature ramp was slower than normal (1 °C/min) because of the size of the RNA (127). 
To prevent in-line cleavage, Mg2+ was excluded from melting buffers (144). 
Superimposition of heating and cooling profiles was used to confirm equilibrium during 
melting. Thermodynamic model information as well as information on fitting and 
parameter estimation are described elsewhere (161). 
 
4.2.4 Interactions of ES7CA with small molecules 
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A 215 compound peptidic amino sugar (PA) library, containing Neo as the model 
aminosugar (222), was screened against ES7CA using a fluorescence displacement assay 
(FD) described by Watkins et al. (223). Fluorescein-neomycin (F-neo) was used as the 
reporter molecule and synthesized as described elsewhere (223).  
4.2.4.1 Kd’s of neomycin and ES7 
Binding studies of F-neo and ES7CA were performed in triplicates in binding buffer 
[50 mM NaCl, 0.4 mM EDTA, 10 mM HEPES (pH 7.0)]. F-neo concentration was 
maintained constant in a 96 well-plate (10 nM) and titrated with serial dilutions of ES7CA 
RNA (1.58E-8 M to 7.63E-12 M, 2x dilutions). Binding of F-neo to ES7HS RNA was 
performed in duplicates in binding buffer. Similarly, F-neo was maintained constant (100 
nM) and titrated with serial dilutions of ES7HS RNA (25E-8 M to 1.22E-8 M, 2x dilutions). 
F-neo excitation was carried out at 485 nm and emission was measured at 525 nm using 
the Genios Pro plate reader (Tecan). Emission of fluorescence intensity decrease with 
increasing concentration of RNA since the interaction between F-neo and RNA quench the 
emission of fluorescence. 
The stoichiometry of the F-neo-ES7 complex was determined from saturation plots. 
Kd’s were calculated from the mass balance describing the relationship between bound F-
neo, [F-neo]b, and the total concentration of F-neo, [F-neo]total, and RNA in the well, 
[RNA]total,: 
[F-neo]b
2 – [F-neo]b ([F-neo]total + [RNA]total + Kd) + [F-neo]total[RNA]total = 0 
The observed emission, I, is the combination of the emission intensities from bound F-neo, 




I = Ib [F-neo]b + If [F-neo]f 
4.2.4.2 Small molecule high throughput screening 
High throughput screening (HTS) was performed in duplicates in binding buffer 
using the FD assay (223). The PA-conjugates (1 µM final concentration) were added to the 
F-neo-ES7 complex (100 nM F-neo and 11.6 nM ES7 RNA, final concentrations), 
previously aliquoted into 96 well-plates. All plates contain two set of controls, the F-neo-
ES7 complex and the F-neo-ES7 complex with Neo added. The displacement of F-neo by 
PA-conjugates was measured by the increase in fluorescence after addition of PAs and 
compared against the fluorescence of the F-neo-ES7 complex (ΔF). The percent of 
displacement of F-neo by PAs was calculated from the change in fluorescence by the 
addition of PAs (ΔFPA) divided by the change in fluorescence obtained by the addition of 
Neo to the F-neo-ES7 complex (ΔFNeo). 
% binding = (ΔFPA/ΔFNeo) × 100 
4.2.4.3 IC50 experiments 
IC50 experiments were performed using the FD assay. The F-neo-ES7 complex was 
maintained at constant concentration (100 nM F-neo and 11.6 nM ES7 RNA, final 
concentrations) and titrated with PA-conjugates in a 96 well-plate. Curve fitting was 
performed with the sigmoid function of Igor Pro. The IC50 is given by the mid-point value 
in the x-axis obtained from the curve fitting. 
 
4.2.5 Determination of minimum inhibitory concentration 
Stocks of PA-conjugates were stored at 1 µM in purified water at -80 °C until use. 
C. albicans SC5314 was cultured in yeast extract-peptone-dextrose (YPD) agar plates at 
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30 °C for 24 h. Colonies were picked and diluted in YPD media to read an OD600 ~ 0.1. 
Eighty µL of cultivated media were aliquoted in 96-well clear flat bottom plates. Double-
fold dilutions of PAs were performed in water and 20 µL of diluted compound was added 
to each well (200, 100, 50, 25, 12.5, 6.25, 3.13, 1.57, 0.78, 0.39, 0.20 and 0.10 µM, final 
concentrations) to obtain a final volume of 100 µL per well. Controls in each plate include 
20 µL of water and 80 µL of YPD media to monitor sterility, and 20 µL of water and 80 
µL of cultivated YPD to measure standard microbial growth. All plates were continuously 
shaken at 30 °C for 24 h in a SynergyTM H4 Hybrid Multimode plate reader (Biotek). 
Absorbance at 600 nm was measured every 10 min. The percent of microbial growth was 
calculated by monitoring the change in absorbance of the culture with PA (A600,PA) 
compared with the absorbance of media only (A600,media) divided by the change in 
absorbance of the microbial culture (A600,CA) and media:  
% growth = (A600,PA-A600,media)/ (A600,CA-A600,media) × 100 
MIC values were determined after incubation of cells with PA-conjugates for 24 h and 
growth rates of ≤ 5 %. 
 
4.2.6 Cytotoxicity studies 
HEK293T cells were grown in Dulbecco’s Modified Eagle’s Medium, 
supplemented with 10% fetal bovine serum. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2. Three thousand cells were seeded in 96-well plates (100 µL total 
vol.). Cell adhesion to the plates was allowed in an initial incubation period of 24 h. PA-
conjugates were added to each well (100 µM final concentrations) and incubation was 
88 
performed for 72 h. The CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega) was used to determine cell viability. Absorbance was measured at 490 nm.  
4.2.7 Three dimensional modeling of ES7CA 
The three dimensional structure of ES7CA was generated using RNAComposer 
(http://rnacomposer.cs.put.poznan.pl) in its automated mode (224). The following user-
defined secondary structure was used as an input: 
(((((((((((......((((..((((.((((.((.....)).))))......))))..))))..((((((((((((((((.(((((((......(.((((((......((((((....
..)))))).......)))))).)....))))).))))))))))........((((...))))....)))))))).....))))))))))). Ten 3D models were 
predicted and subsequently ranked based on the final energy of the 3D structure (225). The 
best structures were evaluated for the conservation of the introduced pairing patterns 
(http://rnapdbee.cs.put.poznan.pl) and used in docking studies (226). 
 
4.3 Results 
The affinities of peptidic aminosugars (PAs) for ES7CA were assessed with FD 
assays, SHAPE and thermal melting. Members of the PA library with high affinity for 
ES7CA were further investigated to determine the minimum inhibitory concentration (MIC) 
needed to induce mortality on C. albicans. PAs with the lowest MIC values were tested for 
cytotoxic effects in HEK293T cells. 
 
4.3.1 Affinities of F-neo for ES7CA and ES7HS 
F-neo binds with high affinity and specificity to ES7CA relative to ES7HS. The extent 
of binding was estimated from changes in fluorescence of F-neo upon titration with RNA. 
The dissociation constant (Kd) for binding to ES7CA was estimated from non-linear fitting 
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of data to mass balance equations. The Kd of F-neo for ES7CA is 2.5 x 10
-9 M ± 9 x 10-10 M 
(Figure C.2A). The Kd of F-neo for ES7HS could not be accurately determined because the 
affinity is lower than the practical limits of the assay. A limiting Kd could be estimated. 
The Kd of F-neo for ES7HS is estimated to be greater than 10 µM (Figure C.2B) The affinity 
F-neo for ES7CA is 4,000 times greater than for ES7HS. By contrast Kd’s for association of 
Neo with A site RNA, its cognate binding site, were previously estimated to be 0.053 µM 
for E. coli and 0.26 µM for human (227). This difference (4-fold) is much less than the 
difference observed for association of F-neo and ES7CA versus the association of F-neo and 
ES7HS.  
The stoichiometry of binding of neomycin (Neo) to ES7CA was estimated from 
saturation binding plots of F-neo (228). Fluorescence of F-neo during ES7CA titration was 
plotted as a function of the ES7CA to F-neo molar ratio. The inflection point at ~0.077 
suggests an approximate stoichiometric ratio of Neo to ES7CA of 13:1 (Figure C.3). The 
binding stoichiometry for ES7HS could not be obtained due to the low affinity of F-neo for 
ES7HS. 
 
4.3.2 The Library 
We investigated the affinity of members of a library of PAs (222) for ES7CA using 
several methods. The library consists of mono and dipeptides linked by glutarate to Neo at 
the 5’ position of the ribose ring. The amino acid positions are numbered from the N-
terminus and are linked at their N-terminus. Some members of the PA library are mono-
peptidic, with amino acids only at position one and some are di-peptidic, with amino acids 
at positions one and two (Figure 4.1). 
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4.3.3 High throughput screening of the PA library for affinity for ES7CA 
Binding of PAs to ES7CA was estimated through high-throughput screening (HTS) 
using a FD assay (Figure 4.1 and 4.2) (222-223). In this assay, ES7CA is first incubated 
with F-neo, which is then competitively displaced by a PA. The assay allows ranking of 
members of the PA library, and is normalized so that F-neo displacement by Neo equals 
100%. PAs with displacements greater than 100% bind to ES7CA with greater affinity than 
Neo. PAs with displacements less than 100% bind with less affinity than Neo. Sixty three 
compounds from the PA library showed greater affinity than Neo for ES7CA in the HTS 




Figure 4.2 Ranking of the PA-conjugates by their tendency to displace F-neo from ES7CA 
relative to displacement of F-neo by Neo. The 20 molecules that most effectively displace 
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F-neo are shown here. Each experiment was performed in duplicate. Standard deviation for 
each compound is shown with error bars. 
4.3.4 IC50 measurements of affinity for ES7CA  
IC50 measurements of PA binding with ES7CA were used to validate selected HTS 
results. IC50 experiments were performed with three compounds from the top five HTS 
binders (Figure 4.3). In the IC50 assay, complexes of F-neo and ES7CA were titrated with 
PA-conjugates and displacement of F-neo was monitored at various ratios of PA to ES7CA. 
In comparison to Neo, binding affinities are 2.2-fold greater for NeoRH, 1.5-fold greater 
for NeoYH and 1.3-fold greater for NeoFN. IC50 measurements confirm the high affinity 
of these molecules for ES7CA. In contrast to HTS, IC50 experiments demonstrate that 
NeoRH is a better binder than NeoFN.  
 
 
Figure 4.3 IC50 measurements of PA-conjugates. Several PA-conjugates displayed higher 
affinity than Neo towards ES7CA RNA. Titration of ES7 was performed with A) Neo, B) 
NeoFN, C) NeoRH and D) NeoYH and F-neo displacement was monitored. Measured IC50 
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values are estimated as: Neo = 393 ± 15 nM, NeoFN = 296 ± 24 nM, NeoRH = 181 ± 6 
nM and NeoYH = 256 ± 18 nM. 
 
4.3.5 Determination of minimum inhibitory concentration 
Minimum inhibitory concentration (MIC) values, which quantitate inhibition of 
microbial growth, are consistent with the results of a single-dose assay (Table 4.1). 
Inhibition of microbial growth by PA compounds was initially assessed through a single-
dose assay. The ten strongest binders identified in HTS (above) were tested at 200 µM for 
inhibition of growth of C. albicans. All the PA-conjugates except NeoRD and NeoPN 
inhibited C. albicans growth at these conditions.  
 MIC studies were performed on PA-conjugates that showed activity in single dose 
assays. In this work MIC values were defined as the lowest concentration of compound 
that inhibit microbial growth by 95% after 24 h. NeoFH, NeoRH and NeoYH exhibited 
MICs of 100 µM, which are the lowest MIC values obtained from our assays. Most 
compounds from the PA library have MICs of 200 µM; these compounds include NeoFN, 
NeoLN, NeoCN, NeoCF, and NeoCP. Neo, without any amino acid conjugation, NeoPN 
and NeoRD have a MICs higher than 200 µM. After 24 h of incubation at 200 µM, none 
of these compounds inhibit microbial growth. Preliminary experiments performed in our 
laboratory (unpublished observations) indicated that Neo have a MIC greater than 5mM in 
C. albicans. 
 Fluconazole is a standard treatment against fungal infections. MIC values for 
fluconazole were determined at our experimental conditions and at experimental conditions 
used by others in YPD media with the same strain of C. albicans (229). The results obtained 
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here are in general agreement with those obtained by Vasicek et al. Most PA-conjugates 
exhibit MIC values that are lower than fluconazole. 
 
Table 4.1 Minimal inhibitory concentration (MIC) values determined in YPD at 30 °C for 
24 h. MIC values were defined as the lowest concentration of compound that inhibit 
microbial growth by 95%. 
Name PA No. C. albicans 
Neo --- >200 
NeoPN 1151 >200 
NeoFN 1150 200 
NeoLN 1149 200 
NeoYH 1182 100 
NeoRH 1173 100 
NeoCF 1212 200 
NeoRD 1159 >200 
NeoCN 1156 200 
NeoCP 1226 200 
NeoFH 1178 100 
Fluconazole --- >200 
 
4.3.6 Cytotoxicity assays 
 Cytotoxicity studies reveal that PA-conjugates are not lethal to human cells (Figure 
4.4). Neo, NeoRH, NeoFH and NeoYH at 100 µM were incubated with HEK293T cells 
for 72 h. These concentrations were set at the MIC values obtained in this work. The results 
indicate a survival rate of more than 69% for all PA-conjugates and for Neo. Useful 




Figure 4.4 Cytotoxicity studies performed with PA-conjugates in human cells. PAs were 
incubated with HEK293T cells for 72 h at 100 µM. Structures of PAs used in this study, 
A) NeoRH, B) NeoFH and C) NeoYH are shown. D) Cell viability is reported in 
comparison to the viability of PA-free cells. 
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4.3.7 General trends in mono- and di-peptide composition  
The HTS results suggest that ten of the twenty best binders in the PA library contain 
aromatic amino acids. The HTS results suggest that single amino acid conjugates exhibiting 
higher affinity than Neo for ES7CA (NeoS, NeoC and NeoN) contain amino acids that are 
polar and uncharged, including serine, cysteine and asparagine (Figure 4.2). An exception 
to this is NeoβA, which contains a non-polar amino acid. Single amino acid conjugates 
NeoD and NeoP show the lowest affinity for ES7CA, displacing F-neo at 68% under our 
experimental conditions (Figure C.4). The observed low displacement by NeoD is expected 
since RNA is negatively charged.   
 Double amino acid conjugates with positively charged and polar amino acids, 
including PAs containing asparagine, histidine or cysteine at either the first or second 
position, exhibit higher affinities for ES7CA. NeoPN displays the highest affinity for ES7CA 
with 140% displacement, followed by NeoFN with 139% displacement, and NeoLN and 
NeoYH with 132% of displacement. The conjugation of two positive charges to the PA-
conjugates does not seem to enhance the binding to ES7CA (Figure C.4). Three of the ten 
worst binders contain an aspartic acid in the first position. Conjugation to a tryptophan is 
also detrimental for binding to ES7CA; seven of the ten worst binders belong to this 
category. The worst binding double amino acid conjugates contain negatively charged or 
bulky amino acids. 
 IC50 results are generally consistent with the HTS results. IC50 results obtained with 
double amino acid conjugates confirm that binding to ES7CA is strengthened when the Neo 
scaffold is conjugated to positively charged and polar amino acids. IC50 results also suggest 
that conjugation to amino acids with smaller aromatic systems and greater hydrogen 
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bonding capabilities can improve the affinity towards ES7CA. Of all the conjugates tested, 
NeoRH displays the greatest affinity. This PA contains the smallest aromatic system and 
the most hydrogen donors/acceptors of the three PAs tested for IC50.   
MIC experiments suggest that the second amino acid position is important for PA 
activity in vivo. Compounds conjugated to a histidine in the second amino acid position 
exhibit the lowest MICs. Overall, the amino acids conjugated at this position follow a well-
defined pattern; most of them are polar, with hydrogen bonding capabilities. NeoRD is an 
exception and exhibited higher values of MIC. Histidine is the smallest aromatic amino 
acid and possesses two sites available for hydrogen bonding. It seems likely that a 
combination of geometry and hydrogen bonding capabilities at the second amino acid 
position offer adequate interactions within the PA-ES7CA complex in vivo. No specific 
contribution could be deduced for the first amino acid position, as no definite trend is 
observed. Based on the results this position could have less of an impact in MIC 
determination.  
  
4.3.8 Secondary structure of ES7CA  
Isolated ES7CA folds to a native-like secondary structure in the presence of Na
+, 
with four primary helices (ES7a, ES7b and ES7c and Helix 25, Figure 4.5). The secondary 
structure of isolated ES7CA was determined by SHAPE footprinting (140), computational 
folding (141) and secondary structure homology modeling. As shown in Figure 4.5A, 




Figure 4.5 SHAPE reactivities of ES7CA. A) SHAPE reactivities mapped onto the ES7CA 
secondary structure confirm the correctness of secondary structural model of ES7CA in the 
presence of Na+ alone. Helical regions are unreactive (white) while loops and bulges are 
reactive (red). B) Addition of Mg2+ does not disrupt secondary structure. C) A delta map 
(Δ), showing changes in reactivity upon addition of Mg2+ indicating Mg+-induced changes 
in the structure of ES7CA. Nucleotides with positive values (red) indicate higher reactivity 
upon addition of Mg2+. Nucleotides with negative values (blue) indicate decreased 
reactivity upon addition of Mg2+. All samples contained 200 mM NaOAc, 50 mM Na-
HEPES (pH 8.0). Data were mapped and figures generated with the program RiboVision 
(126).  
 
4.3.9 ΔMg2+ heat maps of ES7CA  
The structure of isolated ES7CA changes upon addition of Mg
2+. SHAPE reactivity 
obtained in the presence of Na+ alone (Figure 4.5A) was subtracted from the SHAPE 
reactivity obtained in the presence of both Na+ and Mg2+ (Figure 4.5B) to give a ΔMg2+ 
heat map (Figure 4.5C). The ΔMg2+ heat map identifies nucleotides that exhibit Mg2+-
dependence of SHAPE reactivity, which can either increase or decrease. Helical regions 
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are invariant to Mg2+ (white on the ΔMg2+ heat map) as expected (120, 122), indicating 
that secondary structure forms in the presence of Na+ alone and is maintained upon Mg2+ 
addition. Mg2+-specific changes in SHAPE reactivity are focused in bulges, loops and non-
helical regions. It seems probable that these nucleotides are involved in long-range 
interactions in the native state, which are favored by the addition of Mg2+ (120, 122). This 
work provides the first structural data on any rRNA of C. albicans. 
Comparison of SHAPE data obtained for ES7CA (Figure 4.4) and ES7SC (161) show 
that ES7 of these fungi share similar secondary and tertiary structures. Our SHAPE data 
obtained previously for isolated ES7SC matches the predicted models of the ES7SC 
secondary structure (161) and the SHAPE reactivity of the ES7SC of the assembled S. 
cerevisiae ribosome (142). ES7 for both organisms consist of four helices and a main 
junction where Helices ES7a, ES7c and 25 are joined. This junction is the region of greatest 
changes in SHAPE upon addition of Mg2+. Many of the bulges and helical mismatches 
show changes in SHAPE upon addition of Mg2+. The loops and mismatches are conserved 




4.3.10 ΔNeo heat maps of ES7CA  
Neo binds to ES7CA with high stoichiometry, as indicated by binding assays (see 
above) and is therefore assumed to occupy multiple binding sites on ES7CA. SHAPE 
reactivity obtained in the presence of saturating Neo was subtracted from the SHAPE 
reactivity obtained in the absence of Neo to give a ΔNeo heat map (Figure 4.6). We have 
obtained ΔNeo heat maps in the presence and absence of Mg2+. These data, obtained under 
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saturating Neo, do not allow determination of differential affinities of the multiple Neo 
binding sites. 
ΔNeo heat maps in both the presence and absence of Mg2+ (Figure 4.6) show that 
Neo dependent-changes are broadly distributed throughout ES7CA. This distribution is 
consistent with Neo association at multiple binding sites.  Nucleotides located in the main 
junction, helical loops, single-stranded and mismatch regions exhibit the most intense 
signals in both ΔNeo heat maps. The locations of Neo-dependent changes in SHAPE 
reactivity are consistent with greater affinity of Neo for non-canonical secondary structure 
(230-234). Similarities in the ΔNeo heat maps obtained in the absence and presence of 
Mg2+ shows that binding is not substantially altered by formation of tertiary structure. Mg2+ 
does not appear to compete with Neo and it is not required for Neo binding to ES7 (Figure 
4.6A and 4.6B). 
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Figure 4.6 Delta maps exhibiting the changes in SHAPE reactivity of ES7CA upon addition 
of Neo. A) in Na+ only and B) in Na+/Mg2+. C) Docking of Neo (green) on a three-
dimensional model of ES7CA. Data from panel B is mapped onto the three-dimensional 
structure of ES7CA. Nucleotides with positive values (red) indicate higher reactivity in the 
presence of Neo. Nucleotides with negative values (blue) indicate less reactivity with Neo. 
The experimental conditions and data analysis are the same as in Figure 4.5. 
 
4.3.11 Thermal folding/unfolding of ES7CA 
 Isolated ES7CA is well-behaved in solution. As temperature changes, ES7CA folds 
and unfolds reversibly in multi-state processes. The number of melting transitions of ES7CA 
were estimated, along with the Tm’s and thermodynamic parameters, from non-linear 
fitting of observed melting profiles to predictions of a multi-state model with independent 
transitions (Figure 4.7) (143). Thermodynamic parameters were estimated previously for 
ES7SC (161) and ES7HS (Chapter 3). Melting profiles are plots of the derivative of the 
fraction unfolded (dϴ/dT) versus temperature.  
The unfolding of ES7CA is similar to that of ES7SC (161). The best fits for both these 
fungal ESs were obtained with four transition models. For ES7CA in 180 mM NaCl, the 
melting temperatures of the four unfolding transitions (Tm,n) are Tm,1 = 52 °C, Tm,2 = 59 °C, 
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Tm,3 = 68 °C and Tm,4 = 78 °C. Under the same conditions, Tm,1 is the same for ES7CA and 
ES7SC. However, Tm,2 Tm,3, and Tm,4 for ES7CA are around ~ 5 °C less than the 
corresponding Tm’s of ES7SC. The results suggest that ES7CA is less stable than ES7SC. As 
observed for ES7SC, the Tm’s of ES7CA are constant with varying RNA concentrations 
indicating that the transitions are unimolecular. 
 
 
Figure 4.7 Melting profile of ES7CA rRNA. The derivative of the fraction unfolded with 
respect to temperature was computed at 260 nm. The profile was fit to a non-sequential, 
independent transition model, with four transitions with the program Igor Pro. The enthalpy 
(ΔHn), melting temperature (Tm,n) and the relative hyperchromicity (An) were estimated for 
each transition, n. The observed profile is red, the fit is dotted blue and the deconvolution 
of the fit is dashed blue. 
 
Neo stabilizes ES7CA. Melting profiles for ES7CA were obtained at five molar ratios 
of Neo to ES7CA (0 µM Neo, 2.78 µM, 27.8 µM, 139 µM, and 278 µM, at constant 278 
nM ES7CA). The overall stability of ES7CA increases with increasing concentration of Neo 
as indicated by monotonic changes in all four Tm,n’s (Figure 4.8). The results are consistent 
with a model (above) in which Neo binds to ES7CA at broadly distributed sites. It appears 
that Neo binds to both native and partially unfolded intermediates. Additional information 




Figure 4.8 Melting profiles of ES7CA in the presence of Neo. A) The derivative of the 
fraction unfolded with respect to temperature at 260nm reveals four transitions. Each 
transition is indicated with a number at the top of the melting profiles. Increased Neo causes 
the Tm,n to increase. B) Changes in melting temperatures (Tm,n) for ES7CA at increased 
concentrations of Neo for each transition. Each transition is indicated with a number.  
 
4.4 Discussion 
Ribosomes are primary targets for antibacterial agents (235) but thus far, have not 
proven to be useful targets for drugs against pathogenic fungi. Fungal ribosomes are poor 
targets in part because of acute similarities in sequence and structure between fungal and 
human ribosomes in the A site, P site, exit tunnel and peptidyl transfer center regions. 
Instead, chemotherapeutics target fungal cell walls, membranes, and nucleotide 
biosynthetic pathways (90, 236). The diversity of RNA function, which has been only 
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recently understood, suggests that small molecule binding to RNA may provide new 
avenues to useful therapeutics (237). Targets have emerged including ribozymes, 
riboswitches (238), microRNAs (239) and RNA promoters (240). 
Human and fungal ESs are highly divergent, and therefore fungal ESs are inviting 
drug targets. Our goal is to determine if ES rRNAs can be developed as useful targets for 
chemotherapeutics directed at eukaryotic pathogens. Fungal translation can be targeted 
with specificity as evidenced by the activity of Sordarins, which inhibit ribosomal 
translation in fungi by interacting with elongation factor 2 (EF-2) (103).  
Aminoglycosides such as Neo are useful lead compounds for a discovery process 
for targeting fungal ribosomes. Aminoglycosides bind to rRNA and are active against 
gram-positive and gram-negative bacteria (241). In bacteria, Neo associates with the A site 
decoding region of 16S rRNA, inducing changes in mRNA-tRNA conformation leading to 
amino acid misincorporation in the nascent protein (242-243). Aminoglycoside-induced 
mistranslation is thought to promote protein misfolding and cell death (244-245). 
Here we show that Neo binds tightly and selectively to ES7CA in vitro. The Kd of 
F-neo for ES7CA is in the low nanomolar range, similar to the Kd of Neo for the bacterial A 
site (246). Neo appears to be specific for C. albicans ribosomes over human ribosomes. F-
neo binds to ES7CA with 4000x higher affinity than to ES7HS. ES7CA and ES7HS share low 
similarity in sequence, size and structure. ES7HS is four-times larger than ES7CA with 30% 
greater GC content.  
 High throughput screening of a 215 member PA library (Figure 4.1, Figure C.4) 
reveals sixty three compounds that bind with greater affinity than Neo to ES7CA. This 
library was previously screened for antibacterial activity in gram-negative and gram-
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positive bacteria and for binding to E. coli A site rRNA (222). PA compounds in which 
polar and positively charged amino acids are conjugated at the second position (Figure 4.2, 
Figure C.4) exhibit the greatest affinity for ES7CA. NeoFH and NeoYH have lower IC50 
values than Neo and NeoFN. MIC values were determined for the ten best ES7CA binders 
from the HTS using C. albicans. NeoFH, NeoRH and NeoYH exhibited the lowest MIC 
values (100 µM). Our results suggest that the geometry and hydrogen bonding capabilities 
of the second amino acid position are important for binding and antifungal activities. PA 
compounds with histidine at the second position exhibit the lowest IC50 values and MIC 
values. 
Thermal melting, SHAPE and binding experiments suggest that ES7CA has multiple 
binding sites for Neo. Saturation plots suggest that there are ~13 binding sites for Neo in 
ES7. Neo is known to interact with various rRNA structures including hairpins (230-231), 
internal bulges (231), single-stranded RNA (232), telomeric DNA (247), DNA triple 
helices (234, 248-250), RNA triple helices (233-234) and DNA-RNA hybrid helices (233). 
Neo-RNA recognition is generally mediated by structure and not by sequence. SHAPE 
experiments suggest that Neo binds predominantly to internal loops, hairpins, single-strand 
regions and mismatches of ES7CA.  
The results here are consistent with a model in which ES7CA is a target for certain 
PA-conjugates. This model is supported with tight binding to ES7CA in vitro and with the 
MIC results. Binding of PA-compounds to ES7CA in vivo might disrupt core ribosomal 
function or could disturb interactions with non-ribosomal proteins that are essential for cell 
viability (161). In sum, ESs appear to be reasonable targets for future drug target studies. 
ESs may emerge as useful new targets for anti-microbials. 
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It seems unlikely that Neo or PA-compounds bind to the C. albicans A site, which 
is very similar in sequence and structure to the human A site (Figure C.6). It has been 
shown by Arya that Neo binds with very low affinity to the human A site (222). Our 
cytotoxicity studies here suggest that PA-conjugates are non-toxic to human cells. 
 
4.5 Conclusions  
Isolated ES7CA is stable, folds autonomously and adopts a near-native state. PA-
conjugates bind with high affinity and selectivity to ES7CA. Moreover, PA-conjugates with 
high affinity for ES7CA induce mortality on C. albicans but not in HEK293T cells. 
Additional experiments are required to confirm that the mechanism of mortality in C. 




5RECOMMENDATIONS AND CONCLUSIONS 
 
5.1 Recommendations 
5.1.1 In vivo identification of ES-associated proteins 
RNA-protein pull-down experiments provided evidence for the interaction of ESs 
with non-ribosomal proteins/protein assemblies. As stated in Chapter 2 and Chapter 3 our 
experimental procedure identified primary and secondary proteins. The identification of 
multiple complexes essential to cell viability (i.e. ubiquitin-proteasome system and eIF-
complexes) was facilitated by the experimental setup used in our work. However, in order 
to better understand the functions of ESs within the cell and its associations with proteins, 
in vivo experiments will be required.  
Recent development of fluorescent RNA aptamers like Spinach (251) and Broccoli 
(252) could help to determine the fate of RNAs in vivo. Gene constructs that include the 
covalent attachment of fluorescent aptamers to ESs will provide real-time monitoring of 
the fate of ESs inside the cells through confocal microscopy. Moreover, previously 
identified ES-associated proteins (i.e. identified via pull-down experiments) could also be 
fused with fluorescent proteins, like m-cherry and m-strawberry (253), which will open up 
the possibility of simultaneous RNA-protein visualization upon transfection of constructs 
to human cells. The RNA will be observed as green, the proteins in red and the region of 
co-localization will be observed as yellow. Monitoring of ES-protein interactions in vivo 




Figure 5.1 Schematic diagram of human ES7 attached to the SHAPE primer-linker region 
and the broccoli aptamer. Human ES7 secondary structure is shown. The SHAPE primer-
linker region taken from Weeks (124) consist of two regions: the RT primer binding site 
(orange) and the 3’ linker (dark blue). The broccoli aptamer is shown in green and should 
be inserted at locations where it does not disturb the RNA structure (i.e. 5’ or 3’ terminus). 
Aptamer incorporation at the Weeks region ensure that secondary- and three-dimensional 
structures determined by SHAPE are maintained upon transfection.   
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5.1.2 Post-transcriptional modifications of ESs 
rRNAs are subjected to many post-transcriptional modifications, including 
methylation and pseudouridylation (254-255). Post-transcriptional modifications in E.coli 
(256) and Thermus thermophilus (257) are clustered in regions of functional importance in 
the ribosome, with high levels of nucleotide conservation and lacking contacts with 
rProteins. Over 100 modifications have been found in vertebrate 28S cytoplasmic rRNA 
(258), mainly in the common core region.  
ESs rRNAs used in this work were transcribed in vitro and therefore lack naturally-
occurring post-transcriptional modifications. Although several studies (reviewed by 
Maden et al.) do not support the existence of post-transcriptional modifications in ESs, it 
will be important to confirm their presence or absence in ES rRNAs with current 
experimental techniques. Existence of post-transcriptional modifications can alter the 
RNA-protein interactions identified in pull-down experiments and it will be important to 
investigate alternative functions of ESs that could be attributed to these modifications, if 
any. 
 
5.1.3 Confirmation of G-quadruplexes in human rRNAs 
G-quadruplexes are located on telomeric DNAs (259-260), DNA promoter regions 
(261-262) and mRNAs (193, 263). Numerous putative G-quadruplex sequences have been 
identified in the human genome (264-265), but none of them correspond to sequences of 
ribosomal genes. Chapter 3 describes multiple, putative G-quadruplex sequences in human 
rRNA, which are clustered in ES7 and ES27. Gq1ES7 and Gq2ES7 sequences, from ES7, 
were studied via CD experiments and the results suggest G-quadruplex formation in human 
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rRNA. Further research in this field is essential to confirm the existence of G-quadruplexes 
in human rDNA or rRNA.  
Balasubramanian et al. visualized DNA and RNA G-quadruplexes in the cytoplasm 
of human cells using the BG4 antibody (266-267). Identification of BG4 as a selective G-
quadruplex binder expands the repertoire of experiments that can be performed for G-
quadruplex identification. Binding curves to measure the affinity of BG4 for G-
quadruplexes can be acquired with ELISA for all putative G-quadruplex sequences and 
their respective controls. EMSA experiments performed with ESs and BG4 along with CD 
experiments will also assess the formation of in vitro G-quadruplexes.  
In vivo confirmation of G-quadruplexes in human rRNA is necessary to assess the 
validity of in vitro assays. Co-transfection of human cells with a plasmid encoding human 
ES7/ES27 rRNA and BG4 will allow visualization of human rRNA G-quadruplexes in 
cells, if formed, through confocal microscopy. Recently, RNA foot printing techniques 
have also been used to detect and map RNA G-quadruplexes (268-269). Both techniques 
aim to identify G-quadruplexes in functional conditions and represent alternative methods 
for in vivo/functional G-quadruplex identification. 
 Preliminary NMR experiments are being performed by our collaborator Dr. Janez 
Plavec on ES7 putative G-quadruplex sequences and its respective controls to confirm or 
discard G-quadruplex formation. Existence of G-quadruplexes in human ribosomes will be 
of high impact to the RNA field as the specific roles of these structures are not completely 
elucidated, and they have not been identified in rRNA. 
 
5.1.4 Validation of expansion segments as antimicrobial targets 
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Successful discovery of antimicrobials requires both, good targets and good 
libraries of compounds (270). Good targets are essential to the pathogenic organism, 
possess remarkable selectivity, prevent or stop pathogenic growth, and insofar as possible 
promote the development of broad-spectrum antimicrobials. ES7 of pathogenic C. 
albicans, C. neoformans, C. immitis and P. jiroveci, share sequence and structural 
similarities among themselves but differ significantly, in sequence and structure, from ES7 




Figure 5.2 SHAPE reactivities of C. immitis, C. neoformans and P. jiroveci. SHAPE 
reactivities are mapped onto I. C. immitis, II. C. neoformans and III. P. jiroveci ES7 rRNA 
secondary structures. SHAPE reactivities were determined in presence of A) Na+ or B) Na+ 
and Mg2+. Orange or red nucleotides show moderate to high SHAPE reactivity. Ivory or 
white nucleotides show low or no SHAPE reactivity. C) Mg2+ induces changes in SHAPE 
reactivity. Nucleotides in red show increased reactivity in the presence of Mg2+. 
Nucleotides in blue show decreased reactivity. These figures were generated with 
RiboVision. All samples contained 200 mM NaOAc, 50 mM Na-HEPES (pH 8.0). 
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Chapter 4 discusses the HTS of a peptidic aminosugar library of compounds for its 
affinity to ES7CA. Although binding data correlates with MIC calculations, the relationship 
between binding to ES7 and pathogen mortality has yet to be understood. Neomycin targets 
the A site in the SSU of bacteria with good selectivity (242). However, the similarity 
between A sites in eukaryotic species is remarkable (Figure C.6) and it does not represent 
a good target for antifungals. There is no difference between the A sites of C. albicans and 
human ribosomes. It therefore seems unlikely to consider that binding of PA-conjugates to 
the A site of C. albicans will induce mortality on these organisms, but not in human cells. 
Our results suggest that binding of PA-conjugates to ES7 interferes with vital functions of 
the cell, but more studies will have to be performed to fully understand how it does so.  
 Chapter 4 of this thesis described work performed using only C. albicans and ES7 
as test models. It will valuable to investigate if the binding results obtained with ES7CA 
extend to other ES7 of pathogenic fungi including, C. neoformans, C. immitis and P. 
jiroveci and if it will produce similar mortality rates. Further research into the binding and 
selectivity of small molecules to other ESs of pathogenic organisms will provide 




This work investigates the role of various ESs within the ribosome, and therefore, 
its importance for the appropriate functioning of cells. Among the variety of ESs present 
in rRNA, ES7 was chosen as a model of study since it is the largest ES on the LSU, and 
the largest ES on the assembled ribosome. As shown throughout this work, ESs maintain 
their structural conformation in isolation (i.e. in the absence of the complete ribosomal 
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machinery). Thermal denaturation experiments demonstrated that ESs are stable, 
autonomously folded, and contain multiple sub-domains.  
 RNA-protein pull-down experiments demonstrated that ES7 of S. cerevisiae bind 
multiple non-ribosomal proteins, including class I and class II aaRSs, nucleolar, and 
metabolic proteins. Pull-down experiments performed with human ES7 and ES27 indicate 
that multiple non-ribosomal proteins also bind to human ESs. Proteins related with the UPS 
seem to be in association with human ESs. Combined, these results suggest that ESs could 
play important roles in protein synthesis and degradation. 
 Experiments with ES7 of C. albicans suggest that ESs could have potential as 
targets for antimicrobials. Neomycin bind tightly to ES7CA, but showed low affinity 
towards ES7HS. High-throughput screening of PA-conjugates identified several lead 
molecules. Lead molecules showed improved binding for ES7CA and lower MIC values, in 
comparison to Neo. These molecules can be further developed to induce higher mortality 
rates in pathogenic microorganisms. 
 Future steps in the study of ESs should focus on: i) conducting in vivo experiments 
to investigate the nature of the interactions of ESs with cellular proteins (steady vs. 
transient), and how these interactions vary at different stages of the cell cycle, ii) 
understanding the functions of ESs in different organisms and among themselves, and iii) 
studying the correlation (i.e mechanism of action) of small molecule-ES interactions on 
pathogenic mortality. The work presented here provided evidence that ESs are an important 
component of the ribosome assembly, and set the path for more investigations in this field. 
Due to the increasing rate of resistance of fungal pathogens to commonly used 
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antimicrobials and the potential role of these rRNAs in therapeutic treatments further 












SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
A.1 MATERIALS AND METHODS 
A.1.1 PCR reactions 
Primers were dissolved in nuclease-free water to working concentrations of 10 µM 
or 20 µM (strand). Final PCR conditions consisted of 0.2 mM of each dNTP (New England 
BioLabs), 1x Complete Long PCR Buffer (Ambion), 1 µM each of forward and reverse 
primers, 3U of Pfu DNA polymerase and at least 50 ng of DNA template. Reaction 
mixtures were heated to 95 °C for 5 min during an initial denaturation step and cycled 30 
times through denaturation (98 °C for 30 sec), annealing (52.0 °C for 1 min), and 
elongation (72 °C for 2 min/kb). The final elongation step was performed at 72 °C for 10 
min. The target amplification products were purified by preparative gel electrophoresis 
with standard protocols.  
Table A.1 Primers used to isolate S. cerevisiae ES7 from the yeast genome and to insert 
flanking restriction sites.  










a) Restriction sites are underlined and the T7 promoter sequence is in italics. 
 
Table A.2 Primers used to generate the SHAPE structural cassette. 








Table A.3 Primer used in SHAPE RT reactions and the DNA anchor used in RNA-protein 
pull-down assays. 
Gene Primer Sequence (5’ to 3’) 
S. cerevisiae 
ES7 




Table A.4 Primers used to insert aminoacyl tRNA-synthetases in pET21C. 
 
b) Restriction sites are underlined. 
 
A.1.2 Pull-down assays and LC-MS/MS analysis 
Samples were loaded into a WPS-3000TPL RS autosampler (Thermostatted Pulled 
Loop Rapid Separation Nano/Capillary Autosampler, Dionex) and separated by reversed-
phase chromatography on a C18-packed microcapillary column (Magic C18AQ, 3 µm, 100 
µm x 16 cm) using an UltiMate 3000 binary pump with a 110 min gradient of 2-25% 
acetonitrile containing 0.125% formic acid. Samples were detected in a hybrid dual-cell 
quadrupole linear ion trap – Orbitrap mass spectrometer (LTQ Orbitrap Elite, Thermo 
Scientific) using a data-dependent Top 20 method. Cycles included one full MS scan with 
a resolution of 60,000 in the Orbitrap at the Automatic Gain Control target of 1 million and 
up to 20 MS/MS of the most intense ions in the LTQ. Selected ions were omitted from 
further sequencing for 90 sec. Ions with a single or unassigned charge were excluded from 
fragmentation and maximum ion accumulation times were 1000 msec for each full MS 
scan and 50 msec for MS/MS scans. 











 Raw MS files were converted into mzXML format. Precursors for MS/MS 
fragmentation were checked to minimize incorrect monoisotopic peak assignments. All 
MS/MS spectra were searched with the SEQUEST algorithm v.28 against the Yeast ORF 
database (downloaded from http://www.yeastgenome.org/) which include sequences of all 
proteins in this category and common contaminants (271). To estimate the false discovery 
rate (FDR) of peptide identification, all protein sequences were listed in forward and 
reverse orientation (272-273). The following parameters were used in the database search: 
10 ppm precursor mass tolerance, 1.0 Da product ion mass tolerance, and Lys-C enzymatic 
digestion. The parameter file included one differential modification, the oxidation of 
methionine (+15.9949), and one fixed modification, carbamidomethylation of cysteine 
(+57.0215). 
 To evaluate and further control FDRs of peptide identification, the target-decoy 
method was applied (272-273). Linear discriminant analysis was utilized to distinguish 
correct and incorrect peptide identifications based on numerous parameters, including 
XCorr, Cn, and precursor mass error (274-275). Separate linear discriminant models were 
trained for each raw file using forward and reversed peptide identifications to provide 
positive and negative training data, which is similar to other approaches in literature (276-
277). After scoring, peptides less than six amino acids in length were discarded and peptide 
spectral matches were filtered to a less than 1% FDR at the peptide level based on the 
number of decoy sequences in the final dataset. 
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A.1.3 Thermodynamic model used in UV melting studies 
Thermodynamic parameters were estimated from reversible, concentration-
independent melting curves. The data was fitted to multiple linear, independent, two-state 
models to account for the presence of multiple transitions in RNA folding/unfolding (127, 
278). The model was first derived for a single, two-state transition and adjusted to account 
for multiple transitions.  
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N – Native RNA 
U – Unfolded RNA 
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T – Temperature 
ΔG – Gibbs free energy of melting 
ΔS – Entropy of Melting 
K – Equilibrium constant 
R – Universal gas constant 
Θu – Fraction of unfolded RNA 
n – Transition number  
ΔH(n) – Enthalpy of transition n 
Tm(n) – Melting temperature of transition n 
An – Hyperchromicity of transition n 





A.1.4 Melting parameter estimation and fitting 
Data processing and fitting was performed with IgorPro v.6.37. The normalized 
absorbance vs. temperature data was subjected to central differentiation and binomial 
smoothing prior fitting of the calculated derivative. For each transition three parameters 
were varied to fit the calculated derivative to the observed derivative: the enthalpy, the 
hyperchromicity and the Tm of the transition (n). 
 
A.2 RESULTS 
A.2.1 Definitions of expansion segments on S. cerevisiae LSU 
ESs drawn onto the secondary and tertiary structure of the S. cerevisiae LSU 
particle (Figure 2.1) followed the definitions outlined by Petrov et al. (4) which were 
obtained by comparing pre- and post-expanded rRNA structures of E. coli and S. cerevisiae 
(http://apollo.chemistry.gatech.edu/RibosomeGallery/). ESs defined here are ES3, ES4, 
ES5, ES7, ES9, ES12, ES19, ES20, ES26, ES27, ES30, ES31, ES39, and ES41. 
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A.2.2 Protein Binding to S. cerevisiae ES7 
 
Figure A.1 Tandem mass spectrum of peptide ELELNFSRPWK from LysRS. The peptide 
was identified with an XCorr of 3.0 and a mass accuracy of -0.69 ppm. 
Table A.5 Identified peptides corresponding to amino acyl tRNA-synthetases. 
Gene name Annotation 
Unique peptides 
identified 
ALA1 Alanyl-tRNA ligase, cytoplasmic 4 
YDR341C Arginyl-tRNA ligase, cytoplasmic 2 
ASN1 Asparagine-tRNA ligase, cytoplasmic 3 
DPS1 Aspartyl-tRNA ligase, cytoplasmic 2 
CDC60 Leucyl-tRNA ligase, cytoplasmic 2 
KRS1 Lysyl-tRNA ligase, cytoplasmic 2 
TYS1 Tyrosyl-tRNA ligase, cytoplasmic 3 
 
Table A.6 Proteins identified in the RNA-protein pull-down assay performed with S. 
cerevisiae cell lysates and ES7. 
Reference Annotation 
YER164W Chromo domain-containing protein 1 
YBR142W ATP-dependent RNA helicase MAK5 
YDR060W Ribosome biogenesis protein MAK21 
YDR150W Nuclear migration protein NUM1 
YFR053C Hexokinase-1 
YJL053W Vacuolar protein sorting-associated protein 26 
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YKL080W V-type proton ATPase subunit C 
YMR049C Ribosome biogenesis protein ERB1 
YOL145C RNA polymerase-associated protein CTR9 
YAL060W (R,R)-butanediol dehydrogenase 
YBL050W Alpha-soluble NSF attachment protein 
YBR299W Alpha-glucosidase MAL32; Alpha-glucosidase MAL62 
YDR002W Ran-specific GTPase-activating protein 1 
YDR129C Fimbrin 
YDR164C Protein transport protein SEC1 
YGL037C Nicotinamidase 
YGR116W Transcription elongation factor SPT6 
YGR130C Uncharacterized protein YGR130C 
YGR175C Squalene monooxygenase 
YGR185C Tyrosyl-tRNA synthetase, cytoplasmic 
YGR234W Flavohemoprotein 
YGR266W Uncharacterized protein YGR266W 
YJL128C MAP kinase PBS2 
YJR024C Putative aldolase class 2 protein YJR024C 
YJR137C Sulfite reductase [NADPH] subunit beta 
YKR067W Glycerol-3-phosphate O-acyltransferase 2 
YLL018C Aspartyl-tRNA synthetase, cytoplasmic 
YLL034C Ribosome biogenesis ATPase RIX7 
YLR287C-A 40S ribosomal protein S30 
YLR327C Translation machinery-associated protein 10 
YMR114C Uncharacterized protein YMR114C 
YNL015W Protease B inhibitors 2 and 1 
YNL248C DNA-directed RNA polymerase I subunit RPA49 
YNR034W-A Uncharacterized protein YNR034W-A 
YOL010W RNA 3'-terminal phosphate cyclase-like protein 
YOR014W 







Figure A.2 Gel shift analysis of T. thermophilus Domain IIIFragment rRNA with aaRSs. 
Interaction of rRNA with A) AspRS, B) LysRS and C) TyrRS is shown in vitro. RNA, 
protein and RNA-protein complexes were visualized by two color EMSA in a 5% native-
PAGE gel containing 3% glycerol. Binding reactions were performed with 1 μM RNA and 
various protein concentrations at room temperature for 20 min in 20 mM Tris-HEPES, pH 
8.0. Lane 1 contains 10 μM of protein and no RNA. Lane 2 consists of 1 μM RNA only. 
Lanes 3-10 contain 1 μM RNA and increasing protein concentration: lane 3 – 0.25 μM, 
lane 4 – 0.50 μM, lane 5 – 1 μM, lane 6 – 2 μM, lane 7 – 4 μM, lane 8 – 6 μM, lane 9 – 8 





Figure A.3 Gel shift analysis of S. cerevisiae ES7 rRNA with multiple aaRSs. Interaction 
of ES7 rRNA with LysRS and TyrRS simultaneously could not be confirmed in vitro. 
Protein shifts, shown here, were visualized with SYPRO RED in a 5% native-PAGE 
containing 3% glycerol. Binding reactions were performed with 4 μM RNA and 10 μM 
aaRS at room temperature for 20 min in 20mM Tris-HEPES, pH 8.0. Lane 1-3 contains no 
RNA and different aaRSs: lane 1 – 10 μM TyrRS, lane 2 – 10 μM LysRS and lane 3 – 10 
μM LysRS and 10 μM TyrRS. Lanes 4-7 contain 4 μM RNA and different aaRSs: lane 4 – 
no protein, lane 5 – 10 μM TyrRS, lane 6 – 10 μM LysRS and lane 7 – 10 μM TyrRS and 

















A.2.3 Thermal folding/unfolding of S. cerevisiae ES7 
 
 
Figure A.4 Normalized, baseline corrected thermal denaturation curve of S. cerevisiae ES7 





SUPPLEMENTARY INFORMARTION FOR CHAPTER 3 
B.1 MATERIALS AND METHODS 
Table B.1 DNA sequences encoding H. sapiens ES7, ES27, ES27a and ES27b.  









































































a) Restriction sites are underlined, the T7 promoter region is in italics and the Weeks 
cassette is in bold. Additional nucleotides were incorporated to ES27 to confer structural 
stability. These nucleotides are highlighted in gray.   
 
Table B.2 DNA oligomers used in putative G-quadruplex studies.  



















b) Restriction sites are underlined, the T7 promoter region is in italics and G stacks are in 
bold for Gq1ES7 and Gq2ES7. Mutation of G stacks are also shown in bold for C1ES7 and 
C2ES7. Gq1ES7, Gq2ES7, C1ES7 and their complimentary DNA strands were ordered from 
Eurofins MWG Operon. RNAs were transcribed in vitro with HiScribe™ T7 High Yield 
Synthesis Kit (New England BioLabs). C2ES7 RNA was ordered from Integrated DNA 
Technologies.  
 
Table B.3 Primers used in H. sapiens SHAPE RT reactions labeled with [6-FAM] at the 
5’end. 






c) Sequences ordered from Euro MWG Operon.  
 
Table B.4 DNA anchor used in H. sapiens RNA pull-down assays (5’ Biotin label). 
Gene Primer Sequence (5’ to 3’)c 
ES7, ES27, 
ES27b 





B.2.1 Thermal folding/unfolding of human ES7 
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Figure B.1 Thermal denaturation curve of human ES7 rRNA at 260 nm. Multiple melting 
transitions are observed during the unfolding process. 
 
Monovalent ion-dependence 
We investigated the effect of alkali metal cations Li+, Na+, K+, Rb+ and Cs+ on Tm,n 
(Figure B.2, Table B.5). Most features of the unfolding profiles are conserved throughout 
the series. The peaks that are best defined and most prominent (third, fourth, fifth, sixth 
and seven peak using the melting curve of Na+ as a reference) were observed for all cations. 
The two lowest temperature transitions which are broad and ill defined, are the least 
interpretable. All five prominent unfolding transitions of ES7 show the greatest Tm,n in the 
presence of Li+ and the lowest Tm,n in the presence of Na
+. Cs+ appears to be anomalous 
compared to the other alkali cations in that the highest temperature transition is shifted to 
lower Tm,n than expected, relative to other Tm,n’s. In general, there is not strong evidence 





Figure B.2 Melting profiles of ES7 rRNA obtained at different alkali metal cations. The 
derivative of fraction unfolded at 260 nm with respect to temperature was computed. Data 
below 50°C have less statistical significance and is not shown. Experiments were 
performed in 18 mM Li+, Na+, K+, Rb+ or Cs+ and 20 mM Tris-HEPES (pH 8.0). Figures 
were generated with IGOR Pro. 
 
Table B.5 Parameter estimation of thermal unfolding curves of ES7 obtained in different 
monovalent cations. The data was fitted to the minimum number of transitions. Greater 
number of transitions cannot be discarded. Li+, Na+ and K+ were fitted to a seven-state 
transition model. Rb+ and Cs+ were fitted to a six-state transition model. Transitions were 
numbered in order of appearance.  
Parameter Li+ Na+ K+ Rb+ Cs+ 
H1 50.4 56.5 49.1 31.2 63.0 
Tm,1 36.1 36.7 36.2 44.7 49.3 
A1 1.9 0.7 0.6 1.5 0.4 
H2 223.7 71.7 53.5 42.4 73.0 
Tm,2 46.3 49.9 50.3 63.0 62.0 
A2 0.2 0.9 1.7 3.4 0.9 
H3 47.8 73.1 72.2 80.6 100.0 
Tm,3 65.1 61.4 62.8 71.3 73.0 
A3 4.3 2.2 2.0 2.1 1.7 
H4 97.7 96.4 66.4 116.1 165.0 
Tm,4 74.7 71.0 73.8 77.8 77.2 
A4 1.8 3.1 6.4 2.6 1.1 
H5 147.5 151.4 174.6 66.9 120.0 
Tm,5 78.5 75.4 77.7 82.3 81.3 
A5 2.1 2.3 1.2 3.1 1.3 
H6 172.4 208.3 229.4 206.8 190.0 
Tm,6 82.9 79.2 80.9 87.1 84.9 
A6 1.1 1.0 0.9 1.3 0.5 
H7 191.4 176.4 142.4 N/A N/A 
Tm,7 87.4 84.7 86.0 N/A N/A 
A7 1.6 2.4 3.3 N/A N/A 
 
B.2.2 ES-associated proteins 
Human ES27a and ES27b rRNA 
ES27 was cleaved in two fragments, ES27a and ES27b (Figure 3.2) to attempt to 
determine the locus of RNA-protein interactions within ES27. Since no pull-down 
experiments were performed with ES27a, the subset of proteins that associate with ES27 
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and not ES27a would appear to bind specifically to ES27b, although those assignments 
remain tentative.   
Group IES27b,H contains 12 proteins (Table B.14). Eight of those are identical or 
belong to the same protein family as Group IIES27,H (Table B.11). These Group IES27b,H 
proteins include ADP-ribosylation factor 5 (ARF5), Cold-inducible RNA-binding protein 
(CIRBP), MSI1H, Rho GTPase-activating protein 17 (RHG17), Selenocysteine insertion 
sequence-binding protein 2 (SEBP2), Serine/arginine-rich splicing factor 9 (SRSF9), 
Ribonuclease H2 subunit A (RNH2A) and Tubulin beta-2A chain (TBB2A). E3 ubiquitin-
protein ligase BRE1A and Protein phosphatase 1 regulatory subunit 12A (MYPT1) also 
from Group IES27b,H, share similarities with proteins identified in association with ES27 in 
all pull-down experiments. Conversely, seven of the sixteen proteins in Group IES27,H 
belong to Group IIES27b,H (MSI1H, D11L8, BCL9L, ITSN2, SYFB, FA45B, RNH2B), 
while four proteins in Group IES27,H share functions similar to proteins identified in Group 
IIES27b,H (MSI2H, ZCCHV, ARFG2, UBP7). 
Group IIES27b,H contains at least twenty-four proteins classified as UBLs or UPSs or 
that are known to associate with UBLs or UPSs (Table B.15). These proteins include SAE2, 
UBE2O and ULA1, which are also seen to associate with ES7 and/or ES27. Group IIES27b,H 
contains several ADP ribosylation factors, translation initiation factors and aminoacyl 
tRNA synthetases (CysRS, ThrRS and PheRS). The proteins within Group IIES27b,H are in 
general consistent with those seen to associate with ES27 in both HEK293T and MDA-
MB-231 cells.  
 
Protein binding to human rRNA expansion segments 
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Table B.6 Proteins identified in all pull-down assays performed with ES7 and HEK293T 
cells (Group IES7,H). 
Reference Annotationd 
O95400 CD2 antigen cytoplasmic tail-binding protein 2 
P15531 Nucleoside diphosphate kinase A 
P21281 V-type proton ATPase subunit B, brain isoform 
P62495 Eukaryotic peptide chain release factor subunit 1 
Q96G03 Phosphoglucomutase-2 
Q9UBT2 SUMO-activating enzyme subunit 2 
O75179 Ankyrin repeat domain-containing protein 17 
O75496 Geminin 
P07196 Neurofilament light polypeptide 
Q13564 NEDD8-activating enzyme E1 regulatory subunit 
Q32P28 Prolyl 3-hydroxylase 1 
Q8NDI1 EH domain-binding protein 1 
Q96EI5 Transcription elongation factor A protein-like 4 
Q9C0C9 Ubiquitin-conjugating enzyme E2 O 
Q9GZZ9 Ubiquitin-like modifier-activating enzyme 5 
 
d) Proteins involved directly or through secondary interactions to the UBS are colored in 
gray.  
 
Table B.7 Proteins identified in half of the pull-down assays performed with ES7 and 
HEK293T cells (Group IIES7,H). 
Reference Annotationd 
Q08752 Peptidyl-prolyl cis-trans isomerase D 
P19623 Spermidine synthase 
P49591 Serine-tRNA ligase, cytoplasmic 
Q9NZ63 Uncharacterized protein C9orf78 
P31150 Rab GDP dissociation inhibitor alpha 
Q13439 Golgin subfamily A member 4 
Q14694 Ubiquitin carboxyl-terminal hydrolase 10 
Q8IWJ2 GRIP and coiled-coil domain-containing protein 2 
Q8TCU4 Alstrom syndrome protein 1 
Q9NR50 Translation initiation factor eIF-2B subunit gamma 
Q9UPY3 Endoribonuclease Dicer 
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1 
O00154 Cytosolic acyl coenzyme A thioester hydrolase 
O00487 26S proteasome non-ATPase regulatory subunit 14 
O60934 Nibrin 
O75914 Serine/threonine-protein kinase PAK 3 
P00492 Hypoxanthine-guanine phosphoribosyltransferase 
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P09960 Leukotriene A-4 hydrolase 
P35270 Sepiapterin reductase 
P42766 60S ribosomal protein L35 
P49189 4-trimethylaminobutyraldehyde dehydrogenase 
P61011 Signal recognition particle 54 kDa protein 
Q01581 Hydroxymethylglutaryl-CoA synthase, cytoplasmic 
Q12849 G-rich sequence factor 1 
Q14692 Ribosome biogenesis protein BMS1 homolog 
Q16566 Calcium/calmodulin-dependent protein kinase type IV 
Q3MHD2 Protein LSM12 homolog 
Q5W0B1 RING finger protein 219 
Q86U42 Polyadenylate-binding protein 2 
Q8IYQ7 Threonine synthase-like 1 
Q8TD19 Serine/threonine-protein kinase Nek9 
Q92733 Proline-rich protein PRCC 
Q99618 Cell division cycle-associated protein 3 
Q9NUL3 Double-stranded RNA-binding protein Staufen homolog 2 
Q9Y5X3 Sorting nexin-5 
L0R819 Alternative protein ASNSD1 
A6NDU8 UPF0600 protein C5orf51 
O00429 Isoform 4 of Dynamin-1-like protein 
O00507 Probable ubiquitin carboxyl-terminal hydrolase FAF-Y 
O00512 B-cell CLL/lymphoma 9 protein 
O14964 Hepatocyte growth factor-regulated tyrosine kinase substrate 
O15305 Phosphomannomutase 2 
O43423 Acidic leucine-rich nuclear phosphoprotein 32 family member C 
O60508 Pre-mRNA-processing factor 17 
O60814 Histone H2B type 1-K 
O75122 CLIP-associating protein 2 
O94776 Metastasis-associated protein MTA2 
O94788 Retinal dehydrogenase 2 
O95163 Elongator complex protein 1 
O95219 Sorting nexin-4 
O95232 Luc7-like protein 3 
P00568 Adenylate kinase isoenzyme 1 
P00918 Carbonic anhydrase 2 
P07203 Glutathione peroxidase 1 
P13861 cAMP-dependent protein kinase type II-alpha regulatory subunit 
P19022 Cadherin-2 
P22059 Oxysterol-binding protein 1 
P30050 60S ribosomal protein L12 
P30154 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform 
P30566 Adenylosuccinate lyase 
P35244 Replication protein A 14 kDa subunit 
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P37198 Nuclear pore glycoprotein p62 
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha 
P43246 DNA mismatch repair protein Msh2 
P49356 Protein farnesyltransferase subunit beta 
P49585 Choline-phosphate cytidylyltransferase A 
P51003 Poly(A) polymerase alpha 
P51665 26S proteasome non-ATPase regulatory subunit 7 
P54725 UV excision repair protein RAD23 homolog A 
P61019 Ras-related protein Rab-2A 
P61758 Prefoldin subunit 3 
P62266 40S ribosomal protein S23 
P63173 60S ribosomal protein L38 
P68371 Tubulin beta-4B chain 
P98170 E3 ubiquitin-protein ligase XIAP 
Q01433 AMP deaminase 2 
Q06210 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 1 
Q06265 Exosome complex component RRP45 
Q13126 S-methyl-5'-thioadenosine phosphorylase 
Q13242 Serine/arginine-rich splicing factor 9 
Q13542 Eukaryotic translation initiation factor 4E-binding protein 2 
Q13554 Calcium/calmodulin-dependent protein kinase type II subunit beta 
Q13642 Four and a half LIM domains protein 1 
Q15057 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 
Q15404 Ras suppressor protein 1 
Q15637 Isoform 5 of Splicing factor 1 
Q16531 DNA damage-binding protein 1 
Q5PRF9 Protein Smaug homolog 2 
Q5TBB1 Ribonuclease H2 subunit B 
Q7Z2W4 Zinc finger CCCH-type antiviral protein 1 
Q7Z3T8 Zinc finger FYVE domain-containing protein 16 
Q7Z4Q2 HEAT repeat-containing protein 3 
Q86U44 N6-adenosine-methyltransferase 70 kDa subunit 
Q86V81 THO complex subunit 4 
Q8N0Z6 Tetratricopeptide repeat protein 5 
Q8NDV7 Trinucleotide repeat-containing gene 6A protein 
Q8TBC4 NEDD8-activating enzyme E1 catalytic subunit 
Q8WVM8 Sec1 family domain-containing protein 1 
Q8WX92 Negative elongation factor B 
Q92793 CREB-binding protein 
Q92879 CUGBP Elav-like family member 1 
Q969T9 WW domain-binding protein 2 
Q96C36 Pyrroline-5-carboxylate reductase 2 
Q96EK6 Glucosamine 6-phosphate N-acetyltransferase 
Q96H79 Zinc finger CCCH-type antiviral protein 1-like 
Q96S66 Chloride channel CLIC-like protein 1 
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Q99538 Legumain 
Q99598 Translin-associated protein X 
Q99873 Protein arginine N-methyltransferase 1 
Q9BRA2 Thioredoxin domain-containing protein 17 
Q9BUK6 Protein misato homolog 1 
Q9H3P2 Negative elongation factor A 
Q9H910 Hematological and neurological expressed 1-like protein 
Q9NR12 PDZ and LIM domain protein 7 
Q9P289 Serine/threonine-protein kinase MST4 
Q9UJC3 Protein Hook homolog 1 
Q9UJW0 Dynactin subunit 4 
Q9ULJ3 Zinc finger and BTB domain-containing protein 21 
Q9ULR0 Pre-mRNA-splicing factor ISY1 homolog 
Q9UNP9 Peptidyl-prolyl cis-trans isomerase E 
Q9Y263 Phospholipase A-2-activating protein 
Q9Y2J2 Isoform B of Band 4.1-like protein 3 
Q9Y3P9 Rab GTPase-activating protein 1 
Q9Y6K9 NF-kappa-B essential modulator 
Q9Y6X4 Soluble lamin-associated protein of 75 kDa 
Q969G3 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 
O15371 Eukaryotic translation initiation factor 3 subunit D 
O60701 UDP-glucose 6-dehydrogenase 
P47755 F-actin-capping protein subunit alpha-2 
P53367 Arfaptin-1 
P54578 Ubiquitin carboxyl-terminal hydrolase 14 
P54920 Alpha-soluble NSF attachment protein 
P61221 ATP-binding cassette sub-family E member 1 
Q06787 Fragile X mental retardation protein 1 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 
O00161 Synaptosomal-associated protein 23 
O14745 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 
O43347 RNA-binding protein Musashi homolog 1 
O75391 Sperm-associated antigen 7 
P06737 Glycogen phosphorylase, liver form 
P11413 Glucose-6-phosphate 1-dehydrogenase 
P23921 Ribonucleoside-diphosphate reductase large subunit 
P62701 40S ribosomal protein S4, X isoform 
P63220 40S ribosomal protein S21 
Q02878 60S ribosomal protein L6 
Q12792 Twinfilin-1 
Q15819 Ubiquitin-conjugating enzyme E2 variant 2 
Q99436 Proteasome subunit beta type-7 
Q9BVL2 Nucleoporin p58/p45 
Q9NP97 Dynein light chain roadblock-type 1 
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Q9Y5Z4 Heme-binding protein 2 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2 
O14950 Myosin regulatory light chain 12B 
O43395 U4/U6 small nuclear ribonucleoprotein Prp3 
O43396 Thioredoxin-like protein 1 
O75376 Nuclear receptor corepressor 1 
O75475 PC4 and SFRS1-interacting protein 
O75663 TIP41-like protein 
O75886 Signal transducing adapter molecule 2 
P06730 Eukaryotic translation initiation factor 4E 
P09497 Isoform Non-brain of Clathrin light chain B 
P21796 Voltage-dependent anion-selective channel protein 1 
P26196 Probable ATP-dependent RNA helicase DDX6 
P27361 Mitogen-activated protein kinase 3 
P31483 Nucleolysin TIA-1 isoform p40 
P42025 Beta-centractin 
P42285 Superkiller viralicidic activity 2-like 2 
P42696 RNA-binding protein 34 
P45973 Chromobox protein homolog 5 
P45985 Dual specificity mitogen-activated protein kinase kinase 4 
P61106 Ras-related protein Rab-14 
P62263 40S ribosomal protein S14 
P62851 40S ribosomal protein S25 
P82094 TATA element modulatory factor 
Q00839 Isoform Short of Heterogeneous nuclear ribonucleoprotein U 
Q04760 Lactoylglutathione lyase 
Q13085 Acetyl-CoA carboxylase 1 
Q13363 C-terminal-binding protein 1 
Q14011 Cold-inducible RNA-binding protein 
Q14195 Isoform LCRMP-4 of Dihydropyrimidinase-related protein 3 
Q14527 Helicase-like transcription factor 
Q15393 Splicing factor 3B subunit 3 
Q15427 Splicing factor 3B subunit 4 
Q8IY63 Angiomotin-like protein 1 
Q8NEY8 Periphilin-1 
Q92615 La-related protein 4B 
Q96F24 Nuclear receptor-binding factor 2 
Q99426 Tubulin-folding cofactor B 
Q99576 TSC22 domain family protein 3 
Q99966 Cbp/p300-interacting transactivator 1 
Q9BPW8 Protein NipSnap homolog 1 
Q9HD15 Steroid receptor RNA activator 1 
Q9NPA8 Transcription and mRNA export factor ENY2 
Q9NRA8 Eukaryotic translation initiation factor 4E transporter 
Q9UBL3 Set1/Ash2 histone methyltransferase complex subunit ASH2 
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Q9UBW8 COP9 signalosome complex subunit 7a 
Q9UKM9 RNA-binding protein Raly 
Q9UL46 Proteasome activator complex subunit 2 
Q9ULV3 Cip1-interacting zinc finger protein 
Q9UMZ2 Synergin gamma 
Q9UNH7 Sorting nexin-6 
Q9Y2Q3 Glutathione S-transferase kappa 1 
Q9Y570 Protein phosphatase methylesterase 1 
 
Table B.8 Proteins identified in all pull-down assays performed with ES7 and MDA-MB-
231 cells (Group IES7,M). 
Reference Annotation 
Q8NBF2 NHL repeat-containing protein 2 
Q86U42 Polyadenylate-binding protein 2 
Q9Y570 Protein phosphatase methylesterase 1 
Q969G3 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily E member 1 
O75937 DnaJ homolog subfamily C member 8 
Q96PU8 Protein quaking 
P51149 Ras-related protein Rab-7a 
P08865 40S ribosomal protein SA 
P42285 Superkiller viralicidic activity 2-like 2 
 
Table B.9 Proteins identified in half of the pull-down assays performed with ES7 and 
MDA-MB-231 cells (Group IIES7,M). 
Reference Annotationd 
Q92615 La-related protein 4B 
P49189 4-trimethylaminobutyraldehyde dehydrogenase 
P08758 Annexin A5 
O15511 Actin-related protein 2/3 complex subunit 5 
P27708 CAD protein 
Q86TI2 Dipeptidyl peptidase 9 
Q96C19 EF-hand domain-containing protein D2 
Q9Y6M1 Insulin-like growth factor 2 mRNA-binding protein 2 
P09382 Galectin-1 
P43243 Matrin-3 
Q9UHV9 Prefoldin subunit 2 
Q96PK6 RNA-binding protein 14 
P35244 Replication protein A 14 kDa subunit 
P40429 60S ribosomal protein L13a 
P35237 Serpin B6 
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O75410 Transforming acidic coiled-coil-containing protein 1 
Q9UDY2 Tight junction protein ZO-2 
Q15019 Septin-2 
P38606 V-type proton ATPase catalytic subunit A 
P20810 Isoform 5 of Calpastatin 
P53675 Clathrin heavy chain 2 
Q92905 COP9 signalosome complex subunit 5 
P56545 C-terminal-binding protein 2 
Q16531 DNA damage-binding protein 1 
O43324 Eukaryotic translation elongation factor 1 epsilon-1 
Q96RT1 Protein LAP2 
Q2NKX8 DNA excision repair protein ERCC-6-like 
O75369 Isoform 8 of Filamin-B 
O60547 GDP-mannose 4,6 dehydratase 
Q9Y2Q3 Glutathione S-transferase kappa 1 
Q9NRV9 Heme-binding protein 1 
Q9Y6K9 NF-kappa-B essential modulator 
O00410 Importin-5 
Q96PU5 E3 ubiquitin-protein ligase NEDD4-like 
Q96IZ0 PRKC apoptosis WT1 regulator protein 
P50479 PDZ and LIM domain protein 4 
P08237 6-phosphofructokinase, muscle type 
A2BFH1 Peptidyl-prolyl cis-trans isomerase A-like 4G 
Q99873 Protein arginine N-methyltransferase 1 
P25787 Proteasome subunit alpha type-2 
P48556 26S proteasome non-ATPase regulatory subunit 8 
P15927 Replication protein A 32 kDa subunit 
P39019 40S ribosomal protein S19 
Q15637 Splicing factor 1 
Q9BWU0 Kanadaptin 
P35270 Sepiapterin reductase 
Q68CZ2 Tensin-3 
Q96KR1 Zinc finger RNA-binding protein 
Q16204 Coiled-coil domain-containing protein 6 
Q7Z2W4 Zinc finger CCCH-type antiviral protein 1 
P05556 Integrin beta-1 
P09493 Isoform 10 of Tropomyosin alpha-1 chain 
P61158 Actin-related protein 3 
Q12802 A-kinase anchor protein 13 
Q13625 Apoptosis-stimulating of p53 protein 2 
Q96G03 Phosphoglucomutase-2 
Q96NB3 Zinc finger protein 830 
Q96RS6 NudC domain-containing protein 1 
Q9UHX1 Poly(U)-binding-splicing factor PUF60 
O43681 ATPase ASNA1 
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O95801 Tetratricopeptide repeat protein 4 
P09211 Glutathione S-transferase P 
P11172 Uridine 5'-monophosphate synthase 
P12429 Annexin A3 
P14649 Myosin light chain 6B 
P25205 DNA replication licensing factor MCM3 
P25789 Proteasome subunit alpha type-4 
P29034 Protein S100-A2 
P30154 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform 
P30566 Adenylosuccinate lyase 
P38117 Electron transfer flavoprotein subunit beta 
P40763 Signal transducer and activator of transcription 3 
P60900 Proteasome subunit alpha type-6 
P68371 Tubulin beta-4B chain 
P98082 Disabled homolog 2 
Q08752 Peptidyl-prolyl cis-trans isomerase D 
Q12849 G-rich sequence factor 1 
Q13564 NEDD8-activating enzyme E1 regulatory subunit 
Q14008 Cytoskeleton-associated protein 5 
Q17RY0 Cytoplasmic polyadenylation element-binding protein 4 
Q2M2I8 AP2-associated protein kinase 1 
Q2TAL8 Glutamine-rich protein 1 
Q5VT25 Serine/threonine-protein kinase MRCK alpha 
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A 
Q8N6T3 ADP-ribosylation factor GTPase-activating protein 1 
Q8TC07 TBC1 domain family member 15 
Q8WWY3 U4/U6 small nuclear ribonucleoprotein Prp31 
Q96K17 Transcription factor BTF3 homolog 4 
Q99747 Gamma-soluble NSF attachment protein 
Q9NQG5 Regulation of nuclear pre-mRNA domain-containing protein 1B 
Q9NZZ3 Charged multivesicular body protein 5 
Q9Y3Z3 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 
A6ND36 Protein FAM83G 
O00244 Copper transport protein ATOX1 
O15056 Synaptojanin-2 
O15145 Actin-related protein 2/3 complex subunit 3 
O15231 Isoform 2 of Zinc finger protein 185 
O60361 Putative nucleoside diphosphate kinase 
O75223 Gamma-glutamylcyclotransferase 
O75525 
KH domain-containing, RNA-binding, signal transduction-associated protein 
3 
O94905 Erlin-2 
O95684 FGFR1 oncogene partner 
O95747 Serine/threonine-protein kinase OSR1 
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P00167 Cytochrome b5 
P00492 Hypoxanthine-guanine phosphoribosyltransferase 
P02786 Transferrin receptor protein 1 
P04049 RAF proto-oncogene serine/threonine-protein kinase 
P04080 Cystatin-B 
P10644 cAMP-dependent protein kinase type I-alpha regulatory subunit 
P15153 Ras-related C3 botulinum toxin substrate 2 
P18031 Tyrosine-protein phosphatase non-receptor type 1 
P21399 Cytoplasmic aconitate hydratase 
P23526 Adenosylhomocysteinase 
P29692 Elongation factor 1-delta 
P33240 Cleavage stimulation factor subunit 2 
P40261 Nicotinamide N-methyltransferase 
P42025 Beta-centractin 
P46779 60S ribosomal protein L28 
P49137 MAP kinase-activated protein kinase 2 
P51148 Ras-related protein Rab-5C 
P55795 Heterogeneous nuclear ribonucleoprotein H2 
P61088 Ubiquitin-conjugating enzyme E2 N 
P61221 ATP-binding cassette sub-family E member 1 
P63151 
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha 
isoform 
P83881 60S ribosomal protein L36a 
Q04724 Transducin-like enhancer protein 1 
Q04760 Lactoylglutathione lyase 
Q06787 Fragile X mental retardation protein 1 
Q13043 Serine/threonine-protein kinase 4 
Q13107 Ubiquitin carboxyl-terminal hydrolase 4 
Q13363 C-terminal-binding protein 1 
Q13557 Calcium/calmodulin-dependent protein kinase type II subunit delta 
Q13596 Sorting nexin-1 
Q15366 Poly(rC)-binding protein 2 
Q15370 Transcription elongation factor B polypeptide 2 
Q15382 GTP-binding protein Rheb 
Q16626 Male-enhanced antigen 1 
Q3MHD2 Protein LSM12 homolog 
Q52LJ0 Protein FAM98B 
Q5VZF2 Muscleblind-like protein 2 
Q6P3W7 SCY1-like protein 2 
Q6WCQ1 Myosin phosphatase Rho-interacting protein 
Q6YN16 Hydroxysteroid dehydrogenase-like protein 2 
Q6ZSR9 Uncharacterized protein FLJ45252 
Q7Z4H3 HD domain-containing protein 2 
Q8IY63 Angiomotin-like protein 1 
Q8N7H5 RNA polymerase II-associated factor 1 homolog 
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Q8ND56 Protein LSM14 homolog A 
Q8TAT6 Nuclear protein localization protein 4 homolog 
Q92804 TATA-binding protein-associated factor 2N 
Q969T9 WW domain-binding protein 2 
Q96C36 Pyrroline-5-carboxylate reductase 2 
Q96FQ6 Protein S100-A16 
Q96I25 Splicing factor 45 
Q9BRP8 Partner of Y14 and mago 
Q9GZZ9 Ubiquitin-like modifier-activating enzyme 5 
Q9H223 EH domain-containing protein 4 
Q9H3S7 Tyrosine-protein phosphatase non-receptor type 23 
Q9H6S3 Epidermal growth factor receptor kinase substrate 8-like protein 2 
Q9H8Y8 Golgi reassembly-stacking protein 2 
Q9NUL3 Double-stranded RNA-binding protein Staufen homolog 2 
Q9NVE7 Pantothenate kinase 4 
Q9UBQ5 Eukaryotic translation initiation factor 3 subunit K 
Q9UBT2 SUMO-activating enzyme subunit 2 
Q9UJM3 ERBB receptor feedback inhibitor 1 
Q9UMX5 Neudesin 
Q9UMZ2 Synergin gamma 
Q9UNF0 Protein kinase C and casein kinase substrate in neurons protein 2 
Q9Y5Z4 Heme-binding protein 2 
Q9Y678 Coatomer subunit gamma-1 
 
Table B.10 Proteins identified in all pull-down assays performed with ES27 and HEK293T 
cells (Group IES27,H). 
Reference Annotationd 
O43347 RNA-binding protein Musashi homolog 1 
Q96DH6 RNA-binding protein Musashi homolog 2 
A8MPP1 Putative ATP-dependent RNA helicase DDX11-like protein 8 
Q86UU0 B-cell CLL/lymphoma 9-like protein 
Q7Z2W4 Zinc finger CCCH-type antiviral protein 1 
Q9NZM3 Intersectin-2 
O15164 Transcription intermediary factor 1-alpha 
Q9NSD9 Phenylalanine-tRNA ligase beta subunit 
P12277 Creatine kinase B-type 
O00151 PDZ and LIM domain protein 1 
Q8N6H7 ADP-ribosylation factor GTPase-activating protein 2 
P52294 Importin subunit alpha-5 
Q6NSW5 Protein FAM45B 
Q96EA4 Protein Spindly 
Q93009 Ubiquitin carboxyl-terminal hydrolase 7 
Q5TBB1 Ribonuclease H2 subunit B 
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Table B.11 Proteins identified in half of the pull-down assays performed with ES27 and 
HEK293T cells (Group IIES27,H). 
Reference Annotationd 
O00505 Importin subunit alpha-4 
P46939 Utrophin 
Q92905 COP9 signalosome complex subunit 5 
A0MZ66 Shootin-1 
O60343 TBC1 domain family member 4 
O75116 Rho-associated protein kinase 2 
O75369 Filamin-B 
P22314 Ubiquitin-like modifier-activating enzyme 1 
P35221 Catenin alpha-1 
Q92804 TATA-binding protein-associated factor 2N 
Q96LB3 Intraflagellar transport protein 74 homolog 
Q9UHD1 Cysteine and histidine-rich domain-containing protein 1 
Q9UNN5 FAS-associated factor 1 
O14929 Histone acetyltransferase type B catalytic subunit 
O75569 
Interferon-inducible double-stranded RNA-dependent protein kinase 
activator A 
P05023 Sodium/potassium-transporting ATPase subunit alpha-1 
P61326 Protein mago nashi homolog 
P84157 Isoform 2 of Matrix-remodeling-associated protein 7 
Q07955 Serine/arginine-rich splicing factor 1 
Q08170 Serine/arginine-rich splicing factor 4 
Q15813 Tubulin-specific chaperone E 
Q2NKX8 DNA excision repair protein ERCC-6-like 
Q86VS8 Protein Hook homolog 3 
Q8NEZ2 Vacuolar protein sorting-associated protein 37A 
Q8WXD5 Gem-associated protein 6 
Q9BT78 COP9 signalosome complex subunit 4 
Q9HC38 Glyoxalase domain-containing protein 4 
Q9HD26 Golgi-associated PDZ and coiled-coil motif-containing protein 
Q9NQP4 Prefoldin subunit 4 
Q9UKF6 Cleavage and polyadenylation specificity factor subunit 3 
Q9UPY3 Endoribonuclease Dicer 
A6NL28 Putative tropomyosin alpha-3 chain-like protein 
O00170 AH receptor-interacting protein 
O00264 Membrane-associated progesterone receptor component 1 
O00512 B-cell CLL/lymphoma 9 protein 
O14579 Coatomer subunit epsilon 
O14639 Actin-binding LIM protein 1 
O14744 Protein arginine N-methyltransferase 5 
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O60488 Long-chain-fatty-acid-CoA ligase 4 
O75044 SLIT-ROBO Rho GTPase-activating protein 2 
O75663 TIP41-like protein 
O75683 Surfeit locus protein 6 
O95453 Poly(A)-specific ribonuclease PARN 
O95817 BAG family molecular chaperone regulator 3 
P16615 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
P22681 E3 ubiquitin-protein ligase CBL 
P24534 Elongation factor 1-beta 
P25398 40S ribosomal protein S12 
P27448 MAP/microtubule affinity-regulating kinase 3 
P30307 M-phase inducer phosphatase 3 
P35520 Cystathionine beta-synthase 
P36543 V-type proton ATPase subunit E 1 
P51003 Poly(A) polymerase alpha 
P52756 RNA-binding protein 5 
P60174 Triosephosphate isomerase 
P61106 Ras-related protein Rab-14 
P67936 Tropomyosin alpha-4 chain 
Q07157 Tight junction protein ZO-1 
Q10567 AP-1 complex subunit beta-1 
Q12972 Nuclear inhibitor of protein phosphatase 1 
Q13206 Probable ATP-dependent RNA helicase DDX10 
Q13492 Phosphatidylinositol-binding clathrin assembly protein 
Q13838 Spliceosome RNA helicase DDX39B 
Q14155 Isoform 1 of Rho guanine nucleotide exchange factor 7 
Q14315 Filamin-C 
Q14684 Ribosomal RNA processing protein 1 homolog B 
Q15287 RNA-binding protein with serine-rich domain 1 
Q15369 Transcription elongation factor B polypeptide 1 
Q15427 Splicing factor 3B subunit 4 
Q15814 Tubulin-specific chaperone C 
Q16531 DNA damage-binding protein 1 
Q16718 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 
Q4VC05 B-cell CLL/lymphoma 7 protein family member A 
Q5H9R7 Serine/threonine-protein phosphatase 6 regulatory subunit 3 
Q5T5Y3 Calmodulin-regulated spectrin-associated protein 1 
Q5TAX3 Terminal uridylyltransferase 4 
Q69YQ0 Cytospin-A 
Q8TAE8 Growth arrest and DNA damage-inducible proteins-interacting protein 1 
Q96CT7 Coiled-coil domain-containing protein 124 
Q96DF8 Protein DGCR14 
Q96KB5 Lymphokine-activated killer T-cell-originated protein kinase 
Q96MW1 Coiled-coil domain-containing protein 43 
Q96NB3 Zinc finger protein 830 
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Q96RU3 Formin-binding protein 1 
Q9BRX5 DNA replication complex GINS protein PSF3 
Q9BVG4 Protein PBDC1 
Q9BW85 Coiled-coil domain-containing protein 94 
Q9BXB4 Oxysterol-binding protein-related protein 11 
Q9H3Q1 Cdc42 effector protein 4 
Q9HAU0 Pleckstrin homology domain-containing family A member 5 
Q9NQ92 Coordinator of PRMT5 and differentiation stimulator 
Q9NR50 Translation initiation factor eIF-2B subunit gamma 
Q9NRF9 DNA polymerase epsilon subunit 3 
Q9NX58 Cell growth-regulating nucleolar protein 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 
Q9NZT2 Opioid growth factor receptor 
Q9P0L0 Vesicle-associated membrane protein-associated protein A 
Q9UHD8 Septin-9 
Q9ULV4 Coronin-1C 
Q9Y2L1 Exosome complex exonuclease RRP44 
Q9Y4W2 Ribosomal biogenesis protein LAS1L 
Q9Y570 Protein phosphatase methylesterase 1 
Q9Y5M8 Signal recognition particle receptor subunit beta 
C9J7I0 Uncharacterized protein 
Q14527 Helicase-like transcription factor 
P08237 6-phosphofructokinase, muscle type 
P61160 Actin-related protein 2 
P00338 L-lactate dehydrogenase A chain 
O95433 Activator of 90 kDa heat shock protein ATPase homolog 1 
Q8NB90 Spermatogenesis-associated protein 5 
O60547 GDP-mannose 4,6 dehydratase 
P31939 Bifunctional purine biosynthesis protein PURH 
P22307 Non-specific lipid-transfer protein 
P18621 60S ribosomal protein L17 
Q13885 Tubulin beta-2A chain 
Q14011 Cold-inducible RNA-binding protein 
Q15293 Reticulocalbin-1 
Q96A73 Putative monooxygenase p33MONOX 
Q86US8 Telomerase-binding protein EST1A 
Q92973 Transportin-1 
Q92900 Regulator of nonsense transcripts 1 
Q96FZ2 Embryonic stem cell-specific 5-hydroxymethylcytosine-binding protein 
Q13557 Calcium/calmodulin-dependent protein kinase type II subunit delta 
Q9C0C2 182 kDa tankyrase-1-binding protein 
Q8IX90 Spindle and kinetochore-associated protein 3 
P31350 Ribonucleoside-diphosphate reductase subunit M2 
Q9UGU0 Transcription factor 20 
Q9HAV4 Exportin-5 
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Q9NPD8 Ubiquitin-conjugating enzyme E2 T 
P16278 Beta-galactosidase 
Q86TP1 Protein prune homolog 
Q13242 Serine/arginine-rich splicing factor 9 
Q9BVM2 Protein DPCD 
Q9P2N5 RNA-binding protein 27 
P49588 Alanine-tRNA ligase, cytoplasmic 
Q99614 Tetratricopeptide repeat protein 1 
Q6NSI4 Uncharacterized protein CXorf57 
Q6P2H3 Centrosomal protein of 85 kDa 
P42696 RNA-binding protein 34 
Q9NR31 GTP-binding protein SAR1a 
Q9C005 Protein dpy-30 homolog 
Q5PRF9 Protein Smaug homolog 2 
Q8NCA5 Protein FAM98A 
Q9NR46 Endophilin-B2 
Q9NZD8 Maspardin 
Q6UVJ0 Spindle assembly abnormal protein 6 homolog 
Q9UI26 Importin-11 
P54619 5'-AMP-activated protein kinase subunit gamma-1 
P62899 60S ribosomal protein L31 
O14641 Segment polarity protein dishevelled homolog DVL-2 
Q6ZSR9 Uncharacterized protein FLJ45252 
Q96T21 Selenocysteine insertion sequence-binding protein 2 
Q7Z4Q2 HEAT repeat-containing protein 3 
O60361 Putative nucleoside diphosphate kinase 
Q96T37 Putative RNA-binding protein 15 
Q96SI9 Spermatid perinuclear RNA-binding protein 
Q9NRA8 Eukaryotic translation initiation factor 4E transporter 
P04049 RAF proto-oncogene serine/threonine-protein kinase 
Q15418 Ribosomal protein S6 kinase alpha-1 
P00558 Phosphoglycerate kinase 1 
Q13625 Apoptosis-stimulating of p53 protein 2 
Q6P1N0 Coiled-coil and C2 domain-containing protein 1A 
P31483 Nucleolysin TIA-1 isoform p40 
Q00013 55 kDa erythrocyte membrane protein 
P25685 DnaJ homolog subfamily B member 1 
Q99590 Protein SCAF11 
P17858 6-phosphofructokinase, liver type 
O95721 Synaptosomal-associated protein 29 
Q9BW83 Intraflagellar transport protein 27 homolog 
O94762 ATP-dependent DNA helicase Q5 
P18124 60S ribosomal protein L7 
Q16864 V-type proton ATPase subunit F 
Q9BUF5 Tubulin beta-6 chain 
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Q9UKZ1 CCR4-NOT transcription complex subunit 11 
O75792 Ribonuclease H2 subunit A 
Q9UKN8 General transcription factor 3C polypeptide 4 
Q96EP5 DAZ-associated protein 1 
O94830 Phospholipase DDHD2 
P51809 Vesicle-associated membrane protein 7 
P57076 UPF0769 protein C21orf59 
Q92769 Histone deacetylase 2 
P62847 40S ribosomal protein S24 
Q7Z7F0 UPF0469 protein KIAA0907 
P38919 Eukaryotic initiation factor 4A-III 
P30154 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform 
Q9UHF7 Zinc finger transcription factor Trps1 
Q96GX5 Serine/threonine-protein kinase greatwall 
P10619 Lysosomal protective protein 
Q01844 RNA-binding protein EWS 
P11908 Ribose-phosphate pyrophosphokinase 2 
Q15434 RNA-binding motif, single-stranded-interacting protein 2 
O75506 Heat shock factor-binding protein 1 
Q8IY67 Ribonucleoprotein PTB-binding 1 
Q86XZ4 Spermatogenesis-associated serine-rich protein 2 
Q9UBL3 Set1/Ash2 histone methyltransferase complex subunit ASH2 
Q96KG9 N-terminal kinase-like protein 
Q93034 Cullin-5 
Q9Y237 Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 
Q9BY89 Uncharacterized protein KIAA1671 
O15397 Importin-8 
O95819 Mitogen-activated protein kinase kinase kinase kinase 4 
Q9H223 EH domain-containing protein 4 
Q14498 RNA-binding protein 39 
Q9P031 Thyroid transcription factor 1-associated protein 26 
Q9Y580 RNA-binding protein 7 
P40616 ADP-ribosylation factor-like protein 1 
O75844 CAAX prenyl protease 1 homolog 
Q9BVJ6 U3 small nucleolar RNA-associated protein 14 homolog A 
O95218 Zinc finger Ran-binding domain-containing protein 2 
P53675 Clathrin heavy chain 2 
Q9Y2X9 Zinc finger protein 281 
O15381 Nuclear valosin-containing protein-like 
Q5VT06 Centrosome-associated protein 350 
Q15596 Nuclear receptor coactivator 2 
Q8TCG1 Protein CIP2A 
Q99755 Isoform 2 of Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha 
Q14232 Translation initiation factor eIF-2B subunit alpha 
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Q92917 G patch domain and KOW motifs-containing protein 
Q9GZS3 WD repeat-containing protein 61 
P42766 60S ribosomal protein L35 
Q9Y450 HBS1-like protein 
P12814 Alpha-actinin-1 
Q96L91 E1A-binding protein p400 
Q6PK04 Coiled-coil domain-containing protein 137 
P53350 Serine/threonine-protein kinase PLK1 
Q9BTC0 Death-inducer obliterator 1 
Q9BVC5 Ashwin 
Q92997 Segment polarity protein dishevelled homolog DVL-3 
Q8NG31 Protein CASC5 
P99999 Cytochrome c 
P41250 Glycine-tRNA ligase 
Q9ULR0 Pre-mRNA-splicing factor ISY1 homolog 
Q13555 Calcium/calmodulin-dependent protein kinase type II subunit gamma 
P61981 14-3-3 protein gamma 
O00567 Nucleolar protein 56 
Q9Y3B4 Pre-mRNA branch site protein p14 
Q15274 Nicotinate-nucleotide pyrophosphorylase [carboxylating] 
Q969J3 Loss of heterozygosity 12 chromosomal region 1 protein 
Q9BXK5 Bcl-2-like protein 13 
P50750 Cyclin-dependent kinase 9 
Q5VWZ2 Lysophospholipase-like protein 1 
O14730 Serine/threonine-protein kinase RIO3 
Q9BVC3 Sister chromatid cohesion protein DCC1 
Q14469 Transcription factor HES-1 
Q8WUH6 UPF0444 transmembrane protein C12orf23 
P21108 Ribose-phosphate pyrophosphokinase 3 
O94776 Metastasis-associated protein MTA2 
Q9UBE0 SUMO-activating enzyme subunit 1 
Q96J01 THO complex subunit 3 
P15880 40S ribosomal protein S2 
P15531 Nucleoside diphosphate kinase A 
Q8IU60 m7GpppN-mRNA hydrolase 
Q9NQW6 Actin-binding protein anillin 
Q676U5 Autophagy-related protein 16-1 
O75832 26S proteasome non-ATPase regulatory subunit 10 
O95758 Polypyrimidine tract-binding protein 3 
Q9BW61 DET1- and DDB1-associated protein 1 
P61026 Ras-related protein Rab-10 
Q8IWR0 Zinc finger CCCH domain-containing protein 7A 
Q14257 Reticulocalbin-2 
O75694 Nuclear pore complex protein Nup155 
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Table B.12 Proteins identified in all pull-down assays performed with ES27 and MDA-
MB-231 cells (Group IES27,M). 
Reference Annotation 
O75822 Eukaryotic translation initiation factor 3 subunit J 
Q15637 Splicing factor 1 
O95425 Supervillin 
P18583 Protein SON 
P53621 Coatomer subunit alpha 
Q5SW79 Centrosomal protein of 170 kDa 
P20290 Transcription factor BTF3 
 
Table B.13 Proteins identified in half of the pull-down assays performed with ES27 and 
MDA-MB-231 cells (Group IIES27,M). 
Reference Annotationd 
Q14204 Cytoplasmic dynein 1 heavy chain 1 
Q9Y5K6 CD2-associated protein 
Q96A49 Synapse-associated protein 1 
Q00688 Peptidyl-prolyl cis-trans isomerase FKBP3 
P52272 Heterogeneous nuclear ribonucleoprotein M 
O43765 Small glutamine-rich tetratricopeptide repeat-containing protein alpha 
Q96PK6 RNA-binding protein 14 
Q9Y2D5 A-kinase anchor protein 2 
O14818 Proteasome subunit alpha type-7 
Q9Y696 Chloride intracellular channel protein 4 
P11216 Glycogen phosphorylase, brain form 
Q9Y6G9 Cytoplasmic dynein 1 light intermediate chain 1 
P60174 Triosephosphate isomerase 
P35580 Myosin-10 
Q07866 Kinesin light chain 1 
O95793 Double-stranded RNA-binding protein Staufen homolog 1 
Q15084 Protein disulfide-isomerase A6 
P62753 40S ribosomal protein S6 
P22234 Multifunctional protein ADE2 
P60228 Eukaryotic translation initiation factor 3 subunit E 
Q99417 C-Myc-binding protein 
Q99436 Proteasome subunit beta type-7 
P18031 Tyrosine-protein phosphatase non-receptor type 1 
Q9H9H4 Vacuolar protein sorting-associated protein 37B 
O60506 Heterogeneous nuclear ribonucleoprotein Q 
Q96HJ9 Isoform 2 of UPF0562 protein C7orf55 
P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 
P50552 Vasodilator-stimulated phosphoprotein 
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Q9BWU0 Kanadaptin 
Q13148 TAR DNA-binding protein 43 
Q99747 Gamma-soluble NSF attachment protein 
Q71RC2 La-related protein 4 
Q99729 Heterogeneous nuclear ribonucleoprotein A/B 
Q9BRA2 Thioredoxin domain-containing protein 17 
Q86UU0 B-cell CLL/lymphoma 9-like protein 
P62241 40S ribosomal protein S8 
Q14974 Importin subunit beta-1 
Q5H9R7 Serine/threonine-protein phosphatase 6 regulatory subunit 3 
Q6NZY4 Zinc finger CCHC domain-containing protein 8 
P42025 Beta-centractin 
P09914 Interferon-induced protein with tetratricopeptide repeats 1 
P23284 Peptidyl-prolyl cis-trans isomerase B 
Q16762 Thiosulfate sulfurtransferase 
O60547 GDP-mannose 4,6 dehydratase 
Q9Y570 Protein phosphatase methylesterase 1 
O60841 Eukaryotic translation initiation factor 5B 
P51114 Fragile X mental retardation syndrome-related protein 1 
P06737 Glycogen phosphorylase, liver form 
O60869 Endothelial differentiation-related factor 1 
P06703 Protein S100-A6 
Q9UHD8 Septin-9 
P14866 Heterogeneous nuclear ribonucleoprotein L 
P26583 High mobility group protein B2 
Q969H8 UPF0556 protein C19orf10 
P41250 Glycine-tRNA ligase 
P09493 Isoform 2 of Tropomyosin alpha-1 chain 
Q9BVP2 Guanine nucleotide-binding protein-like 3 
O15511 Actin-related protein 2/3 complex subunit 5 
P00568 Adenylate kinase isoenzyme 1 
P84157 Isoform 2 of Matrix-remodeling-associated protein 7 
Q15843 NEDD8 
Q13442 28 kDa heat- and acid-stable phosphoprotein 
Q9Y2V2 Calcium-regulated heat stable protein 1 
Q8IWC1 MAP7 domain-containing protein 3 
P08237 6-phosphofructokinase, muscle type 
Q9NTJ3 Structural maintenance of chromosomes protein 4 
Q16204 Coiled-coil domain-containing protein 6 
P60983 Glia maturation factor beta 
P29218 Inositol monophosphatase 1 
A0MZ66 Shootin-1 
P46013 Antigen KI-67 
Q9HC38 Glyoxalase domain-containing protein 4 
Q5JSH3 WD repeat-containing protein 44 
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Q5T5P2 Sickle tail protein homolog 
Q13573 SNW domain-containing protein 1 
P09211 Glutathione S-transferase P 
Q9BY77 Polymerase delta-interacting protein 3 
P55884 Eukaryotic translation initiation factor 3 subunit B 
P49588 Alanine-tRNA ligase, cytoplasmic 
P62847 40S ribosomal protein S24 
O75223 Gamma-glutamylcyclotransferase 
P20042 Eukaryotic translation initiation factor 2 subunit 2 
P40925 Malate dehydrogenase, cytoplasmic 
Q8NHV4 Protein NEDD1 
Q9UMX5 Neudesin 
O95757 Heat shock 70 kDa protein 4L 
Q6IN85 Serine/threonine-protein phosphatase 4 regulatory subunit 3A 
O75717 WD repeat and HMG-box DNA-binding protein 1 
Q15678 Tyrosine-protein phosphatase non-receptor type 14 
Q96RT1 Protein LAP2 
Q9Y2Q3 Glutathione S-transferase kappa 1 
O43815 Striatin 
Q9NZU5 LIM and cysteine-rich domains protein 1 
Q13564 NEDD8-activating enzyme E1 regulatory subunit 
Q86UE4 Protein LYRIC 
P53004 Biliverdin reductase A 
Q9UPQ9 Trinucleotide repeat-containing gene 6B protein 
O60524 Nuclear export mediator factor NEMF 
Q99832 T-complex protein 1 subunit eta 
Q15276 Rab GTPase-binding effector protein 1 
P05556 Integrin beta-1 
Q9NR45 Sialic acid synthase 
Q96K76 Ubiquitin carboxyl-terminal hydrolase 47 
P12081 Histidine-tRNA ligase, cytoplasmic 
O95684 FGFR1 oncogene partner 
Q86U42 Polyadenylate-binding protein 2 
O75410 Transforming acidic coiled-coil-containing protein 1 
O00762 Ubiquitin-conjugating enzyme E2 C 
P61758 Prefoldin subunit 3 
Q8NBF2 NHL repeat-containing protein 2 
O15460 Prolyl 4-hydroxylase subunit alpha-2 
Q99598 Translin-associated protein X 
O75575 DNA-directed RNA polymerase III subunit RPC9 
O14497 AT-rich interactive domain-containing protein 1A 
O76070 Gamma-synuclein 
O43583 Density-regulated protein 
O00161 Synaptosomal-associated protein 23 
O75369 Isoform 8 of Filamin-B 
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Q96PU8 Protein quaking 
P05388 60S acidic ribosomal protein P0 
Q14151 Scaffold attachment factor B2 
Q14677 Clathrin interactor 1 
Q07065 Cytoskeleton-associated protein 4 
Q13542 Eukaryotic translation initiation factor 4E-binding protein 2 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 
Q9P0L0 Vesicle-associated membrane protein-associated protein A 
P61289 Proteasome activator complex subunit 3 
P49023 Paxillin 
P08708 40S ribosomal protein S17 
P47755 F-actin-capping protein subunit alpha-2 
O43237 Cytoplasmic dynein 1 light intermediate chain 2 
Q9Y5Z4 Heme-binding protein 2 
Q9NRL3 Striatin-4 
P07711 Cathepsin L1 
Q09028 Histone-binding protein RBBP4 
Q6FIF0 AN1-type zinc finger protein 6 
Q9NVA2 Septin-11 
O15305 Phosphomannomutase 2 
Q15811 Intersectin-1 
P07203 Glutathione peroxidase 1 
Q96EP5 DAZ-associated protein 1 
O15371 Eukaryotic translation initiation factor 3 subunit D 
O75886 Signal transducing adapter molecule 2 
Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 family member E 
Q12802 A-kinase anchor protein 13 
P78344 Eukaryotic translation initiation factor 4 gamma 2 
O95373 Importin-7 
Q8IXM2 Chromatin complexes subunit BAP18 
Q8WUF5 RelA-associated inhibitor 
Q8WXX5 DnaJ homolog subfamily C member 9 
Q15003 Condensin complex subunit 2 
P43034 Platelet-activating factor acetylhydrolase IB subunit alpha 
O75506 Heat shock factor-binding protein 1 
Q99618 Cell division cycle-associated protein 3 
Q9UBT2 SUMO-activating enzyme subunit 2 
Q9Y2W2 WW domain-binding protein 11 
A0AVT1 Ubiquitin-like modifier-activating enzyme 6 
P60953 Cell division control protein 42 homolog 
Q92541 RNA polymerase-associated protein RTF1 homolog 
Q9Y4Z0 U6 snRNA-associated Sm-like protein LSm4 
Q99615 DnaJ homolog subfamily C member 7 
O60282 Kinesin heavy chain isoform 5C 
P34910 Protein EVI2B 
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Q9Y263 Phospholipase A-2-activating protein 
L0R819 Alternative protein ASNSD1 
P61201 COP9 signalosome complex subunit 2 
Q8TCU4 Alstrom syndrome protein 1 
Q9HC35 Echinoderm microtubule-associated protein-like 4 
P25787 Proteasome subunit alpha type-2 
P55145 Mesencephalic astrocyte-derived neurotrophic factor 
Q9UKK9 ADP-sugar pyrophosphatase 
Q9BVG4 Protein PBDC1 
Q13283 Ras GTPase-activating protein-binding protein 1 
P99999 Cytochrome c 
Q15020 Squamous cell carcinoma antigen recognized by T-cells 3 
O43776 Asparagine-tRNA ligase, cytoplasmic 
Q9H1H9 Kinesin-like protein KIF13A 
O43491 Band 4.1-like protein 2 
P53618 Coatomer subunit beta 
P52292 Importin subunit alpha-1 
P49368 T-complex protein 1 subunit gamma 
P62266 40S ribosomal protein S23 
 
Table B.14 Proteins identified in all pull-down assays performed with ES27b and 
HEK293T cells (Group IES27b,H). 
Reference Annotationd 
P84085 ADP-ribosylation factor 5 
Q5VTR2 E3 ubiquitin-protein ligase BRE1A 
Q14011 Cold-inducible RNA-binding protein 
Q9Y696 Chloride intracellular channel protein 4 
P40925 Malate dehydrogenase, cytoplasmic 
O43347 RNA-binding protein Musashi homolog 1 
O14974 Protein phosphatase 1 regulatory subunit 12A 
Q68EM7 Rho GTPase-activating protein 17 
O75792 Ribonuclease H2 subunit A 
Q96T21 Selenocysteine insertion sequence-binding protein 2 
Q13242 Serine/arginine-rich splicing factor 9 
Q13885 Tubulin beta-2A chain 
 
Table B.15 Proteins identified in half of the pull-down assays performed with ES27b and 
HEK293T cells (Group IIES27b,H). 
Reference Annotationd 
O95757 Heat shock 70 kDa protein 4L 
Q86U44 N6-adenosine-methyltransferase 70 kDa subunit 
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Q1KMD3 Heterogeneous nuclear ribonucleoprotein U-like protein 2 
O43395 U4/U6 small nuclear ribonucleoprotein Prp3 
Q15025 TNFAIP3-interacting protein 1 
P22307 Non-specific lipid-transfer protein 
P31949 Protein S100-A11 
Q9NXV6 CDKN2A-interacting protein 
O43765 Small glutamine-rich tetratricopeptide repeat-containing protein alpha 
P61758 Prefoldin subunit 3 
Q02878 60S ribosomal protein L6 
Q9BXP5 Serrate RNA effector molecule homolog 
Q86V81 THO complex subunit 4 
Q9NR56 Muscleblind-like protein 1 
P63208 S-phase kinase-associated protein 1 
Q9NQG5 Regulation of nuclear pre-mRNA domain-containing protein 1B 
Q92879 CUGBP Elav-like family member 1 
Q92530 Proteasome inhibitor PI31 subunit 
P35611 Alpha-adducin 
Q96AT1 Uncharacterized protein KIAA1143 
Q9UQN3 Charged multivesicular body protein 2b 
Q9NPI6 mRNA-decapping enzyme 1A 
P55884 Eukaryotic translation initiation factor 3 subunit B 
P62263 40S ribosomal protein S14 
Q92905 COP9 signalosome complex subunit 5 
P07196 Neurofilament light polypeptide 
Q2TAL8 Glutamine-rich protein 1 
O00193 Small acidic protein 
P04792 Heat shock protein beta-1 
O95163 Elongator complex protein 1 
O00231 26S proteasome non-ATPase regulatory subunit 11 
Q9GZR7 ATP-dependent RNA helicase DDX24 
P08621 U1 small nuclear ribonucleoprotein 70 kDa 
Q9UJA5 tRNA (adenine(58)-N(1))-methyltransferase non-catalytic subunit TRM6 
Q9ULV4 Coronin-1C 
Q9UKG1 DCC-interacting protein 13-alpha 
Q9UEE9 Craniofacial development protein 1 
Q9H3U1 Protein unc-45 homolog A 
O75312 Zinc finger protein ZPR1 
P49458 Signal recognition particle 9 kDa protein 
Q13153 Serine/threonine-protein kinase PAK 1 
P62805 Histone H4 
P63220 40S ribosomal protein S21 
P61019 Ras-related protein Rab-2A 
O43809 Cleavage and polyadenylation specificity factor subunit 5 
O95218 Zinc finger Ran-binding domain-containing protein 2 
P38919 Eukaryotic initiation factor 4A-III 
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Q9H2J4 Phosducin-like protein 3 
O94888 UBX domain-containing protein 7 
Q9NR31 GTP-binding protein SAR1a 
O15371 Eukaryotic translation initiation factor 3 subunit D 
P08133 Annexin A6 
Q6NSW5 Protein FAM45B 
Q99570 Phosphoinositide 3-kinase regulatory subunit 4 
P18085 ADP-ribosylation factor 4 
Q96FW1 Ubiquitin thioesterase OTUB1 
Q96H79 Zinc finger CCCH-type antiviral protein 1-like 
Q96IK1 Biorientation of chromosomes in cell division protein 1 
O00429 Isoform 4 of Dynamin-1-like protein 
P50750 Cyclin-dependent kinase 9 
P61088 Ubiquitin-conjugating enzyme E2 N 
Q9UKF6 Cleavage and polyadenylation specificity factor subunit 3 
Q9BUL8 Programmed cell death protein 10 
Q8NE71 ATP-binding cassette sub-family F member 1 
O75575 DNA-directed RNA polymerase III subunit RPC9 
Q92844 TRAF family member-associated NF-kappa-B activator 
P11908 Ribose-phosphate pyrophosphokinase 2 
P19623 Spermidine synthase 
P31483 Nucleolysin TIA-1 isoform p40 
Q9P258 Protein RCC2 
Q7L5N1 COP9 signalosome complex subunit 6 
O75886 Signal transducing adapter molecule 2 
Q92973 Transportin-1 
O95782 AP-2 complex subunit alpha-1 
Q5JTH9 RRP12-like protein 
Q8NEY8 Periphilin-1 
Q15042 Rab3 GTPase-activating protein catalytic subunit 
Q9Y5B6 PAX3- and PAX7-binding protein 1 
Q8IWC1 MAP7 domain-containing protein 3 
O75526 RNA-binding motif protein, X-linked-like-2 
P22090 40S ribosomal protein S4, Y isoform 1 
Q15057 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 2 
Q9P289 Serine/threonine-protein kinase MST4 
P39019 40S ribosomal protein S19 
Q9UM54 Unconventional myosin-VI 
O75844 CAAX prenyl protease 1 homolog 
Q9NTZ6 RNA-binding protein 12 
O94973 AP-2 complex subunit alpha-2 
Q15257 Serine/threonine-protein phosphatase 2A activator 
Q9UPN9 E3 ubiquitin-protein ligase TRIM33 
Q969Z0 Protein TBRG4 
Q7L2E3 Putative ATP-dependent RNA helicase DHX30 
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Q13310 Polyadenylate-binding protein 4 
Q15370 Transcription elongation factor B polypeptide 2 
O14964 Hepatocyte growth factor-regulated tyrosine kinase substrate 
P14649 Myosin light chain 6B 
Q15007 Pre-mRNA-splicing regulator WTAP 
O75391 Sperm-associated antigen 7 
Q9C0C9 Ubiquitin-conjugating enzyme E2 O 
Q9H3R5 Centromere protein H 
Q9Y6A5 Transforming acidic coiled-coil-containing protein 3 
P49589 Cysteine-tRNA ligase, cytoplasmic 
Q14527 Helicase-like transcription factor 
P60983 Glia maturation factor beta 
Q9UNE7 E3 ubiquitin-protein ligase CHIP 
O95400 CD2 antigen cytoplasmic tail-binding protein 2 
P18615 Negative elongation factor E 
O95628 CCR4-NOT transcription complex subunit 4 
O43148 mRNA cap guanine-N7 methyltransferase 
Q9BXF6 Rab11 family-interacting protein 5 
Q04917 14-3-3 protein eta 
Q01085 Nucleolysin TIAR 
Q9H6T3 RNA polymerase II-associated protein 3 
Q8NDV7 Trinucleotide repeat-containing gene 6A protein 
Q5VT25 Serine/threonine-protein kinase MRCK alpha 
Q86TB9 Protein PAT1 homolog 1 
A8MPP1 Putative ATP-dependent RNA helicase DDX11-like protein 8 
Q9H7Z7 Prostaglandin E synthase 2 
O76070 Gamma-synuclein 
Q5TBB1 Ribonuclease H2 subunit B 
Q9UBE0 SUMO-activating enzyme subunit 1 
Q15121 Astrocytic phosphoprotein PEA-15 
P26639 Threonine-tRNA ligase, cytoplasmic 
P55072 Transitional endoplasmic reticulum ATPase 
P49959 Double-strand break repair protein MRE11A 
Q96C19 EF-hand domain-containing protein D2 
Q9NSD9 Phenylalanine-tRNA ligase beta subunit 
P62736 Actin, aortic smooth muscle 
Q9H0L4 Cleavage stimulation factor subunit 2 tau variant 
Q86UU0 B-cell CLL/lymphoma 9-like protein 
Q5VSL9 Striatin-interacting protein 1 
P19838 Nuclear factor NF-kappa-B p105 subunit 
Q8N3F8 MICAL-like protein 1 
O00763 Acetyl-CoA carboxylase 2 
O43251 RNA binding protein fox-1 homolog 2 
Q9NQP4 Prefoldin subunit 4 
Q8IY63 Angiomotin-like protein 1 
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P52907 F-actin-capping protein subunit alpha-1 
P61204 ADP-ribosylation factor 3 
Q9NZM3 Intersectin-2 
Q92793 CREB-binding protein 
P21108 Ribose-phosphate pyrophosphokinase 3 
Q9NYU2 UDP-glucose:glycoprotein glucosyltransferase 1 
Q7Z2K8 G protein-regulated inducer of neurite outgrowth 1 
P07858 Cathepsin B 
P43246 DNA mismatch repair protein Msh2 
Q8IUH3 RNA-binding protein 45 
Q8IX90 Spindle and kinetochore-associated protein 3 
Q96CS2 HAUS augmin-like complex subunit 1 
P10275 Androgen receptor 
Q13564 NEDD8-activating enzyme E1 regulatory subunit 
Q9NVE7 Pantothenate kinase 4 
P25789 Proteasome subunit alpha type-4 
P52789 Hexokinase-2 
O60739 Eukaryotic translation initiation factor 1b 
Q9P0K7 Ankycorbin 
Q9Y570 Protein phosphatase methylesterase 1 
P30154 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A beta 
isoform 
Q9H9A7 RecQ-mediated genome instability protein 1 
Q8N7H5 RNA polymerase II-associated factor 1 homolog 
P45983 Mitogen-activated protein kinase 8 
Q9BY43 Charged multivesicular body protein 4a 
Q9Y5S9 RNA-binding protein 8A 
Q9UBT2 SUMO-activating enzyme subunit 2 
Q92820 Gamma-glutamyl hydrolase 
Q8IWZ3 Ankyrin repeat and KH domain-containing protein 1 
P31689 DnaJ homolog subfamily A member 1 
O94788 Retinal dehydrogenase 2 
Q00013 55 kDa erythrocyte membrane protein 
Q9NZ63 Uncharacterized protein C9orf78 
Q96K17 Transcription factor BTF3 homolog 4 
P08195 4F2 cell-surface antigen heavy chain 
Q9BX40 Protein LSM14 homolog B 
Q9H3N1 Thioredoxin-related transmembrane protein 1 
Q16352 Alpha-internexin 
Q8NHV4 Protein NEDD1 
P50542 Peroxisomal targeting signal 1 receptor 
O00213 Amyloid beta A4 precursor protein-binding family B member 1 
P57678 Gem-associated protein 4 
Q8NCM8 Cytoplasmic dynein 2 heavy chain 1 
Q8NEZ5 F-box only protein 22 
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Q16555 Dihydropyrimidinase-related protein 2 
Q8TE77 Protein phosphatase Slingshot homolog 3 
P80303 Nucleobindin-2 
O75496 Geminin 
Q99576 TSC22 domain family protein 3 
Q8N684 Cleavage and polyadenylation specificity factor subunit 7 
P06737 Glycogen phosphorylase, liver form 
P52948 Nuclear pore complex protein Nup98-Nup96 
Q8IW35 Centrosomal protein of 97 kDa 
P53999 Activated RNA polymerase II transcriptional coactivator p15 
L0R819 Alternative protein ASNSD1 
O75351 Vacuolar protein sorting-associated protein 4B 
Q8N1F7 Nuclear pore complex protein Nup93 
P48507 Glutamate-cysteine ligase regulatory subunit 
Q9H467 CUE domain-containing protein 2 
P30566 Adenylosuccinate lyase 
P06753 Isoform 2 of Tropomyosin alpha-3 chain 
Q02543 60S ribosomal protein L18a 





SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
C.1 MATERIALS AND METHODS 
C.1.1 Sequence design of ES7 of Candida albicans 
ES7 rRNA of C. albicans (ES7CA) is composed of 209 nucleotides. Addition of the 
T7 promoter, restriction sites (EcoRI-5’end and HindIII-3’end) and stability bases provides 
a sequence with a total of 247 nucleotides. The full-length DNA sequence was divided into 
six partially complementary DNA oligonucleotides forming a tile and assembled together 
by recursive PCR (221). 
Table C.1 DNA oligonucleotides used to construct the full-length DNA of ES7CA by 
recursive PCR.  
















a) Restriction sites are underlined and the T7 promoter sequence is in italics. 
Table C.2 Primers used to build ES7CA by recursive PCR. 







C.1.2 Recursive PCR 
Oligos and primers were dissolved in nuclease-free water to working stock 
solutions of 2.5 µM for oligos and 20 µM for primers (strand). Final PCR conditions 
consisted of 0.25 mM of each dNTP (New England BioLabs), 1x Complete Long PCR 
Buffer (Ambion), 500 nM each, of forward and reverse primers, 3U of Pfu DNA 
polymerase, and 50 nM of each DNA oligomer in 50 µL reactions. Reaction mixtures were 
heated to 95 °C for 5 min during an initial denaturation step, and cycled 30 times through 
denaturation (98 °C for 30 sec), annealing (52.0 °C for 1 min) and elongation (72 °C for 1 
min). The final elongation step was performed at 72 °C for 10 min. The target amplification 
products were purified by preparative gel electrophoresis using standard protocols. 
Table C.3 DNA sequence encoding ES7CA  










Table C.4 Primers used to insert the SHAPE structural cassette. 








C.1.3 Docking of F-neo and Neo to ES7CA 
Docking of F-neo and Neo to ES7CA were performed using Autodock Vina 1.1.2 
(279). Default parameters were used with the exception of ‘binding modes’, which was set 
to the maximum allowed value of 20. ES7CA was held rigid. Docking was performed 
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repeatedly, with different random seed numbers, to observe consensus docking sites. 
Approximately 12 distinct binding sites were observed. All rotatable bonds of F-neo and 
Neo were not restrained. AutoDock Tools 1.5.6 was used to prepare receptor and ligand 





C.2 RESULTS AND DISCUSSION 
 
Figure C.1 Sequence alignment of ES7 rDNAs from S. cerevisiae, C. albicans, C. immitis, 
C. neoformans and P. jiroveci. Alignment performed with MAFFT using the L-INS-i 





Figure C.2 Binding assays of ES7 rRNAs with F-neo. Fluorescent binding assay of A) 
ES7CA and B) ES7HS with F-neo were performed to determine the dissociation constant, 
Kd. The Kd for ES7CA and Neo was estimated by fitting as 2.5 x 10
-9 M. The Kd for ES7HS 




Figure C.3 Saturation binding plot of F-neo and ES7CA. Fluorescence titration of F-neo 
with ES7CA was performed by maintaining F-neo constant at 10 nM and increasing the 






Figure C.4 High throughput screening results of the displacement of F-neo from ES7CA by 
members of a 215 peptidyl aminosugar (PA) library. The percent of displacement of F-neo 
by PAs was obtained as stated in the materials and methods. Every experiment was 









Figure C.5 Normalized, baseline corrected thermal melting of ES7CA rRNA at 260 nm. 
Multiple melting transitions are observed in the melting process. 
Table C.5 Estimation of the melting temperatures of ES7CA in the presence of Neo. The 
melting profile, which is the derivative of the fraction unfolded with respect to temperature 
was computed. The profile was fit to a non-sequential, independent transition model with 
the program Igor Pro. The melting temperature (Tm,n) was estimated for each transition, n. 
Molar ratios of Neo to ES7CA are indicated.  
 
 
0 10 100 500 1000 
1 52.3 51.6 53.2 60 61.5 
2 59.3 59.4 61.7 66.9 68.4 
3 68.1 68.0 70.4 75.4 76.8 






Figure C.6 Secondary structure of the A site of E. coli, C. albicans and human. Nucleotides 
in green highlight the difference in sequence between the A site of E. coli and the A site of 
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